The role of FOXM1 in breast cancer chemotherapy resistance by Khongkow, Pasarat
1 
 
The role of FOXM1 in breast cancer 
chemotherapy resistance 
 
 
 
 
Thesis submitted by 
 
 
 Pasarat Khongkow  
Department of Surgery and Cancer, Division of Cancer, 
Imperial College London, Hammersmith Hospital Campus 
London, United Kingdom 
 
 
 
 
 
 
To 
Imperial College London 
For the degree of Doctor of Philosophy 
2015 
2 
 
DECLARATION OF ORIGINALITY 
Unless otherwise stated in the text, the work presented in this thesis, including the 
experiments, analyses and discussions, is entirely the result of my own work.  
The immunohistochemistry studies in chapter 3 and 4 were performed and analysed 
with the collaborators: Prof. Ui-Soon Khoo, Ms. Chun Cong, and Ms. Ellen P. S. Man 
from Department of Pathology, the University of Hong Kong. 
COPYRIGHT DECLARATION 
‘The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers 
are free to copy, distribute or transmit the thesis on the condition that they attribute it, 
that they do not use it for commercial purposes and that they do not alter, transform 
or build upon it. For any reuse or redistribution, researchers must make clear to 
others the licence terms of this work’ 
 
 
 
 
 
 
 
 
3 
 
ABSTRACT 
Resistance to chemotherapeutic agents is the main obstacle to the effective breast 
cancer management. Therefore, it is important to elucidate the molecular 
mechanisms of chemoresistance and develop novel therapeutic strategies in order to 
overcome drug resistance. In this work, I found that FOXM1 is a critical mediator of 
epirubicin and paclitaxel resistance in MCF-7 breast cancer cell lines. FOXM1 
expression was upregulated in both epirubicin resistant MCF-7 (MCF-7 EpiR) and 
paclitaxel resistant MCF-7 (MCF-7 TaxR) cells compared to sensitive MCF-7 cells. 
Interestingly, its depletion dramatically impaired the clonogenic survival and 
significantly induced cellular senescence in the resistant cells. In addition, I identified 
two novel downstream FOXM1 targets, NBS1 and KIF20A, involved in epirubicin and 
paclitaxel resistance, respectively.  
Firstly, I found that FOXM1 transcriptionally regulated NBS1 expression to modulate 
HR-mediated DSB repair and epirubicin resistance. Overexpression of FOXM1 and 
NBS1 lead to the enhancement of HR efficiency to eliminate epirubicin-induced DNA 
damage. Conversely, similar to FOXM1, depletion of NBS1 also sensitised both 
MCF-7 and MCF-7 EpiR cells to epirubicin by inducing cellular senescence. 
Secondly, I identified the mitotic kinesin KIF20A as a direct downstream target of 
FOXM1, participating in the mitotic spindle formation and paclitaxel resistance. 
Depletion of KIF20A caused mitotic spindle abnormalities, inhibition of cell growth as 
well as the induction of senescent cells in both MCF-7 and MCF-7 Tax
R
 cells. 
Consistently, immunohistochemical analysis of breast cancer patient samples 
revealed that high expression levels of FOXM1, NBS1 and KIF20A are strongly 
correlated with poor prognosis in breast cancer, supporting a physiological role of 
FOXM1 and its novel targets in genotoxic drug resistance. 
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Collectively, these findings suggests that FOXM1 and its targets, NBS1 and KIF20A, 
could be reliable prognostic markers for monitoring treatment efficiency as well as 
promising targets for therapeutic intervention to overcome epirubicin and paclitaxel 
resistance in breast cancer. 
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DNA-PKcs  DNA-dependent protein kinase catalytic subunit  
DOX   Doxorubicin 
DR-GFP   Direct repeat-green flouorescent protein 
DSBs   DNA double-strand breaks 
DTT   Dithiothreitol 
EDTA   Ethylenediaminetetraacetic acid 
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EGTA   Ethylene glycol tetraacetic acid 
EMT   Epithelial-mesenchymal transition  
EPI   Epirubicin 
ER   Estrogen receptor 
EV   Empty vector control 
EXO1   Exonuclease 1 
FCS   Foetal calf serum  
FHA   Forkhead-associated domain 
FKH   Forkhead DNA Binding Domain 
FOXM1  Forkhead box protein M1 
FOXO3a  Forkhead box O3 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HER2   Human epidermal growth factor receptor 2 
HFH-11  Hepatocyte nuclear factor 3/fork head homolog 11 
HJ   Holiday junction 
HNSCC  Head and neck squamous cell carcinoma 
HR   Homologous recombination 
HRP   Horseradish peroxidase 
HRT   Hormone replacement therapy 
IgG   Immunoglobulin G 
INCENP  Inner centromere protein 
IR   Ionising radiation 
JNK1   c-Jun N-terminal kinases 
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KIF   Kinesin 
KIF20A   Kinesin family member 20A 
LOX   Lysyl oxidase 
Mad2   Mitotic arrest deficient 2 
MAPs   Microtubule associated proteins  
MDM2  Mouse double minute 2 homolog 
MDR   Multidrug resistance 
MDR   Multidrug resistance 
MEK   MAPK/ERK kinase 
mESC   Mouse embryonic stem cells 
miRNA/ miR  microRNA 
MKLP2  Mitotic kinesin-like protein 2 
MMP-2  Matrix metalloproteinase-2 
MMP-9  Matrix metalloproteinase-9 
MPP2   Membrane protein, palmitoylated 2 
MRE11  Meiotic recombination 11 
MRN    MRE11-RAD50-NBS1 complex 
MRP-1  Multidrug resistance protein -1 
MTs   Microtubules 
Mut   Mutant 
Na3VO4  Sodium orthovanadate  
NaF    Sodium fluoride  
NBS   Nijmegen breakage syndrome 
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NBS1   Nijmegen breakage syndrome gene 
NHEJ    Non-homologous end joining 
NRD    N-terminal Repressor Domain 
NS siRNA  Non-silencing control siRNA 
OIS   Oncogene-induced senescence  
OSCC   Oral squamous cell carcinoma 
PALB2  Partner and localizer of BRCA2 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PDAC   Pancreatic ductal adenocarcinoma 
PgP   P-glycoprotein  
PI   Protease inhibitor 
PI-3K    Phosphoinositide 3-kinase 
PMSF   Phenylmethysulfonyl fluoride  
PR   Progesterone receptor 
PTEN   Phosphatase and tensin homolog 
p16    p16INK4A or cyclin-dependent kinase inhibitor 2A 
p21   p21 CIP1/WAF1 or cyclin-dependent kinase inhibitor 1 
RAB6KIFL  Rab6-binding kinesin 
RAD50  DNA repair protein RAD50 
RB   Retinoblastoma protein 
RIPA   Radioimmunoprecipitation assay buffer 
RNF20  Ring finger protein 20 
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RPA   Replication protein A  
RR   Relative risk 
RS   Replicative senescence 
RT-qPCR  Real-time quantitative reverse transcription PCR 
S.D.   Standard deviation 
SAC   Spindle assembly checkpoint 
SAHF   Senescence-associated heterochromatic foci  
SASP   Senescence-associated secretory phenotype 
SA-βgal  Senescence-associated β galactosidase 
SDS   Sodium Dodecyl Sulphate Reagent 
SDS-PAGE  Sulfate-polyacrylamide gel electrophoresis 
siRNA   Small interfering RNA 
SIRT1   Sirtuin 1 
SKP2    S-phase kinase-associated protein 2 
SMC1   Structural maintenance of chromosomes protein 1 
SRB   Sulforhodamine B  
ssDNA  Single-stranded DNA 
STK11  Serine/threonine-protein kinase 11 
SUMO  Small ubiquitin-related modifier 
TAD   Transactivation Domain 
Tax   Paclitaxel 
TCA   Trichloroacetic acid 
TE   Tris-EDTA buffer solution 
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TEMED  Tetraethylethyleneduanine  
TIS   Therapy-induced senescence 
TMA    Tissue microarray  
TOP2   Topoisomerase II 
TOPBP1  DNA topoisomerase 2-binding protein 1 
TP53   Tumour protein p53 
VEGF   Vascular endothelial growth factor  
WIN   Winged helix 
WRN   Werner syndrome ATP-dependent helicase 
WT   Wild-type 
wtNIP   Wild-type NBS1 inhibitory peptides  
XLF    XRCC4-like factor  
XRCC4  X-ray repair cross-complementing protein 4  
γH2AX  Phosphorylation of the histone H2AX 
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1.1 Breast cancer  
Globally, breast cancer is the most frequently diagnosed malignancy among women. 
There are about 1.38 million new cases and 458,000 deaths per year from breast 
cancer, making it the most common cause of women’s cancer deaths worldwide 
(Ferlay et al., 2010). In the UK, breast cancer remains the most common cancer in 
women and its incidence continues to increase (CRUK, 2015). However, breast 
cancer mortality rates have fallen by over 25% in the past two decades; this is 
largely the result of early detection as well as substantial improvements in breast 
cancer management (Turner and Jones, 2008, Yeo et al., 2014). It is estimated that 
approximately one in nine women who survive to the age of 85 will be diagnosed 
with breast cancer during their lifetime (Kelsey and Berkowitz, 1988). 
1.1.1 Risk factors 
The causes of breast cancer are complex. It has been suggested that breast cancer 
involves the combined effects of numerous genetic, environmental, and behavioural 
risk factors that are unique to each individual. Age is one of the most important risk 
factors for breast cancer. The chances of developing the disease increase with age. 
About 95% of women diagnosed with breast cancer each year are over age 40, and 
about half are aged 61 and older (CRUK, 2015). Reproductive factors are the other 
main breast cancer risk factors, including early onset of menstruation, late age of first 
pregnancy, fewer pregnancies, shorter or no periods of breastfeeding, and a later 
menopause. It therefore seems that the most established breast cancer risk factors 
are thought to influence risk through hormone-related pathways, higher 
concentrations of endogenous oestrogens are strongly associated with increased 
risk for breast cancer in postmenopausal women, and trials have shown that the anti-
oestrogen tamoxifen reduces the incidence of breast cancer (Travis and Key, 2003). 
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The long-term use of exogenous sex hormones, including oestrogen and 
progestogen, may also increase the risk of breast cancer development, such as oral 
contraceptive (Beral et al., 1996) or hormone replacement therapy (HRT) (Million 
Women Study, 2002). In addition, the burden of breast cancer is also associated with 
non-reproductive lifestyle factors including the increase in obesity and alcohol 
consumption, as well as a lack of physical activity (Howell et al., 2014). A strong 
family history with breast cancer is another well-known risk factor, particularly when 
the first degree relatives have been diagnosed with the disease. However, only 5-
10% of the all breast cancer cases are thought to be hereditary, meaning that they 
are a direct result of germline mutations in highly penetrable genes inherited from a 
parent, such as Breast cancer susceptibility  gene 1(BRCA1) and Breast cancer 
susceptibility  gene 2 (BRCA2) (Wooster et al., 1995, Da Silva and Lakhani, 2010, 
Miki et al., 1994). Recently, various other genes, including Checkpoint kinase 2 
(CHK2), Phosphatase and tensin homolog (PTEN), Tumor protein p53 (TP53), 
Ataxia telangiectasia mutated (ATM), Serine/threonine-protein kinase 11 (STK11), 
Cadherin 1 (CDH1), Nijmegen breakage syndrome (NBS1), DNA repair protein 
RAD50 (RAD50), BRCA1-interacting protein 1 (BRIP1) and Partner and localizer of 
BRCA2 (PALB2) have been identified to confer an increased risk of hereditary breast 
cancer (van der Groep et al., 2011). Numerous epidemiological risk factors have also 
been identified to increase a woman’s risk of developing breast cancer, but the 
cause of any individual breast cancer is mostly unknown.  
1.1.2 Medical management of breast cancer 
Over the past half century, there have been outstanding advances in breast cancer 
management which have led to early detection of disease and the development of 
effective treatments, resulting in significant reduction in breast cancer mortality and 
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improved clinical outcomes for women living with the disease. Breast cancer 
treatment commonly involves surgical removal of the tumour, but this is ineffective if 
cancer cells have escaped from their primary site. A wide spectrum of clinical, 
pathologic, and molecular factors are routinely used to categorise patients in order to 
assess prognosis and determine the more effective therapeutic options. These 
include age, axillary node status, tumour size, histological grade, hormone receptor 
status, and HER2 status.  
1.1.3 Molecular classifications of breast cancer 
In recent years, several gene expression microarray studies have categorised breast 
cancer into four distinct molecular subtypes beyond the traditional hormone receptor-
positive and hormone receptor-negative types: the luminal A, luminal B, human 
epidermal growth factor receptor-2 (HER2), and basal-like types (Schnitt, 2010, 
Sørlie et al., 2001). These breast cancer molecular subtypes differ with regard to 
their gene expression profiles, clinical features, prognosis, and response to 
treatment, as summarised in Table1.1. Luminal-type breast cancers express the 
oestrogen receptor (ER) and associated genes and can be targeted with hormonal 
therapies. Subtype A is less aggressive and less sensitive to chemotherapy than 
subtype B. HER2 breast cancers are characterised by overexpression of HER2, with 
amplification of the HER2 gene. They are more aggressive than HER2 negative 
breast cancers, but can be targeted with the monoclonal antibody trastuzumab and 
are highly sensitive to chemotherapy. Basal-like breast cancers do not usually 
express ER, progesterone receptor (PR) and HER2, hence referred to as triple-
negative. This type of breast cancer does not respond to hormonal therapies or 
HER2-targeted therapies. They are highly proliferative and usually have a poor 
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prognosis, although they are highly sensitive to chemotherapy (Sørlie et al., 2001, 
Schnitt, 2010, Allison, 2012, Zhang et al., 2014a). 
Molecular subtype 
 Luminal Her2 Basal 
Gene expression 
pattern 
High expression of hormone 
receptors and ER-related 
genes (luminal A>luminal B) 
High expression of 
HER2 and Her-
associated genes 
Low expression of 
ER and 
associated genes 
High expression of 
basal epithelial genes, 
basal cytokeratins 
Low expression of ER 
and associated genes 
Low expression of 
HER2 
Clinical features 
 
~75% of invasive breast 
cancers ER/PR positive 
 
 
ER/PR negative 
 
 
Most ER/PR and 
HER2 negative (‘triple 
negative’) 
BRCA1 dysfunction  
 
A: Lower-
grade ER+ 
Low Ki67 
B: Higher-
grade ER+ 
High Ki67 
Some 
overexpress 
HER2 
Prognosis A: Good B:Intermediate Worse Worse 
Treatment 
response  
Respond to endocrine 
therapy (but response to 
tamoxifen and aromatase 
inhibitors may be different 
for luminal A and luminal B) 
 
Response to chemotherapy 
variable (greater in luminal 
B than in luminal A) 
 
Respond to 
trastuzumab 
(Herceptin) 
 
Respond to 
anthracycline-
based 
chemotherapy 
 
No response to 
endocrine therapy or 
trastuzumab 
(Herceptin) 
 
Appear to be sensitive 
to platinum-based 
chemotherapy and 
PARP inhibitors 
 
Table 1.1: Major molecular subtypes of breast cancer determined by gene expression 
profiling (Adapted from (Schnitt, 2010)). 
 
These four different breast cancer subtypes represent biologically distinct diseases 
and are managed accordingly in the clinic. The therapeutic choices for breast cancer 
depend on the type of cancer, the menopausal status and stage of disease. 
Endocrine therapies, such tamoxifen or aromatase inhibitors, remain the first-line 
treatment of hormone-sensitive metastatic breast cancer and as adjuvant therapy for 
early breast cancer in patients with hormone-receptor-positive tumours (Buzdar, 
2003, Jaiyesimi et al., 1995); whereas, HER2 monoclonal antibody trastuzumab 
represents as the first-line treatment for patients with HER2-overexpressing 
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metastatic breast cancer (Vogel et al., 2002). The use of endocrine therapy or 
monoclonal antibody therapy has significantly reduced the number of deaths from 
breast cancer over the past decades. However, the majority of these patients will 
eventually develop resistance to endocrine or monoclonal antibody treatment (Ali 
and Coombes, 2002, Lu et al., 2001, Chang, 2012). In this case, and in patients with 
triple-negative, cytotoxic chemotherapy remains the mainstay of treatment in the 
metastatic setting. Altogether, it seems that most breast cancer patients of all 
subtypes receive chemotherapy as a part of the treatment process. 
1.2 Chemotherapy 
In the clinical treatment of breast cancer, chemotherapy is one of the most common 
treatments for the disease. Because cancer cells uncontrollably divide and are able 
to invade or spread to other tissues of the body, most chemotherapy drugs typically 
target rapidly dividing cells and function by interfering with the cell division process. 
Chemotherapy drugs can be divided into several groups based on how they work to 
eliminate cancer cells and their chemical characteristics (Helleday et al., 2008). 
Among the traditional cytotoxic chemotherapeutic drugs, anthracyclines and taxanes 
have emerged as the most powerful treatments in breast cancer (Kröger et al., 
1999).   
1.2.1 Anthracyclines 
Anthracyclines (also known as anthracycline antibiotics), including doxorubicin 
(DOX) and epirubicin, are an important class of anti-tumour drugs with a broad 
spectrum of activities in human cancers, and only a few cancers (e.g. colon cancer) 
are unresponsive to them. DOX is one of the first anthracyclines that were originally 
isolated from the pigment-producing Streptomyces peucetius early in the 1960s. Its 
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chemical characteristics are composed of a four ring structure (rings A-D) and the 
aglycon chromophore, which is linked to an amino sugar (daunosamine) via a 
glycoside bond. DOX is one of the most widely used chemotherapeutic agents in the 
standard treatment of a wide range of solid tumours including breast, lung, gastric, 
thyroid and ovary carcinomas, as well as leukaemia (Minotti et al., 2004). 
Unfortunately, its efficacy in treating cancer is limited by a cumulative dose-
dependent cardiotoxicity, which causes congestive heart failure and several other 
side-effects to healthy tissue (Von Hoff et al., 1979, Ewer and Ewer, 2015). 
Therefore, the modification of this drug to generate new analogues with improved 
activity and lower toxicity has been sought.                              
Over subsequent years with numerous attempts to develop and generate better 
anthracycline analogues, epirubicin, an epimer of DOX, have been approved for 
clinical use for treating a broad range of malignancies including breast, lung, gastric, 
and ovary carcinomas, and leukaemia (Minotti et al., 2004). The chemical structure 
of epirubicin differs from doxorubicin only at the spatial orientation of the C-4 
hydroxyl group on the sugar (Figure 1.1). This slight change contributes to the faster 
elimination rate and reduced cardiotoxicity of epirubicin, making it preferential to 
DOX. 
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Figure 1.1: Structures of the anthracyclines, doxorubicin and epirubicin. Red arrows indicate 
structural modifications in epirubicin compared with doxorubicin (axialto-equatorial epimerisation of 
the hydroxyl group at C-4′ in daunosamine. 
Despite the extensive and long-standing clinical use of anthracyclines, their precise 
mechanisms responsible for the anti-proliferative and cytotoxic effect are not 
completely understood. There are two main proposed mechanisms by which 
anthracyclines act in the cancer cell: (1) intercalation into DNA, leading to inhibition 
of DNA synthesis, and the initiation of DNA damage via the disruption of 
topoisomerase II-mediated DNA repair and (2) generation of free radicals, thus 
adversely altering cell membrane, proteins, and DNA (Minotti et al., 2004, Thorn et 
al., 2011, Gewirtz, 1999). These processes are able to render cancer cells to 
undergo apoptosis, mitotic catastrophe, or senescence.  
DNA Topoisomerase II (TOP2) is likely to be one of the primary targets for the 
activity of the anthracycline antibiotics. DNA Topoisomerase II is an essential nuclear 
enzyme which regulates the topological state of the DNA without any alteration of 
deoxynucleotide structure and sequence. It can cause transient DNA double-strand 
breaks (DSBs) that are resealed after changing the twisting status of the double 
helix. This activity plays a critical role in modulating the supercoiling of the DNA 
double helix according to the cell cycle phase and transcriptional activity.  
Anthracyclines act as topoisomerase II poisons. They stabilise a reaction in which 
DNA strands are cut and covalently linked to tyrosine residues of topoisomerase II, 
eventually preventing DNA resealing and inducing the accumulation of permanent 
DNA damage. The topoisomerase II-mediated DNA damage is then followed by 
growth arrest in G1 and G2 and subsequent the activation of programmed cell death 
(Minotti et al., 2004, Gewirtz, 1999, Guano et al., 1999).  
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1.2.2 Paclitaxel 
Paclitaxel, usually called by its brand name Taxol, is a commonly used microtubule-
binding compound for treating advanced breast, ovarian, and lung cancers. It was 
originally isolated from the bark of Taxus brevifolia (pacific yew tree) in the 1960s 
(Verweij et al., 1994, Wani et al., 1971). Microtubules are composed of heterodimers 
of α-tubulin and β-tubulin. Paclitaxel acts against cancer cells by binding to the β 
subunit of tubulin in microtubules, which stabilise and promote microtubule 
polymerisation, thereby preventing their depolymerisation and interrupting normal 
microtubule dynamics. Because microtubules are an essential part of the mitotic 
microtubule spindle apparatus during mitosis, this action results in cell cycle arrest in 
G2/M phase and, ultimately, cell death through apoptosis, senescence or mitotic 
catastrophe process (Gornstein and Schwarz, 2014). Several studies have indicated 
that paclitaxel-arrested cells are in metaphase and certain concentrations of 
paclitaxel induce multipolar spindles (Weaver, 2014). Paclitaxel may also interfere 
with other cellular functions in which microtubules play a critical role, such as 
maintenance of cell shape, motility, and cellular transport (Goble and Bear, 2003). 
 
Figure 1.2: Molecular structure of Paclitaxel.  The chemical structure of paclitaxel is composed of 
four conjoined rings. The side chain of paclitaxel also holds functional groups that are essential for its 
anti-tumour activity.  
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1.3 Apoptosis and non-apoptotic deaths in treatment response 
The cytotoxic treatment strategies of conventional chemotherapy have relied on the 
assumption that complete cellular destruction of tumours optimises the potential for 
patient survival (Ewald et al., 2010a, Kahlem et al., 2004). Genomic DNA damage is 
the pivotal cellular target of anti-cancer agents, which triggers programmed cellular 
response. Apoptosis has long been considered to be the principal mechanism of 
programmed cell death in response to chemotherapy. However, accumulating 
evidence suggests that in addition to apoptosis, necrosis, autophagy, mitotic 
catastrophe and senescence have also been identified as potential outcomes of 
cancer treatment (Figure 1.3). In particular, the fact that many cancer cells have 
inactivated their apoptotic programme cell death pathway during tumorigenesis, 
which could make non-apoptotic cell death pathway an alternative outcome for 
cancer therapy. The different resulting mechanisms of cytotoxic agents-induced cell 
death are likely determined by the mechanism of action of the drug, the dosing 
regimen used, the genotype of the cell within the tumour as well as the molecular 
status of cell-cycle checkpoints (Morse et al., 2005, Okada and Mak, 2004).  The 
better examination of what we know about chemotherapy-induced cell death is thus 
crucially important in the light of new understanding about non-apoptotic cell death 
signalling pathways. If we can specifically activate molecules that play a critical role 
in mediating the complexity of cell death outcomes, we possibly can succeed in more 
effective and less toxic chemotherapeutic treatments (Ricci and Zong, 2006). In this 
study, I focus on two distinct crucial non-apoptotic mechanisms: senescence and 
mitotic catastrophe, which are usually triggered in cancer cells in response to 
chemotherapeutic drugs.  
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Figure 1.3: Chemotherapeutic agents activate various signalling pathways that can lead to different 
forms of cell death (Adapted from (Ricci and Zong, 2006)). 
 
 
 
 
 
1.3.1 Cellular senescence 
Cellular senescence, the irreversible growth arrest of cells in G1 phase of the cell 
cycle, is crucial for normal healing in damaged tissues, ageing and tumour 
suppression which prevents the growth of cells at risk for neoplastic transformation 
(Rodier and Campisi, 2011). Cellular senescence was originally characterised by 
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Hayflick as a signal transduction process that limits cell proliferation of normal 
human cells in culture (Hayflick, 1965). Cells that undergo senescence cannot 
proliferate even if stimulated by mitogen, but they remain metabolically active and 
display morphological changes, such as enlarged and flatted cell shape, increased 
granularity and a vacuole-rich cytoplasm (Campisi, 2001). In addition to these classic 
morphological characteristics, there are a number of cellular biomarkers that typically 
associated with the senescent phenotype. The most widely used biomarker to 
identify senescent phenotype in both in vitro and in vivo is the increase in 
“senescence-associated β galactosidase” (SA-βgal) activity, which involves a simple 
histochemical staining procedure at pH 6.0 to detect the expanded lysosomal 
compartment in the perinuclear region of aged cells (Dimri et al., 1995b). With 
advances in the biochemical characterisation, several other molecular senescence 
biomarkers have also been described, including high expression levels of p16INK4A 
(p16) and p21CIP1/WAF1 (p21) (Dimri et al., 1995a, Serrano et al., 1997), senescence-
associated heterochromatic foci (SAHF), which are nuclear DNA domains densely 
stained by DAPI, DNA segments with chromatin alterations reinforcing senescence, 
and the senescence-associated inflammatory cytokine secretion (Itahana et al., 
2013, Zhang and Yang, 2011b). This permanent growth arrested state in normal 
human somatic cells is referred to as ‘replicative senescence (RS)’. RS is mainly 
trigged by a combination of two main factors. The first factor is the progressive 
telomere shortening, which provokes a persistent DNA damage response (DDR) 
(D'Adda Di Fagagna et al., 2003). Telomeres become gradually shorter after each 
cell division and are eventually too short to allow the cell to divide, resulting in 
cellular senescence or apoptosis (Harley et al., 1990, Fagagna et al., 2003). The 
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second factor is the activation of tumour-suppressive signals, including activation of 
the p53 and the p16 (also known as INK4A–RB pathways) (Collado et al., 2007). 
In addition to replicative senescence, more recent studies which build on the 
phenomenon of replicative senescence in normal cells approaching the limit of their 
proliferative potential have identified a comparable senescence-like arrest as a 
component of the tumour cell response to chemotherapeutic drugs and radiation. 
This response, which has been termed “premature senescence”, or “accelerated 
senescence”, can be induced by other types of stress such as oncogene activation 
DNA damage, oxidative stress or chemotherapy treatment (Shay and Roninson, 
2004, Kuilman et al., 2010). 
Oncogene-induced senescence (OIS) has been identified in non-malignant human 
tissues as one mechanism of tumour suppression. The oncogenic protein Ras and 
its effectors, including activated mutant RAF, MEK, and BRAF, have been reported 
to trigger senescence (Braig and Schmitt, 2006, Zhang and Yang, 2011b). This form 
of senescence is similar to replicative senescence; however, OIS is much more rapid 
and independent of dysfunctional telomeres. One of the hallmarks shared by cells 
undergoing replicative senescence and OIS is the critical involvement of the p53 and 
p16INK4A–RB pathways (Ben-Porath and Weinberg, 2005). For example, benign 
melanocytic nevi (skin moles) result from the increased activity of the mutant 
oncogene v-raf murine sarcoma viral oncogene homologue B1 (BRAF). After 
increased proliferation and growth, melanocytes arrest, increase the expression of 
p16INK4A, and stain positive for senescence-associated acidic β-galactosidase (SA-β-
gal) activity (Michaloglou et al., 2005, Ewald et al., 2010a). It is now becoming 
increasingly clear that oncogene induced senescence (OIS) is a critical endogenous 
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protective barrier against neoplastic transformation and that senescence in tumours 
may indicate a more benign or favorable outcome. 
As mentioned above, tumour progression involves inhibiting crucial mediators of 
cellular senescence. However, it does not mean that transformed cancer cells have 
completely lost their capacity to undergo senescence. This response can still be 
activated by radiation or genotoxic chemotherapy. Current research suggests that 
therapy-induced senescence (TIS) represents a novel form of cellular senescence 
that may provide an effective approach to induce a persistent growth inhibitory 
response in both early- and late-stage cancers while limiting toxicity (Ewald et al., 
2010b, Schmitt et al., 2002, Xue et al., 2007). TIS can be induced in immortal and 
transformed cancer cells by selected anticancer compounds or radiation, and it 
shares many similarities to OIS (e.g. cellular biomarkers) (Zhang and Yang, 2011a, 
Yang et al., 2012, Rebbaa et al., 2003). TIS has been shown to be a relevant factor 
in determining treatment outcome for breast and lung cancers (te Poele et al., 2002, 
Roberson et al., 2005). Moreover, the effectiveness of senescence-inducing drugs 
could also be a potential alternative approach to treat tumours that are resistant to 
apoptosis-based therapies. Ewald et al. recently screened and identified diaziquone 
(AZQ), a DNA alkylating agent, as a promising senescence-inducing compound in 
prostate cancer cells by using a semi-automated high-throughput method. They also 
revealed that Skp2 participates in regulating TIS in cancer cells (Ewald et al., 2009, 
Ewald and Jarrard, 2012). Similarly, Chan et al. have also shown that a Skp2 
inhibitor, which selectively inhibits Skp2 E3 ligase activity, exhibits potent anti-cancer 
activities in multiple animal models and cooperates with chemotherapeutic drugs to 
reduce cancer cell progression by triggering p53-independent cellular senescence 
(Chan et al., 2013). In addition, a growing number of specific inhibitors that promote 
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senescence response, such as mTOR inhibitor (Everolimus) (Wall et al., 2013), 
CDK4 inhibitor (PD0332991) (Puyol et al., 2010), Aurora A kinase inhibitor 
(MLN8054) (Huck et al., 2010), MDM2 inhibitor (Nutlin3) (Arya et al., 2010, Polański 
et al., 2014, Efeyan et al., 2007), PTEN inhibitor (VO-OHpic) (Alimonti et al., 2010), 
and histone deacetylase (HDAC) inhibitors (Pazolli et al., 2012), have also been 
shown to have a relevant beneficial for cancer treatment .  
However, it remains unclear what determines the choice of a cell to respond to the 
treatment by either triggering apoptosis or senescence (Childs et al., 2014). It could   
depend on exposure time and the dosages of the chemotherapeutic agents used. 
The lower doses induce senescence, whereas the higher doses induce apoptosis 
(Chang et al., 1999). For example, in prostate cancer cell lines, the lower 25 nM 
doses of doxorubicin induce senescence, whereas 250 nM of doxorubicin triggers 
apoptosis (Schwarze et al., 2005, Ewald et al., 2009). Moreover, accumulating 
evidence indicates that TIS reduces toxicity-related side effects, increased tumour-
specific immune activity and improved treatment outcome (Schmitt et al., 2002, Xue 
et al., 2007). Recently, the ability of cancer cells to overcoming TIS has been 
proposed as one mechanism behind cancer recurrence and drug resistance.   
 
 
1.3.2 Mitotic Catastrophe 
The other anti-proliferative response of tumour cells is mitotic catastrophe, a mode of 
cell death characterised by the occurrence of aberrant mitosis or mis-segregation of 
chromosomes leading to the formation of giant interphase cells with abnormal 
nuclear morphology and multiple micronuclei, which are morphologically distinct from 
43 
 
apoptosis, necrosis and autophagy (Table 1.2) (Vitale et al., 2011, Weaver and 
Cleveland, 2005). Centrosomes have an important role in the formation of bipolar 
mitotic spindles, which are essential for accurate chromosome segregation. Mitotic 
catastrophe also takes place as a result of centrosome over duplication, which leads 
to consequent entry into mitosis with multiple spindle poles (Fragkos and Beard, 
2011, Sato et al., 2000) or failure of centrosomes to undergo duplication with the 
consequent failure of chromosome to segregate (Cogswell et al., 2000). In 
mammalian cells, particularly in cancer cells, mitotic catastrophe is mainly related 
with defective cell cycle checkpoints, including both the DNA replication checkpoint 
and the spindle assembly checkpoint, and cellular damage (Castedo et al., 2004). 
The G2 checkpoint of the cell cycle is responsible for blocking cell division when a 
cell has sustained an insult to DNA. DNA damage activates various cellular 
responses, including cell cycle arrest, DNA repair, or cell death. If the G2 checkpoint 
is defective, a cell can enter mitosis inappropriately, before DNA replication is 
complete or DNA damage has been repaired. This aberrant mitosis renders the cell 
to undergo death by mitotic catastrophe. In addition, mitotic catastrophe can be 
triggered by agents influencing the stability of microtubules, various classes of 
chemotherapeutic drugs and ionising radiation, but the pathways of abnormal mitosis 
differ depending on the nature of the inducer and the status of cell-cycle checkpoints 
(de Bruin and Medema, 2008, Roninson et al., 2001). For example, paclitaxel causes 
an abnormal metaphase in which the sister chromatids fail to segregate properly 
(Jordan et al., 1996). CDK1 activation is prolonged abnormally in paclitaxel-treated 
cells, which undergo cell death by mitotic catastrophe. Mitotic catastrophe is driven  
by a number of molecular players, in particular, cell cycle specific kinases (such as 
CDK1, PLK1 and Aurora kinases), cell cycle checkpoint proteins, including survivin, 
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p53, caspases and members of the Bcl-2 family (Castedo et al., 2004). Elucidation of 
the genes and regulatory mechanisms that determine different aspects of treatment-
induced mitotic catastrophe may help in improving the efficacy of anti-cancer 
therapy, providing opportunities for the development of new drugs. 
 
Type of cell death: Apoptosis Senescence Mitotic 
catastrophe 
 
 
 
 
Morphological 
characteristics 
 
Cell 
morphology 
Blebing, membrane 
integrity maintained 
Flattening, increase 
in granularity and 
cell size 
 
 
 
Nucleus 
Nuclear fragmentation, 
chromatin 
condensation, DNA 
laddering 
Accumulation of 
heterochromatin 
(SAHF) foci, 
prolonged γ-H2AX 
foci 
Micronuclei, mis-
segregation of 
chromosomes, nuclear 
fragmentation 
 
Cytoplasm 
Fragmentation 
(formation of apoptotic 
bodies) 
  
 
Biochemical features 
 
 
Caspase dependent 
SA-βgal activity Abnormal CDK1/Cyclin 
B activation, 
Caspase independent 
 
 
 
 
Detection 
Caspase-activity 
assays, TUNEL assay,  
Annexin V staining, 
detection of changes in 
mitochondrial 
membrane potential 
SA-βgal staining, 
Clonogenic assay, 
Flattened cell 
morphology, 
detection of 
increased p53, p21,  
p16 
INK4A
 and 
p19
ARF
, detection of 
elevated SASP 
factors (including 
IL-6 and IL-8)
 
Visualisation of 
multinucleated cells, 
Detection of mitotic 
marker MPM2 
Table 1.2: Cell death pathway characteristic (Adapted from (Okada and Mak, 2004)). 
 
 
1.4 General mechanisms of drug resistance in breast cancer 
Despite advances in detection, adjuvant therapy, and the understanding of the 
molecular biology of breast cancer, about 30% of patients with early-stage breast 
cancer develop recurrent and metastatic disease (Pisani et al., 2002, Moreno-Aspitia 
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and Perez, 2009). Resistance to chemotherapy represents the main obstacle against 
the successful management of breast cancer. It is thought to cause treatment failure 
in over 90% of patients with metastatic cancer.  Drug resistance can be divided into 
two main categories: pre-existent (intrinsic resistance), or induced by drugs 
(acquired resistance). Acquired resistance is a particular problem, as cancers not 
only become resistant to the drugs originally used to treat them, but may also 
become cross-resistant to other anticancer agents with different structure and 
mechanism of action (Longley and Johnston, 2005). Drug resistance can be 
mediated by a number of different biochemical mechanisms (Figure 1.4). These 
include: (1) elevated expression of drug efflux pumps such as permeability 
glycoprotein (P-gp) (Ambudkar et al., 1999); (2) reduced drug influx; (3) increased 
drug inactivation or detoxification; (4) alteration of drug targets; (5) enhancement of 
DNA repair capacity; (6) reduced ability to undergo apoptosis or non-apoptotic cell 
death; or (7) mutations of cell cycle checkpoints leading to overexpression of anti-
apoptotic genes (Broxterman et al., 2003, Holohan et al., 2013, Gottesman, 2002). 
Although chemotherapy resistance is a main problem, an understanding of these 
biochemical changes can provide potential targets to overcoming drug resistance in 
human cancer.      
Chemotherapy resistance also seems to arise from the expression of proteins 
underlying a specific mechanism of action of each anti-cancer drug. For example, 
paclitaxel functions by binding to β-tubulin. Therefore, paclitaxel resistance has been 
linked to a wide variety of mechanisms including molecular mutations in the target 
molecule (β-tubulin) leading to alterations in microtubule dynamics (Minotti et al., 
1991, Giannakakou et al., 1997, Ganguly et al., 2011), alteration of the expression 
pattern of microtubule associated proteins (MAPs) (Rouzier et al., 2005), defective 
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spindle assembly checkpoint (SAC) (Anand et al., 2003), changes in cell death 
regulatory proteins (Ferlini et al., 2003, Wang et al., 2005b), and overexpression of 
multidrug resistance (MDR-1) gene (Wind and Holen, 2011, Murray et al., 2012). 
Resistance to anthracyclines develops via a wide variety of mechanisms including 
mutations in topoisomerase II (the molecular target of the anthracyclines) (Bugg et 
al., 1991, Ganapathi and Ganapathi, 2013), overexpression of DNA repair proteins 
(Monteiro et al., 2013, Kwok et al., 2010a, Millour et al., 2011, Park et al., 2012), 
alterations in cell death signalling (Fan et al., 1994), and increased drug efflux 
mediated by overexpression of ATP-binding cassette transport proteins, such as P-
glycoprotein (Pgp), multidrug resistance (MDR) protein (MRP-1), and breast cancer 
resistance protein (BCRP) (Chien and Moasser, 2008, Minotti et al., 2004). 
Although multiple mechanisms have been identified to be responsible for the 
resistance to a wide range of chemotherapeutic agents, a deeper understanding of 
how the exact mechanism involved in the molecular pathways underlying drug 
sensitivity and resistance is still required. These will eventually lead to the 
development of novel therapeutic strategies which will have the potential to improve 
the efficacy of current treatment of breast cancer with drug resistance 
characteristics. 
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Figure 1.4: Molecular mechanisms of anti-cancer drug resistance. Different mechanisms drive 
cancer cells to become resistant to one or more cytotoxic anticancer drugs known as multidrug 
resistance (MDR) significantly suppress the effectiveness of cancer chemotherapy. Potential factors 
for MDR include: increased drug inactivation or detoxification; alteration of drug targets; enhancement 
of DNA repair capacity; reduced ability to undergo apoptosis or non-apoptotic cell death; decreased 
drug uptake; mutations of cell cycle checkpoints; overexpression of efflux pumps such as P-
glycoprotein (P-gp) multidrug resistance protein family members (MRPs), and breast cancer 
resistance protein (BCRP) (Adapted from (Kapse-Mistry et al., 2014)).  The red crosses represent 
inhibitory processes. 
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1.5 DNA Damage Response (DDR) 
Genomic DNA is the most critical component of cells. The integrity of DNA in each 
cell is continually damaged through a combination of endogenous processes (e.g. 
stalled forked during replication, telomere erosion, the generation of reactive oxygen 
species during oxidative metabolism) and exogenous factors (e.g. radiation and 
genotoxic compounds) that alter the sequence or chemical composition of the DNA 
(Jalal et al., 2011). These lesions may result in the formation of single-strand or 
double-strand DNA breaks, bulky adducts, intrastrand and interstrand crosslinks and 
breakdown of the replication forks. These are dangerous events because they 
compromise the structural stability of chromosomes and induce genomic instability, 
which is one of the hallmarks of cancer. In order to counteract DNA lesions and 
maintain genomic stability, cells can stimulate and amplify various biochemical 
pathways, collectively termed as the DNA damage response (DDR) (Jackson and 
Bartek, 2009). In general, the cellular DNA damage response occurs through an 
integrated sensing and signalling network, which is composed of a number of gene 
products, including sensors, transducers and effectors. DSBs are initially detected by 
DNA damage sensor molecules, which trigger the activation of downstream 
transducing kinases. These transducers amplify damage signals by phosphorylation 
of effector proteins, which in turn regulate cell cycle progression, DNA repair and 
apoptosis (Jackson and Bartek, 2009). Immediately after DSBs, the DSB sites are 
recognised by the MRE11-RAD50-NBS1 (MRN) complex which recruits ataxia 
telangiectasia-mutated (ATM), a key element in the DNA damage response pathway, 
to the damage site. This event also activates ATM by inducing its Ser139 auto-
phosphorylation (Bakkenist and Kastan, 2003, Lee and Paull, 2005). Then, activated 
ATM phosphorylates histone H2AX on Ser139 (Burma et al., 2001). This 
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phosphorylated form, known as γH2AX, induces the recruitment of additional DNA 
damage responsive proteins including BRCA1, MRN complex and 53BP1 to the 
DNA damage sites and results in the formation of DNA damage foci. Activated ATM 
also functions by phosphorylating and activating a number of key proteins, involved 
in DNA damage repair, DNA replication, cell cycle checkpoint arrest and apoptosis, 
such as p53, NBS1, BRCA1, CHK1, CHK2, E2F1, MDM2, and SMC1, to ensure the 
damaged cells do not continue dividing until the DNA damage is repaired 
(Darzynkiewicz et al., 2009, Kurz and Lees-Miller, 2004, Sulli et al., 2012) 
(Figure1.5).  Once a DNA lesion is repaired, DDR foci are disassembled. This is 
probably due to the action of both chromatin remodelling machines and the 
dephosphorylation of γH2AX by dedicated phosphatases. Therefore, promptly 
repaired lesions are expected to display transient and relatively small foci, whereas 
severe or irreparable DNA breaks will induce more protracted DDR signalling and 
increased γH2AX foci spreading and consequently produce visibly bigger foci. DSBs 
that cannot be repaired (for example, uncapped telomeres) cause constitutive DDR 
signalling, prolonged p53-dependent growth arrest and eventually an irreversible 
senescence (d'Adda di Fagagna, 2008). 
50 
 
 
Figure 1.5: The model of the ATM signalling pathway in response to induction of DSBs. When 
DSBs induced by radiation or chemotherapy are present, ATM is recruited and become activated via 
an interaction with the main DNA damage sensor MRN complex, Activated ATM then phosphorylates 
H2AX (also known as γH2AX). In addition, ATM also phosphorylates BRCA1, 53BP1, and MDC1 as 
well as checkpoint protein Chk2. This process is aimed to stop cell cycle progression and to activate 
p53, a downstream effector responsible for DNA repair. DDR-mediated cellular outcomes could be 
transient cell cycle arrest followed by repair of DNA damage and resumption of cell proliferation; cell 
death by apoptosis; or cellular senescence caused by the persistence of unrepaired DNA DSBs 
(Adapted from (Sulli et al., 2012)). 
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1.5.1 DNA double strand break repair 
Cells possess a number of distinct, but partially compensatory, DNA repair 
mechanisms, each addressing a specific form of DNA breaks (Jackson and Bartek, 
2009). DNA double-strand breaks (DSBs) are considered the most deleterious form 
of DNA lesions, which can lead to genomic instability, cancer, cell death, or cellular 
senescence (Vilenchik and Knudson, 2003). Therefore, the activation of cellular 
checkpoints and effective repair in response to DSBs are the critical barriers to 
prevent malignant transformation. DNA DSBs can be caused by many different 
environmental factors, including reactive oxygen species, ionising radiation and 
certain chemotherapeutic agents, such as anthracyclines and topoisomerase 
inhibitors. Alternatively, DSBs can result from endogenous factors, especially during 
DNA replication process (Khanna and Jackson, 2001). Moreover, DSBs naturally 
occur at chromosome ends, related to human cell ageing and replicative senescence 
(D'Adda Di Fagagna et al., 2003). Persistent or incorrectly repaired DSBs can cause 
chromosome translocations and genomic instability, potentially leading to multiple 
cancers and immunodeficiency. The prevalence of DNA DSBs in cancer due to 
uncontrolled cell proliferation and defects in repair opens up a potential therapeutic 
window for cancer treatment. Therefore, targeting the proteins that is essential for 
the repair of DSBs with chemotherapeutic agents has become a potential strategy 
for cancer therapies. 
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In mammalian cells, there are two main pathways responsible for DSBs, namely 
homologous recombination (HR) pathway and non-homologous end joining (NHEJ) 
pathway (Figure 1.6). The choice of cells to trigger either NHEJ or HR pathway is 
dependent on the phase of the cell cycle. The HR pathway is active specifically in S 
and G2 cell cycle phases, the stages when a sister chromatid is available as a 
template for targeted HR (Johnson and Jasin, 2000). This process allows for error-
free repair of DNA damage. By contrast, the NHEJ pathway is an error-prone DNA 
repair pathway, which processes and ligates the two broken DNA ends directly and 
can be activated in all cell cycle phases (Choudhury et al., 2009). NHEJ is often 
mutagenic because deletions or insertions can be induced at the repair sites. 
In NHEJ, both ends of the DNA break are first bound by the Ku70/Ku80 heterodimer, 
which recruits and activates the DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) to form the DNA-PK holoenzyme (Giffin et al., 1996). Broken DNA ends 
are then processed by the Artemis nuclease before being ligated by a multimeric 
complex consisting of X-ray repair cross-complementing protein 4 (XRCC4), 
XRCC4-like factor (XLF) and DNA ligase IV. HR takes over if NHEJ is unsuccessful 
in re-joining the broken DNA ends or when the DSB is first recognised by the 
MRE11-RAD50-NBS1 (MRN) complex rather than by Ku70/Ku80 (Symington and 
Gautier, 2011).    
Another important regulatory step that determines the choice between HR and NHEJ 
DSB repair pathway is the process of DSB resection, which is required for HR but 
not NHEJ. Immediately after DSBs, the DSB sites are firstly recognised by the 
MRE11-RAD50-NBS1 (MRN) complex. In conjunction with CtBP-interacting protein 
(CtIP), the RECQ family helicases, and the nucleases EXO1 and DNA2, the MRN 
complex resects DSBs to generate short 3’-single stranded DNA (ssDNA) 
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overhangs, which are immediately coated with replication protein A (RPA) before 
being replaced by RAD51 with the help of the BRCA2-PALB2 complex that plays key 
roles in detecting and repairing interstrand cross-links, particularly at sites of stalled 
DNA replication (Sartori et al., 2007, Zou and Elledge, 2003, Bernstein and 
Rothstein, 2009). The RAD51 nucleofilament, together with various other HR factors, 
then searches and invades into the homologous template forming a displacement 
loop to initiate repair. The second of the broken chromosome is captured and 
anneals the complementary strand of the DNA molecules, leading to the formation of 
two Holiday junctions (HJs). After the process of DNA synthesis by DNA 
polymerases and DNA end ligation of both strands by Ligase I, the double HJ is then 
cleaved by DNA helicase and resolvase enzymes in order to complete repair 
(Moynahan and Jasin, 2010, Krejci et al., 2012).  
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Figure 1.6: DNA double strand break repair mechanisms. In NHEJ, DNA DSBs are recognised by 
the Ku70/80 heterodimer which in turn recruits DNA-PK. The blunt ends of DNA breaks are processed 
by Artemis nuclease. The DNA-PK complex then phosphorylates and stimulated the NHEJ effector 
complex (Ligase IV/XRC44/XLF) that ligates the broken DNA. In HR, ATM is recruited to DSBs via an 
interaction with the MRN (Mre11/Rad50/Nbs1) complex. Once ATM becomes activated, it 
phosphorylates several DNA damage effectors. DSBs are resected forming ssDNA strands by various 
nucleases activities, such as MRE11, EXO1, DNA2 and CtIP. These ssDNAs are immediately coated 
with replication protein A (RPA) before being replaced by RAD51. The Rad51 nucleoprotein filaments 
then induce invasion into the undamaged sister strands forming a Holliday junction (HJ). HR is 
completed by new DNA synthesis and the double HJ is finally cleaved by HJ resolvase enzymes.    
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1.5.2 NBS1 
NBS1 (NBN/Nibrin), the gene product of mutation in Nijmegen breakage syndrome 
(NBS) patients, is the p95 component of the MRE11-RAD50-NBS1 (MRN) complex. 
The MRN complex is one of the main players in cellular response to DSBs, involving 
damage sensing and activation of signaling pathways that control cell-cycle 
checkpoints in response to damage and repair (Stavridi and Halazonetis, 2005). The 
importance of NBS1 in DNA repair is indicated by systemic defects in Nijmegen 
breakage syndrome (NBS)  patients including premature ageing, immunodeficiency 
and a high frequency of malignancies (Kobayashi et al., 2004). Moreover, NBS 
defective cells are hypersensitive to radiation, chromosomal fragility, and abnormal 
cell cycle checkpoint regulation, as well as having a high frequency of malignant 
phenotypes similar to those of ataxia telangiectasia mutated (ATM) (Saito et al., 
2013). The gene responsible for Nijmegen breakage syndrome, NBS1, was originally 
identified in 1998 (Carney et al., 1998, Varon et al., 1998). As shown in Figure 1.7, it 
contains 16 exons encompassing 50kb on chromosome 8q21 (Saar et al., 1997, 
Varon et al., 1998, Kobayashi et al., 2004). Human NBS1 encodes a 754 amino 
acid-NBS1 protein, which is composed of three functional regions: the N-terminus; 
central region; and the C-terminus. The N-terminus of NBS1 contains a forkhead-
associated (FHA) domain and two breast cancer C-terminus (BRCT) domains. The 
FHA/BRCT domain directly interacts with histone γH2AX, the phosphorylated form of 
H2AX in response to the presence of DSBs, then recruits MRE11 and RAD50, 
forming the MRN complex to the vicinity of the DSB sites (Figure 1.7). Moreover, it 
has been shown to interact with MDC1, γH2AX, TOPBP1, and WRN. The C-terminal 
motifs are indispensable for binding to MRE11, ATM, RAD18, and RNF20 (Saito et 
al., 2013). For the functional relationship between ATM and NBS1, NBS1 appears to 
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function as a downstream mediator of ATM in response to DNA damage. ATM 
specifically interacts with and phosphorylates NBS1 on specific residues, serine 278 
and serine 343, in response to DNA damage (Figure 1.7). This process is essential 
for S phase checkpoint activation, formation of DNA damage foci and rescue of 
hypersensitivity to ionizing radiation (Zhao et al., 2000, Gatei et al., 2000, Lim et al., 
2000). However, recent studies revealed that the mutation of members of the MRN 
complex or NBS1 leads to impaired ATM activation. Furthermore, the binding of 
NBS1 is critical for ATM activation to be fully functional in response to DNA damage; 
therefore, NBS1 acts both upstream and downstream of ATM (Cariveau et al., 2007, 
Kang et al., 2005).            
 
 
Figure 1.7: The structure and protein interaction sites of human NBS1/Nibrin. The NBS1 protein 
is composed of three main functional domains: the FHA/BRCT domain at the N-terminus; ATM-
phosphorylated serine residues, S278 and S343, at a central region; and MRE11-binding region at 
the C-terminus. The N-terminal FHA/BRCT domain directly interacts with γ-H2AX, TopBP1 and 
MDC1, whereas the C-terminal motifs are indispensable for binding MRE11, ATM, RAD18, and 
RNF20 (Adapted from (Kobayashi et al., 2004)). 
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1.6 The cell cycle and cancer 
The cell cycle, or cell division cycle, is defined as the tightly controlled series of 
events that take place in a cell leading to its division and duplication. Cell division 
consists of two consecutive steps, mainly characterised by DNA replication and 
segregation of replicated chromosomes into two separate cells. The typical 
mammalian cell cycle is divided into four distinct phases: gap1 (G1), gap2 (G2), DNA 
synthesis (S), and Mitosis (M). The G1 phase prepares the cell for DNA replication, 
and is followed by S-phase during which chromosomes are actively replicated. 
Subsequently, the cell enters a further gap period (G2) prior to chromosome 
segregation and cytokinesis in M phase (Swanton and Jones, 2001). The G1, S and 
G2 represent the interphase of a proliferating cell. Cells in G1 can, before 
commitment to DNA replication, enter a resting state called G0. Cells in G0 account 
for the major part of the non-proliferating cells in the human body and they can re-
enter into G1 if appropriate signals are received (Vermeulen et al., 2003).                    
The M phase is itself composed of two main processes: mitosis, in which the sister 
chromatids are aligned along the equator of the cell and then splits into two identical 
daughter cells; and cytokinesis, in which the cytoplasm and its components are 
equally divided into those cells. Mitosis can be subdivided into four distinct phases: 
prophase, metaphase, anaphase and telophase (Figure 1.8).   
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Figure 1.8: The four main stages of mitosis in MCF-7 cells. Cells were immunostained with 
antibody against α-tubulin (Green), Cells were immunostained with antibody against α-tubulin 
(Green), γ-tubulin (Red) and Nuclei were stained with DAPI (Blue). Cells were visualised with Leica 
TCS SP5 (63X magnification).   
Prophase The chromatin condenses into chromosomes by dehydrating and coiling and CDK1-
CyclinB translocates to the nucleus. 
Metaphase Chromosomes are attached to spindle microtubules and moved to align at the centre of 
the spindle in a “bi-oriented” configuration. Unattached kinetochores generate a checkpoint signal that 
prevents the metaphase/anaphase transition until all of the kinetochores are correctly bi-oriented. 
Anaphase Once the mitotic checkpoint has been approved, the APC ubiquitin ligase is activated. 
Ubiquitin-dependent proteolysis of the inhibitor securin leads to activation of separase, a protease that 
cleaves the cohesin proteins that hold sister chromatids together. This allows the chromosomes to 
separate. 
Telophase After the chromosomes reach the poles, CDK1 activity is inhibited by APC-mediated 
destruction of Cyclin B. The reduction in CDK1 activity allows for reformation of the new nuclear 
envelope, decondensation of chromosomes, dividing the cytoplasmic components and entry into G1.    
 
 
 
 
 
7.5 µm 
59 
 
1.6.1 Cell cycle checkpoints 
The orderly progression of one cell cycle phase to another is crucial for ensuring 
faithful DNA replication and chromosome segregation, thereby preserving genetic 
stability of daughter cells. A complex network of cell cycle control mechanisms, 
called cell cycle checkpoints, are responsible for ensuring that DNA replication 
occurs at  G1 point. The next checkpoint (G2) ensures that mitosis only starts after 
chromatids have been precisely replicated and DNA repair completed (Swanton and 
Jones, 2001). The checkpoint during mitosis ensures that chromosome segregation 
is corrected. Cells can be temporarily arrested at cell cycle checkpoints to allow for 
DNA damage to be repaired. Persistent checkpoint signalling may also result in 
activation of pathways leading to programmed cell death or senescence if damaged 
DNA cannot be repaired (Pietenpol and Stewart, 2002). Defective cell cycle 
checkpoint regulation frequently results in genomic instability, gene mutations, 
chromosome damage, and aneuploidy/polyploidy, all of which can contribute to 
uncontrolled proliferation essential for cancer development (Pietenpol and Stewart, 
2002). The transition from one phase of the cell cycle to the next is regulated by 
different cellular proteins. Key regulatory factors of the cell cycle are CDK/Cyclin 
complexes.  
G1/S checkpoint (restriction point) is the first checkpoint located at the mid G1 
phase, prior to entering S phase, making the critical decision of whether the cell 
should divide, arrest/delay division or enter a resting stage called G0. This 
checkpoint is regulated by the Rb protein (pRb), the product of the retinoblastoma 
tumour suppressor gene. To pass this restriction point, CDK4/6 and CDK2 form 
active complexes with CyclinD and Cyclin E, respectively. The activity of active 
CDK4/Cyclin D and CDK2/Cyclin E complexes induce the phosphorylation of pRb, 
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leading to the inactivation of its function as a transcriptional repressor. When pRb is 
bound to E2F, the complex acts as a growth suppressor, prevents cell cycle 
progression and the cell remains activity in the G1 phase; however, once hyper-
phosphorylated, pRb releases E2F. The release of E2F activates a number of S-
phase genes, including Cyclin D, Cyclin E and Cyclin A, prior entering into the S 
phase (Pietenpol and Stewart, 2002). 
CDK activity is negatively regulated by CDK inhibitors, which specifically inactivate 
CDK/Cyclin complexes and thereby cause cell cycle arrest. These CDK inhibitors 
(CKIs) are divided into two families: the INK4 and the Cip/Kip inhibitors. INK4 CKIs 
include p15INK4B, p16INK4A, p18INK4C, and p19INK4D. The second family, the CIP/KIP 
CKIs, consist of p21CIP1/WAF1, p27KIP1 and p57KIP2. The INK4 family specifically inhibits 
CDK4 and CDK6 activity by displacing the cyclins from CDKs during the early G1 
phase of the cell cycle, while the CIP/KIP family can inhibit CDK activity during all 
phases of the cell cycle. Both families of CDK inhibitors play an important role in anti-
proliferative signals by arresting cells in G1 to enable such diverse processes as 
repair of DNA damage, terminate differentiation and cellular senescence (Sherr and 
Roberts, 1995). Accumulating evidence suggests that the signal for the G1/S 
checkpoint is unreplicated DNA rather than DNA damage. After passing the 
restriction point, pRb is maintained in a hyper-phosphorylated state by the sequential 
activities of CDK2/Cyclin A and CDK1/CyclinA, thereby ensuring cell cycle 
progression into G2 phase. During S and G2 phases, cells accumulate CDK1/Cyclin 
B1 complexes in their inactive form due to the inhibitory phosphorylation by Wee1 
(Russell and Nurse, 1987) and Mik1 kinase (Lundgren et al., 1991). CDC25C 
phosphatase is the main factor that activates CDK1/Cyclin B1 complex, leading to 
the onset of mitosis. Therefore, the CDK1/CyclinB1 complex is also known as M-
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Phase-promoting factor (MPF) (Rhind and Russell, 2012, Pietenpol and Stewart, 
2002). However, when cells encounter DNA damage in G2, the G2/M checkpoint 
stops the cell cycle in order to prevent the cell from entering mitosis. In response to 
DNA damage during G2 phase, members of PI-3K family, including ATM, ATR and 
DNA-PK become activated and start signal transduction pathways that regulate cell 
cycle progression and DNA repair (Canman and Lim, 1998). The ATM-dependent 
signalling induced by DNA damage triggers the activation of CHK1 and CHK2 
kinases (Sanchez et al., 1997, Furnari et al., 1997, Matsuoka et al., 1998). The 
activated CHK1 and CHK2 then phosphorylate CDC25C. This phosphorylation 
promotes the binding of CDC25C with 14-3-3 adaptor proteins and inhibits the ability 
of CDC25C to activate CDK1/Cyclin B1, leading to cell cycle arrest at the G2/M 
transition. Several studies also revealed that CHK1 and CHK2 mediated 
phosphorylation of p53 play an important role in the stabilising DNA repair proteins in 
response to DNA damage (Shieh et al., 2000). Moreover, p53-dependent 
transcription elevates the CDK inhibitor p21CIP1, which interacts with CDK/Cyclin 
complexes to inhibit the phosphorylation of pRB. Hypo-phosphorylated pRB tightly 
binds to E2F, preventing E2F from mediating the biosynthesis of Cyclin B1 and 
CDK1 (Pietenpol and Stewart, 2002). Both tumour suppressors, p53 and p21
CIP1
, 
have been shown to be necessary for maintaining the G2/M arrest in response to 
DNA damage and to maintain genomic stability (Di Leonardo et al., 1994). Once 
DNA damage is completely repaired, the DNA damage checkpoint is silenced so that 
cell cycle progression is allowed to resume by the upregulation and activation of 
CDK1/CyclinB complex, leading to the onset of mitosis. 
In mitosis, the spindle assembly checkpoint (SAC), also known as mitotic checkpoint, 
acts to maintain genomic stability by delaying the segregation of chromosome in 
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anaphase until sister chromatids are properly attached and bi-oriented on the 
microtubule spindle via their specialised protein structures, called kinetochores 
(Lara-Gonzalez et al., 2012, Kops et al., 2005, Musacchio and Salmon, 2007). In the 
presence of unattached kinetochores the SAC is ‘on’ and anaphase is halted.  
During early mitosis, unattached kinetochores contribute to the formation of the 
spindle assembly checkpoint (SAC), consisted of Mad2, BubR1, Bub3 and CDC20, 
leading to the CDC20-dependent inhibition of the anaphase-promoting 
complex/cyclosome (APC/C). Once all sister chromatids are aligned with their 
kinetochores attached to the spindle (metaphase), the SAC signal is silenced and 
releases CDC20. The free CDC20 then activates APC/C activity, resulting in the 
ubiquitination and degradation of Cyclin B and securin. The degradation of securin 
activates separase, which in turn cleaves a subunit of the cohesin ring structure, 
Scc1. This event triggers the separation of sister chromatids and marks the initiation 
of anaphase. Meanwhile, the loss of Cyclin B also inactivates the master mitotic 
kinase CDK1/Cyclin B, initiating cytokinesis and the mitotic-exit programme 
(Musacchio and Salmon, 2007, Lara-Gonzalez et al., 2012).  
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1.7 Kinesins and Cancer 
The mitotic spindle is an effective and validated target for cancer chemotherapeutic 
drugs. Well-known anti-mitotic drugs, such as taxanes and vinca alkaloids, which 
target tubulin and interfere with mitotic-spindle microtubule dynamics, are clinically 
successful anticancer drugs for metastatic breast cancer, as well as lung and ovarian 
carcinoma. Unfortunately, these spindle poisons have limitations, such as the 
development of drug resistance and dose-limiting toxicities, making it necessary to 
find alternative ways for targeting the mitotic spindle. An important family of proteins 
that has been shown to be essential for mitosis and that is emerging as a potential 
molecular target for novel chemotherapeutic intervention is the kinesin superfamily 
(Rath and Kozielski, 2012). 
The kinesin (also known as KIF) superfamily is a group of molecular motor proteins 
that consume energy from ATP hydrolysis to move along microtubules (MT) toward 
plus end (Vale et al., 1985, Vale et al., 1996, Vicente and Wordeman). It is 
composed of two main functional domains: an ATP-hydrolysing motor domain and a 
tail domain. The motor domain is highly conserved among the different kinesin 
families and enables motor binding and stepping along microtubules by converting 
the chemical energy of ATP hydrolysis into a mechanical force (Goldstein and Philp, 
1999). Because of their specialised structure, KIF proteins have been functionally 
linked to several essential cellular activities, including mitotic spindle formation and 
chromosome partitioning, and migration, as well as intracellular movements of 
organelles and vesicles (Rath and Kozielski, 2012, Hirokawa et al., 1998). In mitosis, 
the activities of KIFs on the spindle microtubules are precisely regulated to ensure 
that mitotic events are orchestrated in the correct order throughout mitosis. 
Currently, at least 12 kinesins have been implicated in coordinating mitosis and 
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cytokinesis. KIFC1 (a member of the kinesin-14 family), Eg5 (a member of the 
kinesin-5 family),  and KIF2A (a member of the kinesin-13 family) play roles in mitotic 
spindle dynamics; KIF2C (a member of the kinesin-13 family), KIF18 (a member of 
the kinesin-8 family), CENP-E (a member of the kinesin-7 family), KIF14 (a member 
of the kinesin-3 family), and KID (a member of the kinesin-10 family) are essential for 
chromosome alignment; KIF4A and KIF4B (members of the kinesin-4 family) is 
associated with anaphase spindle dynamics; and MKLP1 and MKLP2/KIF20A 
(members of the kinesin-6 family) are required for cytokinesis (Zhu et al., 2005, Rath 
and Kozielski, 2012). Besides the role in mitosis, the impacts of kinesins in tumour 
development and progression, as well as in the development of drug resistance, are 
beginning to emerge in more detail (Rath and Kozielski, 2012). 
1.7.1 KIF20A 
Kinesin family member 20A (KIF20A), also known as RAB6KIFL/mitotic kinesin-like 
protein 2 (MKLP2), is a newly identified member of the Kinesin superfamily proteins 
(KIFs), which was originally identified to contribute to Golgi apparatus dynamics via 
interaction with the GTP-bound form of Rab6 during interphase (Echard et al., 1998). 
KIF20A has previously been reported to accumulate in mitotic cells, where it 
localises to the midzone of the spindle during anaphase and at the midbody during 
telophase (Hill et al., 2000, Fontijn et al., 2001). KIF20A is believed to be essential 
for cell cycle regulation during successful cytokinesis, and its depletion causes a 
failure of cleavage furrow ingression and cytokinesis (Hill et al., 2000, Neef et al., 
2003, Fontijn et al., 2001). KIF20A is required to relocate and regulate chromosomal 
passenger protein Aurora B and the mitotic regulator PLK1 to the central spindle 
during anaphase (Gruneberg et al., 2004, Neef et al., 2006). Moreover, a study in 
Drosophila also showed that Subito, which is an orthologue of KIF20A in mammalian 
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cells, localises to the spindle midzone during anaphase and is also required for 
localisation of PLK1, INCENP and Aurora B, which are essential for cytokinesis 
(Cesario et al., 2006). Microinjection of antibodies against KIF20A led to multinuclear 
cells, further supporting a critical role of KIF20A in cytokinesis (Taniuchi, Nakagawa 
et al. 2005). KIF20A expression appears to be tissue specific. It is widely expressed 
in human fetal tissues. It is also expressed in the adult during haematopoiesis and in 
various proliferating tissues, and is abundantly expressed in adult thymus, bone 
marrow and testis (Lai et al., 2000). By contrast, there is no expression of KIF20A in 
adult quiescent human liver cells, suggesting that KIF20A contributes to both normal 
and pathological proliferation as well as cancer progressiveness in human cells 
(Gasnereau et al., 2012). Recent studies revealed that KIF20A is overexpressed in 
pancreatic ductal adenocarcinoma (PDAC) cells and its downregulation inhibits cell 
growth in pancreatic and gastric cancer (Yan et al., 2012).  The role of KIF20A in 
mitotic spindle formation and cytokinesis has been well studied in mitosis. However, 
little is known about the transcriptional regulation of KIF20A and it remains to be 
elucidated whether KIF20A plays a role in carcinogenesis or anti-cancer drug 
resistance.  
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1.8 FOXM1 
1.8.1 FOXM1 gene and its protein structure 
Transcription factors are proteins that bind specifically to defined DNA sequences to 
promote gene expression. FOXM1, also known as Trident (in mouse), WIN or INS-1 
(in rat), MPP2 (partial human DNA), and HFH-11 (in human), belongs to the 
superfamily of forkhead transcription factors. The forkhead family comprises a large 
number of transcription factors which share an evolutionally conserved ‘winged helix’ 
DNA binding domain (Korver et al., 1997a). FOXM1 regulates the expression of its 
target gene via its binding to sequence-specific motifs on DNA sequence 
TAAA(C/T)A (Korver et al., 1997b) and activates cell proliferation and regulatory cell 
cycle-associated genes (Laoukili et al., 2007). Recent research has revealed that 
FOXM1 is a direct transcriptional target of FOXO3a, an important downstream 
effector of PI3K-AKT-FOXO signalling pathway. Activated FOXO3A antagonizes 
FOXM1 activity by competitively binding to the same target genes, which are 
involved in cancer initiation, progression and chemotherapeutic sensitivity and 
resistance (Lam et al., 2013, Karadedou et al., 2012). 
As shown in Figure 1.9A, the human FOXM1 gene consists of 10 exons, spanning 
approximately 25 kb on the 12p13.3 chromosomal band. Two exons, named exon 
Va and Vlla, can be alternatively spliced, to provide three distinct isoforms, including 
FOXM1a, FOXM1b, and FOXM1c (Lam et al., 2013, Koo et al., 2012). The FOXM1a 
isoform harbours both Va and Vlla exons and is transcriptionally inactive due to the 
disruption of its transactivation domain by the inhibitory exon Vlla. However, 
FOXM1a can still interact with DNA. Therefore, it is considered to function as a 
dominant negative regulator of other FOXM1 isoforms. By contrast, both FOXM1b, 
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which contains none of the alternative exons, and FOXM1c which contains only the 
Va exon, are transcriptionally active and can directly promote target gene expression 
in an isoform-specific manner (Ye et al., 1997).  Interestingly, the FOXM1b isoform is 
expressed mostly in testis, suggesting that FOXM1 activity can be modulated 
through tissue-specific alternative splicing (Yao et al., 1997). The transcriptional 
activity of FOXM1 is regulated in part through dynamic interactions between its 
different domains. The full-length protein has three main components, including a 
central DNA-binding Forkhead box (FKH), an N-terminal auto-inhibitory domain 
(NRD) and a C-terminal transcriptional transactivation domain (TAD) (Figure 1.9B).  
Figure 1.9: The FOXM1 gene and its mRNA and protein structure. (A) The FOXM1 gene is 
composed of 10 exons. Va and VIIa can be spliced to generates three different splice variants, 
encoding for three FOXM1 protein isoforms, namely FOXM1a, FOXM1b, and FOXM1c. (B) The 
structure and phosphorylation sites of FOXM1. Phosphorylation by PlK1 increases FOXM1 activity, 
while CDK/CyclinA relieves the inhibitory function of the NRD. CHK2 enhances FOXM1 stability and 
Raf/MEK/MAPK mediated phosphorylation stimulates nuclear translocation. (NRD: N-terminal 
Repressor Domain, FKH: Forkhead DNA Binding Domain, TAD:  Transactivation Domain, NLS: 
Nuclear localization signals) 
68 
 
1.8.2 FOXM1 in cell cycle and proliferation 
In normal cells, the FOXM1 transcription factor plays an essential role in the 
regulation of a wide spectrum of cellular activities, including cell proliferation, cell 
cycle progression, cell differentiation, DNA damage repair, tissue homeostasis, and 
apoptosis (Koo et al., 2012). FOXM1 is considered as a critical cell cycle regulator, 
which controls the expression of genes required for both G1/S and G2/M transition 
(Laoukili et al., 2005; Wang et al., 2005). It is also essential for mitotic entry and 
progression, ensuring the maintenance of chromosome stability (Laoukili et al., 
2005). The expression and the transcriptional activity of FOXM1 depend on the 
progression of cell cycle.  FOXM1 mRNA and protein levels are actively high in 
proliferating cells at the entry to S phase and persist throughout the G2 and M-
phases, and then gradually degrade during mitotic exit (Korver et al., 1997a, Laoukili 
et al., 2007). Conversely, FOXM1 expression is decreased in quiescent and 
terminally differentiated cells (Laoukili et al., 2008a, Yao et al., 1997, Korver et al., 
1997a). FOXM1 induces the expression of Cyclin A2, JNK1, ATF2 and CDC25A 
phosphatase, all of which are critical for G1/S transition and DNA replication (Wang 
et al., 2002). In addition, FOXM1 also regulates the transcription of Skp2 and Cks1, 
essential for the ubiquitinylation and degradation of the Cyclin-dependent kinase 
inhibitors (CKIs), p21CIP1 and  p27KIP1, suggesting that FOXM1 negatively regulates 
the stability of p21CIP1 and p27KIP1, leading to increased CDK2 activity and enhanced 
G1/S transition (Costa, 2005, Wang et al., 2005a, Wang et al., 2008).  
Progression through the G2/M transition requires activation of the CDK1-Cyclin B 
complex through the removal of inhibitory phosphates at Thr-14 and Tyr-15 by the 
CDC25B and CDC25C phosphatases (Borgne and Meijer, 1996, Wells et al., 1999, 
Timofeev et al., 2010). Inactivation of FOXM1 results in diminished expression of 
69 
 
CDC25B and delayed accumulation of Cyclin B1, inhibiting CDK1/Cyclin B kinase 
activation and blocking progression into mitosis (Costa et al., 2005a). Moreover, 
during mitosis, FOXM1 also controls the expression of several genes critical for the 
spindle assembly checkpoint, chromosome segregation and cytokinesis, such as 
Aurora B kinase, Suvivin, Polo-like kinase 1 (PLK1), CENP-A, B and F isoforms 
(Laoukili et al., 2008a, Koo et al., Wang et al., 2005a). Consistently, inhibition of 
FOXM1 expression leads to cell cycle arrest, mitotic spindle defects, chromosome 
mis-segregation, and mitotic catastrophe (McGovern et al., 2009). Collectively, these 
published studies indicate that FOXM1 is a crucial cell cycle regulator. It stimulates 
the expression of multiple proteins required for DNA replication and mitosis (Figure 
1.10). In late M phase and early G1, FOXM1 is actively degraded during mitotic exit 
by the APC/C complex to prevent unscheduled expression of mitotic proteins and 
this degradation also requires Cdh1, a well-known co-factor of APC/C (Laoukili et al., 
2008a). Interestingly, a recent study in our laboratory has provided evidence that 
FOXM1 activity is also controlled by SUMO1 conjugation and deconjugation. 
SUMOylation of FOXM1 promotes its degradation in the cytoplasm by the APC/Cdh1 
complex, leading to the silencing of FOXM1 activity and, consequently, mitotic delay 
(Myatt et al., 2014). In addition, FOXM1 itself has an auto-repressive function. The 
interaction of N-terminal auto-inhibitory domain with the C-terminal half of the 
transcription factor leads to the inactivation of FOXM1 activity (Laoukili et al., 2008b, 
Park et al., 2007). The phosphorylation of pRb by CDK4/Cyclin D1 has been shown 
to be important for relieving FOXM1 repression by disrupting the FOXM1 N-terminus 
TAD interaction thereby strongly stimulating FOXM1 transcriptional activity for G1/S 
transition, whereas CDK2/Cyclin A complex is required to phosphorylate and activate 
FOXM1 during G2 (Laoukili et al., 2008b, Wierstra and Alves, 2006).  
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Figure 1.10:  FOXM1 is a crucial cell cycle regulator of genes essential for DNA replication, 
G2/M progression, chromosomal segregation and cytokinesis. FOXM1 is expressed in G1 phase 
and reaches its maximum level in late G1. This is maintained throughout G2 and mitosis. FOXM1 is 
translocated to the nucleus by the activation of MAPK signalling. FOXM1 transcriptional activity 
requires binding of the CDK2/Cyclin A during G1/S phase or CDK1/Cyclin B during G2/M phase. The 
binding of CDK1/Cyclin B complexes to its C-terminal transactivation domain is required for efficient 
phosphorylation of the CDK site, thereby mediating recruitment of the CBP coactivator protein. 
FOXM1 transcriptional target genes involved in G2/M progression include, PLK1, CENP-F, CDC25B, 
Aurora B and Cyclin B genes. In early G2 phase, PLK1 phosphorylates Cyclin B. This mediates its 
nuclear import and activates the onset of mitosis. PLK1 also participates in mitotic exit by activating 
the CDC20–APC/C complex to degrade the CDK1/Cyclin B complex. Aurora B kinase activity is 
required for both cytokinesis and accurate chromosome segregation because it regulates the 
localisation of several spindle assembly checkpoint proteins, such as BubR1 and Mad2. FOXM1 also 
regulates transcription of CENP-A and CENP-B, both of which are essential for kinetochore assembly. 
(Adapted from (Costa, 2005, Wang et al., 2005a)) 
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1.8.3 FOXM1 in tumorigenesis and cancer progression 
Since FOXM1 has been shown to play critical roles in regulating the expression of 
genes involved in cell proliferation and cell cycle progression, it is not surprising that 
elevated expression of FOXM1 has been detected in a wide range of cancer cell 
lines as well as in tumour tissues obtained from cancer patients (Koo et al., 2012). 
Some of the early studies revealed that FOXM1 is upregulated in basal cell 
carcinoma (BCC) in comparison to normal skin cells (Teh et al., 2010). Genome-
wide gene expression profiling analysis identified FOXM1 as one of the most 
commonly upregulated genes in solid tumours of the breast, prostate, lung, bladder, 
ovary, colon, liver, kidney, stomach, and pancreas (Pilarsky et al., 2004, Uddin et al., 
2011). An aberrant increase in the activity or expression of FOXM1 has also been 
found in the development of a variety of other cancers including cervical cancer 
(Chan et al., 2008), esophageal squamous cell carcinoma (Hui et al., 2012), head 
and neck squamous cell carcinoma (Gemenetzidis et al., 2009), nasopharyngeal 
carcinoma (Chen et al., 2012), ovarian cancer (Zhao et al., 2014), acute myeloid 
leukaemia (AML) (Nakamura et al., 2010), oral cavity squamous cell carcinoma 
(Chen et al., 2009) and malignant peripheral nerve sheath tumours (Yu et al., 2011).  
More importantly, elevated expression of FOXM1 is also correlated with clinical 
aggressive behaviour and poor prognosis of numerous human cancers, suggesting 
that FOXM1 can serve as a novel prognostic marker for cancer patients (Yu et al., 
2011, Zhao et al., 2014, Yang et al., 2009, Koo et al., 2012). Therefore, it has 
become apparent that FOXM1 not only promotes tumorigenesis by increasing 
proliferative capacity and leading to uncontrolled cell division at the early stage of 
cancer development but also affecting several features of cancer progression 
including enhanced angiogenesis, tumour invasion, migration and metastasis, 
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increasing the resistance of cancer cells to chemotherapy, inducing replicative 
immortality, contributing to genomic instability and metabolism (Zhang et al., 2008, 
Raychaudhuri and Park, 2011, Halasi and Gartel, 2013b, Koo et al., 2012, S.C. 
Wilson et al., 2011). 
The role of FOXM1 in angiogenesis is strongly associated with the activation of 
vascular endothelial growth factor (VEGF), which is the main angiogenesis protein 
produced and secreted by cancer cells. FOXM1 has been reported to directly 
regulate the promoter activity of VEGF. Depletion of FOXM1 caused decreased 
expression and activity of VEGF resulting in impaired angiogenesis, whereas 
overexpression of FOXM1 increased VEGF expression and promoted angiogenesis 
in brain, gastric, and breast cancer cell lines. This evidence suggests that FOXM1 is 
required for VEGF induced angiogenesis in cancer cells (Zhang et al., 2008, Li et al., 
2009, Karadedou et al., 2012, Koo et al., 2012). Moreover, FOXM1 has also been 
described as the master regulator of tumour metastasis, due to its effects on various 
aspects of the metastatic process, including epithelial-mesenchymal transition 
(EMT), migration, invasion, and pre-metastatic niche formation (Halasi and Gartel, 
2013a, Koo et al., 2012, Raychaudhuri and Park, 2011). Matrix metalloproteinases 
(MMPs) have a critical role in the processes of tumour cell invasion and metastasis 
by degrading the basement membrane collagen (Overall and Kleifeld, 2006, Wang et 
al., 2010). It has been shown that downregulation of FOXM1 causes decreased 
expression and activity of MMP-2 and MMP-9, leading to reduced migration and 
invasion of pancreatic, breast, and bone cancer cell lines (Wang et al., 2007, Ahmad 
et al., 2010, Dai et al., 2007). FOXM1 directly activates the transcriptional activity of 
MMP-2 (Dai et al., 2007), and indirectly regulates MMP-9 through its target JNK1 to 
induce migration and invasion of cancer cells (Wang et al., 2008). Moreover, 
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overexpression of FOXM1 with the loss of its inhibitor p19Arf induces liver cancer 
cells to undergo metastasis to the lung (Park et al., 2010). From the same study, 
Park and colleagues also observed that FOXM1 directly regulates the expression 
and activity of Stathmin, lysyl oxidase (LOX), and lysyl oxidase like‐2 (LOXL2) to 
increase cell invasiveness in cancer cells (Park et al., 2010). 
1.8.4 FOXM1 and DNA damage 
Recently, the novel role of FOXM1 in DNA damage repair and in the maintenance of 
genome stability has been demonstrated in Foxm1-deficient MEF cells which exhibit 
defects in cytokinesis and chromosome mis-segregation as well as an increase in 
DNA breaks (Tan et al., 2007). High levels of DNA damage, as evidenced by γH2AX 
foci, were also observed in U2OS cells depleted of FOXM1 using siRNA, and this 
correlated with reduced expression of the base excision repair factor X-ray cross-
complementing group 1 (XRCC1) and breast cancer-associated gene 2 (BRCA2), 
two genes involved in DNA repair (Tan et al., 2007). Although both genes have been 
proposed as FOXM1 targets in U2OS cells, knockdown of FOXM1 in breast cancer 
cells did not cause the downregulation of its proposed downstream targets, XRCC1 
and BRCA2 (Kwok et al., 2010b). This study suggested that FOXM1 might regulate 
the expression of other genes involved in DNA damage repair pathways (Kwok et al., 
2010b).  Interestingly, a recent study from our laboratory has demonstrated for the 
first time that FOXM1 is required for DNA double strand break (DSB) repair by HR 
repair but dispensable for NHEJ repair (Monteiro et al., 2013). FOXM1 has also been 
identified as a direct transcriptional regulator of HR repair proteins, such as BRIP 
(Monteiro et al., 2013), Rad51 (Zhang et al., 2012), BRCA2 (Tan et al., 2007), EXO1 
(Zhou et al., 2014), RFC4, and cyclin D1 (Jirawatnotai et al., 2011). Interestingly, 
FOXM1 not only controls DNA damage repair, but FOXM1 itself is also regulated in 
74 
 
response to DNA damage. Treatment with DNA damaging agents, such as IR and 
DNA damaging agents has been reported to induce FOXM1 phosphorylation by 
CHK2 , leading to its stabilisation at the protein level (Tan et al., 2007). 
1.8.5 FOXM1 and Chemotherapy resistance 
Besides mitosis, tumorigenesis and DNA Repair, FOXM1 has also been implicated 
in mediating chemotherapy sensitivity and resistance in various types of cancer 
including breast cancer (Francis et al., 2009). In breast cancer cell lines, 
upregulation of FOXM1 expression has been found to confer resistance to DNA 
damaging agents, such as cisplatin, doxorubicin and epirubicin, and its depletion 
was able to resensitise resistant cell lines to the respective cytotoxic drugs (Kwok et 
al., 2010a, Millour et al., 2011, Monteiro et al., 2013, Park et al., 2012). FOXM1 has 
also been related to genotoxic drug resistance in glioblastoma. FOXM1 knockdown 
sensitises resistant glioblastoma cells to alkylator temozolomide by downregulating 
the expression of DNA-repair gene Rad51 (Zhang et al., 2012). As DNA damaging 
agents exert their effect by inducing DNA damage and cell death and FOXM1 has 
been reported to drive the transcription of DNA repair genes. As a result, FOXM1 
may promote resistance through enhancing the expression of DNA damage repair 
genes. Another possible epirubicin resistance mechanism through FOXM1 is 
mediated via the loss of p53 expression, which in turn suppresses E2F activity by the 
activation of the retinoblastoma pRB and/or the increase in ATM expression and 
activation (Millour et al., 2011). In addition, FOXM1 has also been associated with 
paclitaxel or docetaxel resistance in breast, ovarian, and gastric cancer cell lines 
(Carr et al., 2010, Zhao et al., 2014, Li et al., 2014). Car and colleagues revealed 
that FOXM1 can alter microtubule dynamics by regulating directly the expression of 
the tubulin destabilising protein Stathmin in order to protect tumour cells from 
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paclitaxel-induced apoptosis (Carr et al., 2010). Therefore, targeting FOXM1 could 
be a viable strategy in circumventing acquired resistance. 
Figure 1.11: Functional roles of FOXM1. FOXM1 regulates a variety of crucial cellular activities 
through regulating the transcriptional activity of its target genes, which is critical for cell cycle 
progression, cell proliferation, DNA damage repair, angiogenesis, cell migration, cellular senescence 
and chemotherapeutic drug resistance. Adapted from (Koo et al., 2012). 
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1.9 Thesis Aims 
Epirubicin and paclitaxel are the most effective and widely used chemotherapeutic 
agents for treating patients with advanced or metastatic breast cancer, triple 
negative breast cancers or ER-positive cancers that have become resistance to 
endocrine therapy. Resistance to chemotherapy represents the main obstacle 
against the successful management of breast cancer. Understanding the molecular 
mechanisms underlying epirubicin and paclitaxel resistance is thus crucial for the 
development of effective chemotherapeutic strategies for breast cancer treatment.   
Overexpression of the oncogenic transcription factor FOXM1 has been implicated in 
the development of drug resistance to various cytotoxic agents. However, the exact 
molecular mechanism underlying sensitivity and resistance to epirubicin and 
paclitaxel are not completely understood. Therefore, the aim of this study is to 
elucidate the role of FOXM1 in the development of epirubicin and paclitaxel 
resistance in breast cancer. Epirubicin and paclitaxel are known to act through 
distinct mechanisms. Therefore, this study has been divided into two main parts: 
i. To investigate the role of FOXM1 in DNA damage response and epirubicin 
resistance. 
ii. To investigate the role of FOXM1 in mitotic control and paclitaxel resistance. 
 
 
 
 
 
 
77 
 
 
 
 
 
 
 
CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Cell culture and cell lines 
2.1.1 The human breast cancer cell lines: MCF-7 and MDA-MB-231 
The human breast cancer MCF-7 and MDA-MB-231 cell lines originated from the 
American Type Culture Collection and were acquired from Cancer Research UK 
(London, UK), where they were tested and authenticated. Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (Sigma, Poole, UK) supplemented with 4 mM 
L-glutamine and penicillin–streptomycin (Gibco), and 10% fetal calf serum (FCS) 
(First Link Ltd, Birmingham, UK) in a humidified incubator at 37°C with 10% CO2.    
2.1.2 MCF-7 EpiR and MCF-7 TaxR 
The epirubicin resistant MCF-7 (MCF-7 EpiR) cells and the paclitaxel resistant MCF-7 
(MCF-7 TaxR) cells were previously established in the laboratory by chronic 
exposure of the parental MCF-7 cells to stepwise increase concentrations of both 
drug until they acquired resistance to 10 µM epirubicin and 0.05 µM paclitaxel, 
respectively (Millour et al., 2011, Khongkow et al., 2013). Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (Sigma, Poole, UK) supplemented with 4mM L-
glutamine and penicillin–streptomycin (Gibco), and 10% fetal calf serum (FCS) (First 
Link Ltd, Birmingham, UK) in a humidified incubator at 37°C with 10% CO2.    
2.1.3 Mouse embryonic fibroblasts (MEFs) 
The wild-type and Foxm1-/- mouse embryonic fibroblasts (MEFs) as previously 
described (Laoukili etal., 2005), were kind gifts from Professor René Medema 
(Netherlands Cancer Institute, Amsterdam, the Netherlands). Cells were also 
cultured in Dulbecco’s Modified Eagle’s Medium (Sigma, Poole, UK) supplemented 
with 4mM L-glutamine and penicillin–streptomycin (Gibco), and 10% fetal calf serum 
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(FCS) (First Link Ltd, Birmingham, UK) in a humidified incubator at 37°C with 10% 
CO2.    
2.1.3 HeLa cells carrying DR-GFP 
The HeLa cell line carrying the DR-GFP (direct repeat-green flouorescent protein) 
reporter construct, as described previously (Pierce et al., 1999), was a gift from 
Professor Maria Jasin (Memorial Sloan-Kettering Cancer Center, New York, USA). 
Cells were cultured as described above for MCF-7 cells. 
2.1.4 Maintaining Cultured Cells 
Adherent cells were cultured and split at approximately 80% confluency (80% of the 
flask surface covered by cell monolayer). To sub-culture, the culture medium was 
aspirated from the flask and the cells were gently washed once with sterile PBS 
(Oxord Ltd, Basingstoke, UK) to get rid of any FCS in the residual culture media. 
Cells were detached by incubation 1x trypsin diluted in EDTA (Sigma-Aldrich, UK) at 
37°C. After being detached, the cells were then resuspended in the completed media 
to stop the trypsin reaction and transferred into the new flask or the appropriate cell 
culture dishes. 
2.1.5 Cell line storage 
Healthy and low passage cells were trypsinised, as described above, resuspended in 
culture media and transferred into a sterile centrifuge tube. The cells were collected 
by centrifuging at 800×g for 4 min. The cell pellet was resuspended in 1 mL of sterile 
freezing solution, containing 10% di-methyl sulfoxide (DMSO) in FCS (Sigma-
Aldrich, UK) and then transferred into suitable vials or cryotubes.  The tube was 
placed into the isopropanol freezing box (VWR International, Lutterworth, UK) at -
80°C overnight before storage in liquid nitrogen. 
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For defrosting cells, cryotubes were rapidly thawed by placing them in a 37°C water 
bath. Cell suspension was mixed with 1 mL of complete medium and centrifuged at 
800×g for 4 min. The freezing solution was discarded and the cell pellet were 
resuspended in the fresh complete medium and placed into an appropriate culture 
flask to recover and grow. 
2.2 Drug treatment 
Epirubicin (2 mg/mL) (Medac, Germany) and Paclitaxel (6 mg/mL) (Teva UK Limited, 
East Sussex, UK) were obtained from Imperial College Healthcare, UK. Both 
chemotherapeutic agents were stored at 4°C. Thiostrepton (from Streptomyces 
azureus, 90% purity) was obtained from Sigma, UK and stored at -20°C. 
2.3 Plasmid constructs 
The pcDNA3-FOXM1B expression plasmid has been described previously (Leung et 
al., 2001, Kwok et al., 2010). The pmCherry-FOXM1B expression plasmid was 
generated by cloning the full-length FOXM1 cDNA from pcDNA3-FOXM1B into the 
EcoRI and BamHI sites of the pmCherry-N1 vector (Clontech, Mountain View, CA, 
USA). The pCMV-I-Scel was a gift from Dr. Joanna Morris (University of 
Birmingham, UK). The human NBS1 promoter-luciferase constructs have previously 
been described (Chiang et al. 2003). Putative forkhead site mutagenesis within the 
NBS1 promoter was generated in the laboratory using Quickchange Site-Directed 
Mutagenesis Kit according to the manufacturer’s instructions (Agilent technologies, 
CA, USA).  
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2.3.1 Cloning of WT and mut KIF20A luciferase reporter constructs 
To generate KIF20A-WT and KIF20A-MUT luciferase reporter constructs, the 
KIF20A-WT, KIF20A-MUT1, and KIF20A-MUT2 fragments (Figure S10) were initially 
designed and synthesised by GeneArt (Life Technologies, Darmstadt, Germany). 
The synthesised DNA fragments were then amplified and cleaved with the restriction 
enzymes XhoI and Bglll and cloned into the XhoI/Bglll sites of the pGL3-basic vector 
(Promega, Madison, WI). DNA extracted from all the positive clones were re-
digested with XhoI and Bglll enzymes and performed gel electrophoresis to confirm 
the gene inserts (as shown in the Figure 4.7B). 
2.4 Transfection 
2.4.1 Gene Silencing with Small Interfering RNAs (siRNAs) 
For gene silencing, cells were transiently transfected with siRNA SMARTpool 
reagents purchased from Thermo Scientific Dharmacon (Lafayette, CO, USA) using 
Oligofectamine (Invitrogen, UK) according to the manufacturer’s instructions. All 
siRNAs used for the work in this thesis were ON-TARGETplus SMARTPool siRNAs 
(Dharmacon Thermo Scientific, CO, USA). This technology comprises a mixture of 4 
distinct siRNAs against the target gene. Pooling reduces the concentration of each 
individual siRNA therefore decreasing potential off-target effects. The SMARTPool 
siRNAs used were:  FOXM1 siRNA (L-009762-00) targeting all isoforms of FOXM1, 
NBS1 siRNA (L-009641-00), KIF20A siRNA (J-004957-06) and the NS control siRNA 
(D-001810-10-05), confirmed to have minimal targeting of known genes. All the 
siRNA were diluted to 20 µM in 1X siRNA buffer and stored at -20°C. Briefly, one day 
before transfection, cells were plated into six-well culture dishes to get a 70%-80% 
confluency at the time of transfection. For each well, 5 µL Oligofectamine (Invitrogen, 
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UK) was diluted with 60 µL of Opti-MEM (Life Technology, UK), mixed gently and 
incubate at room temperature for 5 min. Then the siRNA dilution was prepared by 
adding 7.5 µL of 20 µM siRNA stock in 250 µL of Opti-MEM. The diluted 
Oligofectamine was combined with the diluted siRNA, vortexed briefly and incubated 
for 20 min at room temperature to allow the siRNA/Oligofectamine complexes to 
form. Opti-MEM was added to final volume of 500 µL. The culture media was 
removed and the cells were washed once with warm PBS, the siRNA-Oligofectamine 
transfection mixtures were then added to the cells. The plate was returned to 
incubate at 37°C. 6 h after transfection, the completed media was added to each 
well. The cells were incubated at 37°C in a CO2 incubator for 24-72 h until they are 
ready to assay for gene knockdown. 
2.4.2 FuGENE 6 transfection 
The cells were transfected with DNA plasmids using the FuGENE 6 transfection 
reagent (Roche Diagnostics, West Sussex, UK) at a ratio of 1:3 ratio (1 µg of DNA 
plasmid: 3 µL of FuGENE 6). Briefly, one day before transfection, cells were plated 
into six-well culture dishes to get a 50%-60% confluent at the time of transfection. 
FuGENE 6 was diluted in serum-free DMEM medium (Sigma-Aldrich, Poole, UK) 
and incubated for 5 min at room temperature. 1 µg of the DNA plasmids was added 
into the diluted FuGENE 6, vortexed briefly and incubated for 15 min at room 
temperature to allow the DNA/Fugene 6 complex to form. The DNA/Fugene 6 
complex was then added into the cells in a drop-wise manner. Cells were then 
incubated at 37°C in a CO2 incubator for 24-72 h until they were ready to be assayed 
for gene expression. 
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2.4.3 Xfect mESC transfection 
Xfect Mouse Embryonic Stem Cell Transfection Reagent (Xfect mESC) was used to 
transfect MEFs at a 2:1 ratio (5 µg of DNA plasmid: 2.5 µL of Xfect mESC reagent). 
One day before transfection, early passage of WT or Foxm1-/- MEFs were plated into 
six-well culture dishes to get an approximately 70-80% confluent at the time of 
transfection. For each transfection, 5 µg of plasmid DNA was diluted in 95 µL of 
Xfect reaction buffer, and 2.5 µL of Xfect mESC polymer was diluted separately in 
97.5 µL of Xfect reaction buffer. The diluted plasmid DNA was then mixed with the 
Xfect mESC polymer dilution and incubated at room temperature for 10 min to allow 
nanoparticle complexes to form. The nanoparticle complex solution was next 
dropwised to the cells and incubated at 37°C in a CO2 incubator for 3 h before 
replacing with 2 mL fresh media. Cells were then returned to the 37°C incubator for 
48-72 h until they were ready to be assayed for gene expression. 
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2.4.4 Co-transfection of plasmid DNA and siRNA using Lipofectamine 2000 
HeLa cells containing DR-GFP construct were co-transfected with plasmid DNA and 
siRNA using the Lipofectamine2000 transfection reagent (Life technologies, UK).  
One day before transfection, cells were plated into six-well culture dishes to get a 70-
80% confluent at the time of transfection. For each well, 5 µL Lipofectamine 2000 
(Invitrogen, USA) was diluted with 244 µL of Opti-MEM (Life Technologies, UK) 
mixed gently and incubate at room temperature for 5 min. Then the DNA 
plasmid/siRNA dilution was prepared by adding 2.5 µL of 20 µM siRNA stock and 7.5 
µL of 100ng/uL DNA plasmid in 240 µL of Opti-MEM. The diluted Lipofectamine was 
combined with the diluted DNA plasmid-siRNA, vortexed briefly and incubated for 20 
min at room temperature to allow the DNA-siRNA/Lipofectamine complexes to form. 
The DNA-siRNA/Lipofectamine transfection mixture was then added into the cells in 
a drop-wise manner and incubated at 37°C in a CO2 incubator for 6 h before 
replacing with 2 mL fresh media. Cells were then returned to the 37°C incubator for 
48-72 h until they were ready to be assayed for gene expression. 
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2.5 Quantitative real time PCR 
2.5.1 RNA extraction and quantification 
Total RNA was isolated from cell pellets using the RNeasy kit (Qiagen, Crawley, UK) 
according to manufacturer’s instructions. The RNA purity and concentration were 
then determined by measuring the spectrophotometric absorbance at 260 nm and 
280 nm with a ND-1000 NanoDrop (Thermo Fisher Scientific, Wilmington, Delaware 
USA).  
2.5.2 cDNA synthesis (Reverse transcription) 
The RNA was reverse transcribed into first strand cDNA using Superscript III First-
Strand system (Life technologies, UK). Briefly, 2 µg of RNA was mixed with 1 µL of 
50 µM Oligo (dT)20 primer, 1 µL of 10mM dNTPs mix and DEPC-treated water up to 
13 µL.  Samples were denatured at 65°C for 5 min and then place on ice for 1 min. 
Subsequently, 6 µL of cDNA synthesis solution (consisting of 1 µL of the reverse 
transcriptase superscript III (200U/µl), 1 µL of 0.1 M DTT, 1 µL of RNaseOUT 
recombinant inhibitor and 4 µL of 1X first strand buffer) was added into the 
denatured RNA, mix gently and briefly centrifuged to collect the liquid down at the 
bottom of the tube. All the cDNA synthesis solution’s components were obtained 
from Life technologies. The reaction tube was placed into a thermocycler and run the 
following programme:  incubated at 25°C 10 min for the initial step, then 50 min at 
50°C for the reverse transcription step, and at 70°C for 15 min to inactivate the 
reverse transcription enzyme. The cDNA mixture was diluted 1:4 with DEPC-treated 
water and used immediately for RT-qPCR or stored at -20°C. 
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2.5.3 Primers Design and optimisation 
All primers (Table 2.1 and 2.2) were designed using Primer Express 3 software 
(Applied Biosystems) and purchased from ABI (Life technologies).  
The forward and reverse human primers used were: 
Target gene 5’-Forward-3’ 5’-Reverse-3’ 
FOXM1 
(detection of 
all isoforms) 
TGCAGCTAGGGATGTGAATCTTC GGAGCCCAGTCCATCAGAACT 
NBS1 TTTTCAACCAGTTTTCCGTTACTTC ACACTGCGCGTATAAGCCAAT 
ATM AATATCCATTCACCGCAGCC TGCCCATCCGGGACAA 
MRE11 TGAGAACTGGCCTTCGATTCA GGAGCCCAGACAAGCATGAT 
RAD50 TCCAAATCTTGTGGAAGTGCAT CTGCAAGCAGCCAGAACTTG 
KIF20A GCCAACTTCATCCAACACCT GTGGACAGCTCCTCCTCTTG 
L19 GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA 
Table 2.1: List of human RT-qPCR primers used in this study 
The forward and reverse mouse primers used were:  
Target 5’-Forward-3’ 5’-Reverse-3’ 
Foxm1 AGAAATGTGACCATCAAAACTGAAAT GAGGGAGCAGAGGCTTCATCTT 
Nbs1 TGACAACCCGATAGAGGAGCAT TCTTGGCTCTCTGTCTGTCCAG 
Atm  GCGCCACGCCTTGT CAAACGTTGCCTGAAT 
L19 CCCGTCAGCAGATCAGGAA GTCACAGGCTTGCGGATGA 
Table 2.2: List of mouse RT-qPCR primers used in this study 
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2.5.4 Real time quantitative PCR (RT-qPCR) 
RT-qPCR analysis was carried out on a 7900HT Fast Real-time PCR System 
(Applied BioSystems, UK) using Power SYBR green (Applied Biosystem, UK). SYBR 
Green is a DNA binding dye that intercalates tightly to double-stranded DNA. This 
intercalation causes the SYBR to fluoresce. The qPCR machine detects the 
fluorescence and software calculates Ct values from the intensity of the 
fluorescence. Transcript levels were quantified using the relative standard curve 
method. All analyses were carried out in triplicate, and the target gene expression 
levels were normalised to a control mRNA level of ribosomal protein L19.  
Briefly, a mixture containing optimised concentration of gene-specific forward and 
reverse primer pairs with 12 µL of SYBR-Green Master Mix was added to 2 µL of the 
cDNA (~100ng). For each reaction, DEPC-treated water was added to adjust the 
final volume to 25 µL. Transcript levels were quantified using the relative standard 
curve method. The standard curve was made by mixing 5 µL from each cDNA 
sample into a single tube and diluted 1:4 for four serial dilutions. The standard 
dilution included 1, 1:4, 1:16, 1:64, 1:256, and NT (only water, no cDNA). All 
analyses were carried out in triplicate. The PCR program was set to 95°C for 10 min 
for the enzyme activation, followed by 40 cycles of denaturing at 95°C for 10 sec, 
and primer annealing at 55°C for 30 sec. After the real-time PCR run, a dissociation 
curve was generated to confirm the absence of non-specific amplification. 
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2.6 Western Blot Analysis 
Western blot analysis was used to detect protein expression. A complex mixture of 
proteins extracted from the cells was separated according to molecular weight using 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Following 
electrophoresis, the separated proteins were transferred into nitrocellulose 
membrane for immunoblotting. 
2.6.1 Protein extraction and quantification 
Cells were harvested by trypsinisation as described above. Cell pellets were washed 
with PBS, transferred into a new eppendof tube, and centrifuged at 300×g for 4 min. 
To prepare whole cell extracts, cell pellets were lysed in lysis buffer, which consists 
of 1% (v/v) Nonidet P-40, 50 mM Tris-HCL (pH7.4), 0.5 mM EDTA, 150 mM NaCL, 
50 mM HEPES, 1 mM sodium fluoride (NaF), 1 mM sodium orthovanadate (Na3VO4), 
2 mM phenylmethysulfonyl fluoride (PMSF) and complete protease inhibitors mixture 
(Roche Applied Science), and incubated on ice for 15 min. The protein extracts were 
then centrifuged at 14,000 rpm for 10 min at 4 °C to remove insoluble cellular debris. 
The supernatant was then transferred in to the new eppendof tube and protein 
quantification was determined using Bio-Rad Dc protein assay according to 
manufacturer's protocol. Absorbance of the samples was read at 700 nm using the 
Sunrise spectrophotometer (Tecan, Reading, UK).  
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2.6.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)  
SDS polyacrylamide gel electrophoresis (SDS-PAGE) involves the separation of 
proteins based on their molecular size. The standard SDS-PAGE gels composed of 
two different layers, an upper stacking gel and a lower running gel. The gel was 
made with varying amounts of bis-acrylamide solution, the percentages of the gel 
used varying for 5 to 14. Lower percentage of gels allowed better examination of 
proteins of higher molecular weight. The bis-acrylamide with ammonium persulphate 
(APS) and tetraethylethyleneduanine (TEMED) were the catalysts for gel 
polymerisation. Table 2.3 showed the components of different percentages of gels. 
Reagents 
Resolving gel Stacking gel 
5% 7% 10% 12% 14% 5% 
dH20 (mL) 6.19 5.02 4.02 3.35 2.68 3.67 
1.5M Tris pH 8.8 (mL) 2.5 2.5 2.5 2.5 2.5 - 
1.5M Tris pH 6.8 (mL) - - - - - 0.42 
30% Acrylamide/0.8% Bis (37.5:1) (mL) 1.16 2.33 3.33 4.00 4.67 0.83 
10% SDS (µL) 100 100 100 100 100 50 
25% APS (µL) 40 40 40 40 40 20 
TEMED (µL) 10 10 10 10 10 10 
Total (mL) 10 10 10 10 10 5 
Table 2.3: Components of the difference percentage of SDS-PAGE gels 
For protein expression analysis, 20 µg of protein extracts were mixed with 6X SDS 
protein dye (0.375 M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6 M DTT, 0.06% 
bromophenol blue), boiled at 100°C for 10 min. Samples were then loaded into the 
SDS-PAGE gels in Tris-glycine electrophoresis running buffer (25 mM Tris-Base, 
109 mM Glycine, and 0.1% (w/v) SDS) and run at a constant voltage of 90 volts.  
After electrophoresis, proteins were electro-transferred onto nitrocellulose 
membranes (Whatman International, Kent, UK) using Bio-Rad Mini Trans-Blot 
system, filled with transfer buffer ( 25M Tris-Base, 190 mM glycine and 20% (v/v) 
ethanol)  and run at a constant 90 volts for 90 min at room temperature.  
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2.6.3 Immunoblotting 
The membranes were blocked with 5% bovine serum albumin (BSA) for 30 min at 
room temperature and then incubated with specific primary antibodies overnight at 
4°C. Next day, the membranes were washed three times, 10 min each with TBS-T.  
Secondary antibodies (DAKO, Ely, UK) diluted 1:2000 in TBS-T were added for 45 
min at room temperature and membranes were washed three times with TBS-T. 
Immunoblots were visualised using the ECL detection system (Amersham 
Biosciences, UK). 
2.6.4 Antibodies 
Primary antibodies used in this study are shown in the Table 2.4. Secondary 
antibodies used were goat anti-mouse and goat anti-rabbit HRP (horseradish 
peroxidase) were from Dako (Ely, UK). For immunostaining studies, Alexa Fluor  488 
goat anti-rabbit IgG (H+L), Alexa Fluor 488 goat anti-mouse IgG (H+L), Alexa Fluor 
555 goat anti-rabbit IgG (H+L), and Alexa Fluor 555 goat anti-mouse IgG (H+L) were 
obtained from Molecular Probes (Invitrogen, Carlsbad, CA, USA). 
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NO. Antibody Product number Species Company Dilution 
1 ATM 04-200 Rabbit Calbiochem 1:1000 
2 CHK2 2662 Mouse Cell Signaling 1:1000 
3 
FOXM1  
(detection of all 
isoforms) 
C-20/sc-502 Rabbit Santa Cruz 1:1000 
4 H2AX 2595 Rabbit Cell Signaling 1:1000 
5 I-Sce1 sc-98269 Rabbit Santa Cruz 1:1000 
6 MRE11 NB-100-142 Rabbit Novus Biologicals 1:1000 
7 NBS1 3002 Rabbit Cell Signaling 1:1000 
8 PARP 9542 Rabbit Cell Signaling 1:1000 
9 p-ATM (Ser1981) MAB3806 Mouse Millipore 1:500 
10 p-CHK2 (Thr68) 2661 Rabbit Cell Signaling 1:1000 
 11 p-NBS1 (Ser343) 3001 Rabbit Cell Signaling 1:1000 
12 RAD50 NB100-154 Mouse Novus Biologicals 1:1000 
13 β-tubulin (H-235) H-235/sc-9104 Rabbit Santa Cruz 1:1000 
14 γ-H2AX (Ser 139) 9718 Rabbit Cell Signaling 1:1000 
15 Cyclin B1 H-433/ sc-752 Rabbit Santa Cruz 1:1000 
16 KIF20A  Ab104118 Rabbit Abcam 1:1000 
17 KIF20A D-3/ sc-374508 Mouse Santa Cruz 1:1000 
18 Cleaved-caspase7 9491 Rabbit Cell Signaling 1:1000 
19 p21 sc-397 Rabbit Santa Cruz 1:1000 
20 p53 sc-374087 Mouse Santa Cruz 1:1000 
21 Rabbit HRP P0448 goat Dako 1:2000 
22 Mouse HRP P0447 goat Dako 1:2000 
Table2.4: List of primary antibodies used for western blotting 
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2.7 Immunofluorescent Staining 
2.7.1 γ-H2AX assay 
Cells grown on chamber culture slides were fixed in 4% paraformaldehyde (Thermo 
Scientific, Rockford, IL, USA) for 15 min followed by permeabilisation for 10 min with 
0.2% Triton X-100 in PBS. After being washed with PBS, cells were blocked with 5% 
goat serum in PBS for 30 min. Slides were incubated overnight at 4°C with rabbit 
polyclonal anti-γ-H2AX pS1981 primary antibody (Cell signalling, UK) diluted 1:250 
in 0.2% goat serum, rinsed with PBS and subsequently incubated with a 1:500 
dilution of Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody 
(Molecular Probes, Invitrogen) for 45 min at room temperature. After washing with 
PBS, cells were stained with DAPI for 10 min and mounted with Vectashield 
mounting solution (Vector Laboratories). Images were captured with a Leica TCS 
SP5 confocal microscope (Leica Microsystems, Mannhein, Germany) equipped with 
a 63X oil immersion objective and LAS-AF software. For each experimental 
condition, at least 100 cells were captured and quantified for the number of γ-H2AX 
foci using FociCounter software. 
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2.7.2 α-tubulin immunostaining to detect mitotic catastrophe 
Cells grown on chamber culture slides were fixed in 4% paraformaldehyde (Thermo 
Scientific, Rockford, IL, USA) for 15 min followed by permeabilisation for 10 min with 
0.2% Triton X-100 in PBS.  After being washed with PBS, cells were blocked with 5% 
goat serum in PBS for 30 min. The slides were incubated overnight at 4 °C with 
primary antibodies, anti-α-tubulin (clone DM1A) and anti-γ-tubulin purchased from 
Sigma-Aldrich (St. Louis, MO, USA). The slides were then rinsed with PBS and 
subsequently incubated with a 1:500 dilution of Alexa Fluor 488-conjugated goat 
anti-mouse and Alexa Fluor 555-conjugated goat anti-rabbit secondary antibodies 
(Molecular Probes, Invitrogen) for 45 min at room temperature. After washing with 
PBS, cells were mounted with Vectashield mounting solution containing DAPI 
(Vector Laboratories). Mitotic cells were visualised with a Leica TCS SP5 confocal 
microscope (Leica Microsystems, Mannhein, Germany) equipped with a 63X oil 
immersion objective and LAS-AF software. For each condition, images of at least 50 
mitotic cells were captured and analysed. 
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2.8 Luciferase reporter assay 
Cells were seeded into 96-well plates at a density of approximately 10,000 cells/well 
and co-transfected with a firefly luciferase reporter plasmid, the  transfection control 
Renilla plasmid (pRL-TK; Promega, Southampton, UK) and pcDNA3-FOXM1 
plasmids using FuGENE 6 transfection reagent (Roche Diagnostics, UK). Twenty-
four hours after transfections, cells were harvested to determine luciferase activity, 
using the Steadylite plus™ Reporter Gene Assay (Perkin Elmer, UK) according to 
manufacturer’s instruction. Luminescence was then determined using a PHERAstar 
Plus microplate reader (BMG Labtech, Aylesbury, UK). Each firefly luciferase was 
normalised by well to the Renilla readings and six replicates were measured per 
condition. 
2.9 HR Repair Assay 
HeLa cells carrying DR–GFP reporter system were used to measure HR repair as 
described (Morris et al., 2009, Pierce et al., 1999). Cells were transfected with either 
siRNA or DNA expressing plasmid. Cells were left for 24 h before transfection with 
pCMV- I-Scel plasmid to induce DSBs and stimulates HR repair. 72 h after I-Scel 
transfection, cells were harvested and the number of GFP positive cells was 
determined by BD FACS Canto II flow cytometer system (BD Biosciences, Oxford, 
UK) using the FACSDiva acquisition software (BD Bioscience, UK). The result were 
analysed by using a two-dimensional dot plot (green fluorescence (FL1-H) on y-axis 
and auto-orange florescence on the x-axis (FL2-H). For each condition, 50,000 cells 
were analysed and the frequency of HR events was calculated from the number of 
GFP-positive cells divided by the total number of cells analysed. 
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2.10 Sulforhodamine B (SRB) assay 
The sulforhodamine B (SRB) assay was used to measure drug-induced cytotoxicity 
and cell proliferation. The assay relies on the ability of SRB, a bright-pink 
aminoxanthene dye, to bind with basic amino-acid residues in protein components of 
cells under acidic conditions. As the binding of SRB is stoichiometric, the amount of 
dye extracted from stained cells is directly proportional to the cell mass (Vichai and 
Kirtikara, 2006). Approximately 3,000 cells were plated in each well of the 96-well 
plates (Falcon, USA). 24 h after culturing, cells were treated with different 
concentrations of epirubicin or paclitaxel for 48 h. After an incubation period, 
monolayer cells were fixed with 100 µL of 40% (w/v) trichloroacetic acid (TCA) and 
incubated for 1 h at 4°C. The plates were then rinsed with water for three times 
before staining with 0.4% SRB solution (0.4% SRB in 1% acetic acid) for 1 h at room 
temperature. The excess dye is removed by washing repeatedly with 1% (v/v) acetic 
acid and the plated were dried overnight. The protein-bound dye was dissolved in 10 
M Tris base solution for 30 min at room temperature with agitation. Absorbance was 
measured at 492 nm using a Sunrise spectrophotometer (Tecan, Medford, MA, 
USA). The results were normalised to 0 h or untreated wells. All the reagents were 
obtained from Sigma-Aldrich. 
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2.11 Clonogenic Assay 
Clonogenic assay, a useful long-term survival assay, was used to examine the 
effectiveness of anticancer cytotoxic agents on colony forming ability. Cells were 
seeded in 6-well plates at a density of approximately 2,000 cells/ well overnight. The 
cells were then treated with different concentrations of epirubicin or paclitaxel for 48-
72 h. The drug was removed and replaced with fresh completed media. The 
surviving cells were left to form colonies. After 14 days of incubation, cell colonies 
were fixed with 4% paraformaldehyde for 15 min at room temperature then washed 
with PBS for three times. 0.5% crystal violet was used to stain the fixed cells for 30 
min. The excess crystal violet was removed and the plates were washed with tap 
water. Plates with colonies were then left to dry overnight. Digital images of the 
colonies (at least 5 random fields) were obtained using a camera. Quantification was 
achieved by solubilising dye with 1 mL of 33% (w/v) acetic acid and the absorbance 
was measured at 592 nm using a microplate reader (Tecan, Medford, MA, USA). 
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2.12 Senescence-Associated β-Galactosidase assay 
Senescence-associated β-galactosidase (SA-β-gal), a widely used biomarker of 
senescence (Itahana et al., 2007), was detected by histochemical staining of cells 
using the artificial substrate X-gal. Briefly, cells were seeded 6-well plates at a 
density of approximately 20,000 cells/well before treatment with epirubicin or 
paclitaxel for 48 h. After culture for a further 5 days, cells were fixed and stained 
using a Senescence β-Galactosidase Staining Kit (#9860), purchased from Cell 
Signalling Technology (Beverley, MA, USA). Plates were incubated overnight at 
37°C in a dry incubator (no CO2). Cells were then detected for blue staining under a 
bright-field microscope. The percentage of SAβ-gal-positive cells was calculated by 
counting the cells in five random fields. 
2.13 Cell Cycle Analysis 
Cell cycle analysis was done by propidium iodide staining. Briefly, cell pellets were 
harvested, washed in 500 µl  PBS, and spun at 300xg (4ºC) for 2 min before being 
fixed with 5 mL of 90% ethanol at 4ºC for overnight. Cells were then spun at 300xg 
(4ºC) for 5 min. The supernatant was discarded and the cells washed twice in 2 mL 
PBS. The supernatant was discarded and the cells were stained using 600 µl 
propidium iodide (50 µmol/l) for 1 h in the dark. The cell cycle profile was then 
analysed using a FACS canto and FACSDiva software (BD Biosciences). 
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2.14 Chromatin Immunoprecipitation (ChIP) 
Cells were cross-linked in 1% formaldehyde for 10 min and glycine treated for 5 min 
before cell scraping and centrifugation. The pellets were washed with PBS+1X PI 
and resuspended in 1 mL LB1 buffer (50 mM HEPES-KOH, pH 7.5; 140 mM NaCl; 1 
M EDTA; 10% glycerol; 0.5% Igepal CA-630; 0.25% TritonX-100+1X PI) for 10 min 
on a rotating platform at 4°C. Samples were centrifuged at 2000×g for 5 min at 4°C 
before lysis in 1 mL LB2 buffer (10 M Tris–HCl, pH 8; 200 M NaCl; 1 mM EDTA; 0.5 
mM EGTA+1X PI) for 5 min on a rotating platform. Lysates were centrifuged as 
before and pellets were resuspended in 300 µl LB3 buffer (10M Tris-HCL, pH 8.0; 
100 M NaCl; 1 M EDTA; 0.5 M EGTA; 0.1% Na-deoxycholate and 0.5% N-
lauroylsarcosine+1X PI). DNA was fragmented to an average size of 150-200 bp 
using Bioruptor (Diagenode, Denville, USA) with the setting 4 cycles with 5 min 
duration. After sonication, TritonX-100 was added to a concentration of 1%. The 
mixture was centrifuged at 13,000×g for 10 min at 4°C. Five percent of each sample 
was taken as input and frozen until the next day. 40 µl per sample of Dynabeads 
conjugated to Protein A (Invitrogen) was transferred into fresh tubes and blocked by 
washing three times with PBS containing 0.5% bovine serum albumin (PBS-BSA) 
before incubation with 4 μg of the indicated antibodies overnight at 4°C. Anti-FOXM1 
antibody (SC502) was from Santa Cruz Biotechnology (Santa Cruz, Heidelberg, 
Germany) and rabbit IgG control (X0903) was obtained from Dako (Cambridgeshire, 
UK). Dynabeads were then washed twice with PBS-BSA to remove unbound 
antibody, and the 100 µL chromatin samples prepared the previous day were added 
to the appropriate Dynabead samples and rotated overnight at 4°C. Dynabeads were 
subsequently washed six times in RIPA buffer (50 mM HEPES-KOH, pH 7.5; 0.5 M 
LiCl; 1 mM EDTA; 1% NP-40; 0.7% Na-deoxycholate) and two times in TE buffer (20 
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mM Tris–HCl, pH 7.6; 150 mM NaCl) before incubating overnight in 100 μl elution 
buffer (1% SDS, 0.1 M NaHCO3) at 65°C to elute protein–DNA complexes and to 
reverse formaldehyde-induced cross-links. At the same time, input samples were 
defrosted and subject to elution. The next day, the supernatant was transfer to a 
fresh tube and diluted with 200 μl TE buffer. To get rid of contaminating RNA and 
protein, samples were incubated with 8 μl of 1 mg/mL RNAse and 4 μl 20 mg/mL 
proteinase K (Invitrogen), respectively. ChIP DNA was purified by phenol chloroform 
extraction and resuspended in deionised water and subject to quantitative real-time 
PCR using primers specific to KIF20A gene (Table 2.5). Data were presented as % 
Input using the following formula: % Input = 100 × 2^(CT adjusted Input sample − CT 
immunoprecipitated sample). At least two individual repeats of the entire experiment 
were conducted (** P<0.001). 
Primer Forward (5’-3’) Reverse (5’-3’) 
KIF20A TTCCTTACGCGGATTGGTAG AGCCGCAGAGCACAACTC 
Negative  control CCGCCTCCCTCTTAGCATAA CAGGAAATTGCATCTCGGGG 
Table 2.5: Primers used for quantitative real-time PCR following ChIPs                                           
The negative control primer specifically binds and amplifies the region located at the 5’ upstream non-
coding region (-813/-938 bp) of KIF20A gene. 
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2.15 Clinical data analysis  
2.15.1 Tissue Microarray 
A set of patients samples described in Chen et al., 2010 was used. Briefly, 116 
cases of breast cancer diagnosed between the years 1992 to 2001 together with 
clinical follow up data were retrieved from the records of the Department of 
Pathology, Queen Mary Hospital of Hong Kong. Histological features of all cases 
were determined by the pathologist, the representative paraffin tumour blocks were 
chosen as donor block for each case and the selected areas were marked for 
construction of tissue microarray (TMA) blocks. A total of 116 was assessed and 
scored for FOXM1, NBS1 and KIF20A staining. The expression pattern and 
subcellular localisation were analysed and correlated with various clinicopathological 
features, including histological type, histological grade, clinical stage, estrogen and 
progestrogen receptor status, lymph node metastasis as well as survival time. 
2.15.2 Immnohistochemistry   
The TMA slide was deparaffinised with xylene, rehydrated with decreasing 
concentrations of ethanol. Citrate buffer (0.01 M, pH 6.0) was used for antigen 
retrieval. To quench endogenous peroxidase, the slides were then immersed into 3% 
H2O2 methanol for 10 min at room temperature. Following with rinsing in 0.05% 
Tween in PBS (PBS-T) twice, 200 µL of 1:50 primary specific antibody dilution (Table 
2.6) was added to each section and incubated at 4°C overnight. The slides were 
then washed in PBS-T and 4-5 drops of DAKO Polymer were then added onto each 
sample and incubated at room temperature for 30 min. After washing, Chromogen 
DAB/substrate reagent was applied on the slides and incubated for 3 min. Finally, 
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the dehydration of slides was performed using increasing concentrations of ethanol 
solution, followed by clearing in xylene. Then, slides were mounted. 
The high resolution images of the stained TMA slides were scanned and captured by 
ScanScope scanners. Individual stained TMA spots were visualized and scored for 
FOXM1, NBS1 and KIF20A expression using Aperio ScanScope ® system (Aperio 
technology, USA) by two independent individuals and the average scores were used 
for calculations.  
NO. Antibody 
Product 
number 
Species Company Dilution 
1 FOXM1 NBP1-30961 Rabbit Novus biologicals 1:50 
2 NBS1 2662 Mouse Cell Signaling 1:50 
3 KIF20A Ab104118 Rabbit Abcam 1:50 
Table 2.6: List of primary antibodies used for immnohistochemistry 
2.15.3 Staining scoring and Statistical Analysis 
Tissue sections were scored according to their intensity and percentage of stained 
tumour cells. As FOXM1, NBS1, and KIF20A were detected in both the cytoplasm 
and the nucleus, separate evaluation on cytoplasm and nucleus was carried out. The 
intensity of staining was scored as follows: 1 = weak, 2 = moderate, or 3 = strong. 
The percentage of cells positively stained was scored as follows: 1 ≤ 25%, 2 ≤ 50%, 
3 ≤ 75%, or 4 > 75%. For each case, a final score was obtained by multiplying the 
score of intensity with the score of percentage. The total score is the sum of the 
cytoplasm and nucleus scores. 
Statistical analysis was performed using the SPSS programme. The correlation 
between FOXM1/NBS1, or FOXM1/KIF20A expression were obtained by bi-variate 
Pearson Correlation analysis. Survival analysis was estimated by Kaplan Meier 
analysis with log-rank test. Correlation of FOXM1 expression and clinical-
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pathological parameters and patient survival were also estimated by multivariate 
analysis with Cox-regression model.  
2.16 Statistic Analysis  
The statistical significance of differences between the means of two groups was 
evaluated by two-tailed unpaired Student’s t-test using the Microsoft Excel 
programme and GraphPad Prism version 4.03 (GraphPad Software Inc, San Diego, 
CA). In all cases, difference were considered to be significant when * P ≤ 0.05, ** P ≤ 
0.01 and *** P ≤ 0.005 and n.s. for non-significant. 
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CHAPTER 3 
THE ROLE OF FOXM1 IN DNA DAMAGE RESPONSE                            
AND EPIRUBICIN RESISTANCE 
 
 
 
 
 
 
 
 
104 
 
3.1 Introduction  
Anthracyclines (also known as anthracycline antibiotics), including doxorubicin and 
epirubicin are some of the most effective anticancer agents. Particularly, epirubicin 
(Epi) represents a commonly used chemotherapeutic agent in the standard 
treatment of a wide range of tumours including breast, lung, gastric, and ovary 
carcinomas, and leukaemia (Minotti et al., 2004). The precise mechanism 
responsible for the anti-proliferative and cytotoxic effects of epirubicin is not 
completely understood, but is likely to be involved in inducing DNA intercalation and 
DNA double-strand breaks (DSBs), which render cells to undergo apoptosis, mitotic 
catastrophe, terminal growth arrest, and increased clonogenic tumour cells killed. 
Epirubicin effectively blocks the growth and spread of cancer cells and is also 
associated with a significant reduction in breast cancer mortality; however, intrinsic 
and acquired chemoresistance is becoming a major obstacle for successful breast 
cancer management. Elucidation of the molecular mechanisms underlying epirubicin 
resistance is therefore needed to improve patient survival. As epirubicin exerts its 
cytotoxic effects by causing DNA damage, the enhancement in DNA repair could be 
a possible mechanism that enables cancer cells to survive and develop resistance to 
this DNA damaging agent. 
The Forkhead box M1 (FOXM1) transcription factor is responsible for the regulation 
of a wide range of biological processes, including the cell cycle, cell proliferation, 
apoptosis, and tumorigenesis (Lam et al., 2013, Myatt and Lam, 2007). Deregulated 
FOXM1 has been proposed to be involved in cisplatin and epirubicin resistance, and 
this could occur through an enhancement of DNA damage repair (Millour et al., 
2011, Kwok et al., 2010a, Monteiro et al., 2013). In response to DNA damage, CHK2 
has been report to activate and stabilise FOXM1, which in turn stimulates the 
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expression of DNA repair genes, BRCA2 and XRCC1 (Tan et al., 2007). Recently, 
results from our laboratory have identified BRIP1 as a new target of FOXM1 in 
response to DNA damage repair (Monteiro et al., 2013). However, the mechanistic 
aspects of how FOXM1 modulates DNA repair still remain unclear. Therefore, the 
aim of this chapter was to investigate the new roles of FOXM1 and its downstream 
targets in DNA damage response and cellular senescence, which are vital for both 
the tumour progression and the development of chemotherapeutic drug resistance. 
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3.2 Results  
3.2.1 FOXM1-deficient MEFs exhibit increased levels of DNA damage upon 
epirubicin treatment 
Deregulated FOXM1 has been proposed to be involved in cisplatin and epirubicin 
resistance and this may be due to the enhancement of DNA repair (Millour et al., 
2011, Kwok et al., 2010). However, the precise molecular mechanisms by which 
FOXM1 mediates DNA repair events are still not completely understood. To 
investigate the involvement of FOXM1 in DNA repair mechanism, Foxm1-/- and wild-
type (WT) MEFs were either non-treated or treated with 0.1 µM epirubicin, a 
concentration which does not induce considerable cell death over a short time 
course (up to 48 h), but instead triggers differential senescence effects on Foxm1-/- 
and WT MEFs (Monteiro et al., 2013, Khongkow et al., 2014), for 0, 0.5, 2, 4, 24, 48 
and 24 h and immunostained for phosphorylated histone H2AX (γH2AX) foci, a well-
known marker of DNA double-strand breaks induced by ionising radiation or 
chemotherapeutic agents (Rogakou et al., 1998, Clingen et al., 2008, Ivashkevich et 
al., 2012). Analysis of γH2AX foci formation by confocal microscopy revealed that 
Foxm1-/- MEFs displayed higher levels of spontaneous DNA breaks upon epirubicin 
treatment compared to WT MEFs (Figure 3.1). In WT MEFs, maximal foci numbers 
were reached between 4-24 h of epirubicin treatment. After 24 h of the treatment, as 
repair progressed there was a significant reduction in the number of γH2AX foci and 
only a small fraction of the foci persisted for 72 h, indicating that the damaged DNA 
had been repaired. By contrast, the number of γ-H2AX foci remained considerably 
higher in Foxm1-/- MEFs, indicating that the depletion of FOXM1 led to a significant 
increase in DNA damage induced by epirubicin and this could be associated with the 
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impairment of DNA damage repair. Taken together, these results suggest that 
FOXM1 may be involved in the repair of DSBs induced by epirubicin. 
3.2.2 FOXM1 reconstitution in Foxm1-/- MEFs exhibits the decreased 
accumulation of γH2AX foci in response to epirubicin treatment 
The functional roles of FOXM1 are believe to be mediated by two transcriptionally 
active isoforms, FOXM1b and FOXM1c (Wierstra and Alves, 2007). However, 
extensive studies have shown that FOXM1B is the predominant isoform that is 
overexpressed and highly associated with cancer development, progression and 
poor prognosis in various cancer cell lines (Lam et al., 2013, Tan et al., 2007, Ye et 
al., 1997, Costa et al., 2003, Kalinichenko et al., 2004, Myatt and Lam, 2007, Liu et 
al., 2006, Dai et al., 2007, Li et al., 2009, Xue et al., 2014, Wang et al., 2014, 
Nakamura et al., 2010, Gemenetzidis et al., 2009). Therefore, to further confirm the 
role of FOXM1 in response to DSBs, Foxm1-/- MEFs were transiently transfected with 
either mCherry-FOXM1B or empty-mCherry control plasmids for 48 h. Then, the 
transfected cells were either non-treated or treated with 0.1 µM epirubicin for 0, 0.5, 
4, 24, 48 and 72 h and immunostained for phosphorylated histone H2AX foci to 
determine DNA double-strand breaks. The confocal microscopic analysis confirmed 
that Foxm1-/- MEFs were effectively transfected with mCherry-FOXM1B or empty-
mCherry control plasmids (Red). mCherry-FOXM1 protein localised in the nucleus 
(Figure 3.2A), whereas mCherry-empty control protein was observed in both the 
nucleus and cytoplasm of Foxm1-/- MEFs (Figure 3.2B). The analysis of γH2AX foci 
formation revealed that Foxm1-/- MEFs expressing mCherry-FOXM1B exhibited 
decreased DNA breaks after epirubicin treatment compared with the neighbouring 
mCherry-FOXM1 negative cells (Figure 3.2A). However, Foxm1-/- MEFs transfected 
with the empty-mCherry control have similar kinetics for γH2AX foci accumulation as 
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the mCherry negative cells (Figure 3.2B). Collectively, these results clearly suggest a 
critical role of FOXM1 in DNA double strand break repair. 
 
Figure 3.1: Foxm1
-/-
 MEFs exhibited higher level of DNA breaks than WT MEFs after epirubicin 
treatment. WT and Foxm1
-/-
 MEFs cultured on chamber slides were either non-treated (0 h) or 
treated with 0.1 µM epirubicin for 0.5, 2, 4, 24, 48 and 72 h. Cells were then fixed and immunostained 
for γH2AX foci (green). Nuclei were counterstained with DAPI (blue). Images were acquired with 
Leica TCS SP5 (63X magnification). (b) For each time point, images of at least 100 cells were 
captured and used for quantification of γH2AX foci number. The graph represents average of three 
independent experiments ± S.D. Statistical analyses were conducted using Student’s t-tests against 
the correspondent time point (***P≤0.005, significant; ns, non-significant). 
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Figure 3.2:  Foxm1
-/-
 MEFs expressing ectopic FOXM1B-mcherry plasmids exhibited decreased 
DNA breaks after epirubicin treatment. Foxm1
-/-
 MEFs were transfected with either ectopic FOXM1-
mCherry plasmids. −ve mCherry-FOXM1 negative cells; +ve, mCherry-FOXM1 positive cells (Red) 
(A) or with mCherry empty vector control plasmids. −ve mCherry negative cells; +ve, mCherry positive 
cells (Red) (B). 2 days after transfection, cell were then treated with epirubicin for 0, 0.5, 4, 24, 48 and 
72 h and immunostained for phosphorylated histone H2AX foci (green) to determine DNA double-
strand breaks. Nuclei were counterstained with DAPI (blue). Images were acquired with Leica TCS 
SP5 (63X magnification). For each time point, images of at least 100 cells were captured and used for 
quantification of γH2AX foci number. The graph represents average of three independent experiments 
± S.D. Statistical analyses were conducted using Student’s t-tests against the correspondent time 
point (*P≤0.05, ***P≤0.005, significant; ns, non-significant). 
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3.2.3 FOXM1 deletion significantly inhibits long-term clonogenic ability and 
induces premature senescence in response to DNA damage  
From the previous results, I found that Foxm1-/- MEFs accumulated significantly 
higher numbers of γH2AX foci compared to WT MEFs at prolonged times of 24, 48 
and 72 h following epirubicin treatment. Interestingly, accumulation of persistent 
γH2AX foci has been considered as one of the important markers for unrepaired or 
irreparable damaged DNA in senescent cells. These suggested that FOXM1 may 
protect cells from genotoxic agent-induced cell death or senescence by enhancing 
DNA damage repair mechanisms. However, the role of FOXM1 in promoting long-
term clonogenic survival in response to chronic DNA damage induced by epirubicin 
treatment has not yet been investigated. To address this, WT and Foxm1-/- MEFs 
were treated with a wide range of epirubicin doses (0-100 nM) and their long-term 
viability was investigated by clonogenic assay (Figure S3). The results showed that 
at 0, 20 and 40 nM epirubicin, the colony formation capacity of Foxm1-/- MEFs was 
significantly impaired compared with WT MEFs (Figure 3.3A, Figure S3). 
Interestingly, previous studies from our laboratory have shown that these low 
epirubicin concentrations (20 or 40 nM) do not induce considerable cell death over 
shorter time courses (up to 48 h) (Millour et al., 2011, Monteiro et al., 2013). I 
therefore hypothesised that low levels of DNA damage induced by epirubicin may 
trigger senescence-associated anti-proliferative responses instead of activating 
apoptosis. To test this hypothesis, WT and Foxm1-/- MEFs were assayed for 
senescence-associated β-galactosidase (SA-βgal) activity, a well-established 
biomarker of senescence, following low doses of epirubicin treatment (Figure 3.3B). 
At 20 and 40 nM epirubicin treatment, significantly higher numbers of Foxm1-/- MEFs 
112 
 
displayed distinct SA-βgal activity and ‘flat cell’ morphology compared with WT 
MEFs.  
To confirm this further, WT and Foxm1-/- MEFs were exposed to moderate levels of 
ionising-radiation (Figure 3.3C-D). At 5Gy γ-irradiation, the colony formation capacity 
of Foxm1-/- MEFs was also significantly reduced compared to WT MEFs (Figure 
3.3C). Consistently, Foxm1-/- MEFs also displayed higher percentages of senescent 
cells compared with WT MEFs following exposure to 5 Gy of γ-irradiation (Figure 
3.3D), suggesting that FOXM1 has a key role in protecting the cell against DNA 
damage-induced senescence.  
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Figure 3.3: FOXM1 deletion inhibits clonogenic growth and induces cellular senescence in 
response to DNA damage in MEFs. (A) Clonogenic assays were performed to assess the colony 
formation efficiency of Foxm1
-/-
 and WT MEFs. 2,000 cells were seeded in six well plates, treated with 
0, 20 and 40 nM of epirubicin and grown for 15 days. The cells were then stained with crystal violet 
(left panel). The result (right panel) represents average of three independent experiments ± SD. 
Statistical significance was determined by two-tailed unpaired Student’s t-test (**P ≤ 0.01). (C) 
Clonogenic assay of Foxm1
-/-
and WT MEFs were either non-irradiated or exposed to 5 Gy of γ-
irradiation. (B) SA-βgal staining of Foxm1
-/-
and WT MEFs treated with 0, 20 and 40 nM of epirubicin. 5 
days after treatment, cells were stained for SA-β-galactosidase activities. (D) SA-βgal staining of 
Foxm1
-/-   
and WT MEFs treated with irradiation (0 and 5 Gy). The graphs (B, right panel) and (D, right 
panel) show the percentage of SA-βgal positive cells as measured from five different fields from two 
independent experiments. Bars represent average ± SD. Statistical significance was determined by 
Student’s t-test (**P ≤ 0.01, significant; ns, non-significant).        
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3.2.4 Knockdown of FOXM1 leads to increased levels of DNA damage in MCF-7 
EpiR cells. 
In order to investigate whether FOXM1 confers epirubicin resistance through the 
enhancement of DNA damage repair, I decided to assess the effect of silencing 
FOXM1 using siRNA targeting all isoforms of FOXM1 in the previously established 
epirubicin-resistance MCF-7 (MCF-7 EpiR) breast cancer cells, which were generated 
by the repeated passages of MCF7 cells in increasing concentrations of epirubicin 
(Millour et al., 2011). MCF-7 EpiR cells cultured on slide chambers were transiently 
transfected with either NS or FOXM1 siRNA for 24 h. The transfected cells were then 
treated with 1 µM epirubicin, a clinical concentration generally used in cancer 
therapy (Iwakiri et al., 2008, Millour et al., 2011),  and fixed at the indicated time 
points (0, 4, 24, 48, and 72 h) prior to immunostaining for γH2AX. The γH2AX foci 
formation analysis revealed that  knockdown of endogenous FOXM1 expression in 
MCF-7 EpiR cells displayed a significant increase in DNA breaks after epirubicin 
treatment (Figure 3.4). The induction of γH2AX foci was observed following 4 h of 
epirubicin treatment and remained persistently high through the entire time points, 
suggesting that diminished FOXM1 expression caused a deficiency in DNA repair 
which leads to an increase in DNA breaks. This result indicates that depletion of 
FOXM1 is sufficient to render epirubicin resistant MCF-7 EpiR cells more susceptible 
to epirubicin-induced DSBs. 
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Figure 3.4: Knockdown of FOXM1 leads to increased levels of DNA damage in MCF-7 Epi
R
 
cells.  (A) MCF-7 Epi
R
 cells were transfected with control siRNA (NS siRNA) or with FOXM1 siRNA 
for 24 h. Cells were cultured on chamber slides and treated with 1 μM of epirubicin for 0, 4, 24, 48 and 
72 h and then stained for γH2AX (green) and DAPI (blue). (B) The graph below shows quantification 
of γH2AX foci number. Bars represent an average of three independent experiments ± S.D. Statistical 
analyses were conducted using two-tailed unpaired Student’s t-test against the correspondent time 
point (***P≤0.0001, significant; n.s., non-significant). (C) The silencing effect of FOXM1 siRNA was 
detected by western blot analysis. 
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3.2.5 Knockdown of FOXM1 significantly sensitises MCF-7 breast cancer cells 
to epirubicin-induced cellular senescence 
The effects of FOXM1 depletion by siRNA on the long-term viability of MCF-7 and 
the MCF-7 EpiR breast cancer cell lines were next examined by clonogenic assays 
(Figure 3.5). FOXM1-knockdown sensitised MCF-7 cells to long-term proliferative 
arrest at relatively low epirubicin concentrations (10 and 20 nM) (Figure 3.5A), 
whereas at higher concentrations the colony formation ability was completely lost in 
MCF-7 cells. Notably, FOXM1-depletion alone almost completely impaired the 
colony formation ability of MCF-7 EpiR cells irrespective of the dosage of epirubicin 
used (Figure 3.5C), suggesting that MCF-7 EpiR cells are dependent on high FOXM1 
expression for long-term survival. Similar to FOXM1 deletion in MEFs, FOXM1 
knockdown in MCF-7 cells also enhanced the number of cells exhibiting SA-βgal 
activity and changed in morphology at 0 and 10 nM epirubicin (Figure 3.5B). 
Consistently, FOXM1 knockdown in MCF-7 EpiR cells resulted in almost all cells 
displaying senescence-associated SA-βgal activity and morphology independent of 
epirubicin levels (Figure 3.5D), suggesting that MCF-7 EpiR cells have become 
dependent on FOXM1 to override senescence. As mentioned earlier, senescent cells 
accumulate γH2AX foci as markers for unrepaired or irreparable damaged DNA. To 
confirm this further, I studied the effects of FOXM1 knockdown on nuclear γH2AX 
foci formation in MCF-7 and MCF-7 EpiR cells following 5 Gy of γ-irradiation, a 
radiation dosage which induced senescence in MCF-7 cells (Karimi-Busheri et al., 
2010). Quantification of γH2AX foci showed that γ-irradiation induced significantly 
higher number of foci formation over the prolonged time course of 24, 48 and 72 h in 
FOXM1 depleted cells in comparison to control siRNA-transfected MCF-7 (Figure 
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3.6A) and MCF-7 EpiR cells (Figure 3.6B), further indicating that FOXM1 has a 
critical role in overcoming DNA damage-induced senescence. 
Figure 3.5: Knockdown of FOXM1 suppresses cell growth and induces cellular senescence in 
MCF-7 and MCF-7 Epi
R
 cells. A) MCF-7 and (C) MCF-7 Epi
R
 were transfected with NS siRNA or 
FOXM1 siRNA. Twenty-four hours after transfection, 2,000 cells were seeded in six well plates, 
treated with epirubicin, grown for 15 days and then stained with crystal violet (left panel). The graphs 
(A; right panel) and (C; right panel) represent average of three independent experiments ± SD. 
Statistical significance was determined by two-tailed unpaired Student’s t-test (**P ≤ 0.01, significant; 
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ns, non-significant). In parallel, (B) MCF-7 and (C) MCF-7 Epi
R
 transfected with NS siRNA or 
siFOXM1 were seeded in six well plates, treated with epirubicin. 5 days after treatment, cells were 
stained for SA-β-galactosidase activity. The graphs (B; right panel) and (D; right panel) show the 
percentage of SA-β-galactpsidase-positive cells as measured from five different fields from two 
independent experiments. Bars represent average ± SD. Statistical significance was determined by 
two-tailed unpaired Student’s t-test (**P ≤ 0.01, significant; ns, non-significant). 
 
Figure 3.6: Knockdown of FOXM1 causes the accumulation of γH2AX foci in response to γ-
irradiation. (a) MCF-7 and (b) MCF-7 Epi
R
 were transfected with NS siRNA or FOXM1 siRNA. 
Twenty-four hours after transfection, cells were either non-exposed or exposed to 5 Gy of γ-irradiation 
for 24, 48 and 72 h. Cells were then fixed and immunostained for γH2AX foci (green). Nuclei were 
counterstained with 4′-6-diamidino-2-phenylindole (DAPI; blue). Images were acquired with Leica TCS 
SP5 (63X magnifications). For each time point, images of at least 100 cells were captured and used 
for quantification of γH2AX foci number. Results represent average of three independent 
experiments±S.D. Statistical analyses were conducted using two-tailed unpaired Student’s t-test 
against the correspondent time point (**P ≤ 0.01, significant; n.s., non-significant). 
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3.2.6 FOXM1 and DNA repair gene, NBS1, are up-regulated in MCF-7 EpiR cells 
Previous studies in our laboratory have shown that FOXM1 is essential for 
homologous recombination (HR) DNA repair activity after DSBs (Monteiro et al., 
2013). In order to elucidate in detail the mechanistic role of FOXM1 in DNA damage-
induced senescence and epirubicin resistance, I next compared the expression 
patterns of FOXM1 and the main HR repair proteins, including NBS1, MRE11, 
RAD50  and ATM (Bartkova et al., 2008) in response to epirubicin treatment in both 
parental MCF-7 cells and MCF-7 EpiR cells. Western blot analysis showed that in 
MCF-7 cells there was a transient induction of FOXM1 protein at 4 h post epirubicin 
treatment before decreasing gradually over the treatment time. By contrast, the 
MCF-7 EpiR cells expressed a significantly higher level of FOXM1 compared to the 
parental MCF-7 cells and this high level of FOXM1 was maintained throughout the 
timecourse treatment (Figure 3.7A, Figure S4). Furthermore, the expression levels of 
DNA repair proteins; NBS1, MRE11, RAD50, and ATM were observed at higher 
levels in the MCF-7 EpiR cells compared with the expression levels in MCF-7 cells.  
Interestingly, I also found that NBS1 as well as its phosphorylated form, P-NBS1, 
exhibited similar kinetics to FOXM1 in response to epirubicin in both MCF-7 and 
MCF-7Epi
R
 cells (Figure 3.7A, Figure S4).  Consistent with these observations, RT-
qPCR analysis also revealed that NBS1 mRNA levels increased 2 fold in MCF-7 
EpiR cells compared to the parental MCF-7 cells which exhibited decreased NBS1 
transcriptional level by almost 50% after 24 h epirubicin treatment (Figure 3.7B). 
These results suggest that FOXM1 may transcriptionally regulate NBS1 expression 
and this regulation could mediate epirubicin resistance in breast cancer cells.  
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Figure 3.7: Epirubicin resistant cell line exhibits increased FOXM1 and NBS1 protein and 
mRNA expression levels (A) Representative western blot of three independent experiments, 
determining the protein expression levels of FOXM1, NBS1, P-NBS1, MRE11, RAD50, P-ATM, and 
ATM in MCF-7 and MCF-7 Epi
R 
cell lines after being treated with 1 µM of epirubicin at different time 
points. β-tubulin was used as a loading control. (B) NBS1 mRNA transcript level was carried out by 
RT-qPCR analysis and normalised to the ribosomal protein L19 RNA expression. Bars represent 
average ± SD. Statistical significance was determined by two-tailed unpaired Student’s t-test (**P ≤ 
0.01, ***P≤0.005, significant; ns, non-significant). 
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3.2.7 FOXM1 enhances NBS1 expression and ATM activity to promote DNA 
damage repair signalling 
To test whether NBS1 is a downstream target of FOXM1 required for conferring 
epirubicin resistance in breast cancer cells, both MCF-7 and MCF-7 EpiR cells were 
depleted of FOXM1 by employing FOXM1 siRNA transfection for 24 h. 
Subsequently, cells were treated with 1 µM epirubicin for 24 h and harvested for 
western blot and RT-qPCR analysis. Western blot and RT-qPCR analysis showed 
that FOXM1 knockdown caused a significant decrease in the NBS1 protein and 
mRNA levels in both MCF-7 and MCF-7 EpiR cells, whereas only a significant 
reduction was observed for the RAD50 and MRE11 proteins (Figure 3.8A, Figure 
S5), but not at the mRNA level, upon FOXM1 knockdown (Figure 3B). This suggests 
that in contrast to NBS1, RAD50 and MRE11 are not direct downstream targets of 
FOXM1, raising the possibility that their protein expression levels might be stabilised 
through the formation of an active MRN complex. NBS1 have been recently shown 
to function upstream of ATM activation in addition to its well-established role 
downstream of ATM (Uziel et al., 2003, Wu et al., 2012, Horejsi et al., 2004, Lee and 
Paull, 2007, You et al., 2005). From the western blot analysis, it is also notable that 
P-ATM levels were strongly induced by epirubicin treatment, but this induction was 
abolished after FOXM1 silencing by siRNA in both MCF-7 and MCF-7 EpiR cells 
(Figure 3.8A, Figure S5), suggesting that FOXM1 may be involved in the regulation 
of NBS1 expression and ATM activity.  
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Figure 3.8: MCF-7 and MCF-7 Epi
R
 cells depleted in FOXM1 expression revealed significant 
decreases in both protein and mRNA levels of NBS1. MCF-7 and MCF-7 Epi
R
 cells were either 
transfected with non-specific control siRNA or siRNA against FOXM1 for 24 h. After transfection, cells 
were treated with 1 µM epirubicin for 0 and 24 h. (A) Representative western blot of three 
independent experiments, determining the protein expression levels of FOXM1, NBS1, P-NBS1, 
MRE11, RAD50, P-ATM, and ATM. β-tubulin was used as a loading control.  (B) RT-qPCR was 
performed to indicate the relative FOXM1, NBS1, MRE11 and RAD50 mRNA transcriptional level. 
Bars represent average ± SD. Statistical significance was determined by two-tailed unpaired Student’s 
t-test (**P ≤ 0.01, ***P≤0.005, significant; ns, non-significant). 
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3.2.8 FOXM1-deficient cells display decreased expression of the DNA repair 
gene NBS1 
To confirm further that FOXM1 modulates ATM activity through regulating NBS1 
expression, WT and Foxm1-/- MEFs were treated with 0.1 µM epirubicin for 0, 0.5, 2, 
4, 16, and 24 h. The expression levels of FOXM1, P-ATM, P-NBS1 and NBS1 were 
subsequently investigated by western blot analysis (Figure 3.9). Consistent with the 
results from the breast cancer cell lines, NBS1 and P-NBS1 were modulated with 
similar kinetics as FOXM1 in WT MEFs following epirubicin treatment, but were 
barely detectable in Foxm1-/- MEFs. By contrast, RAD50 and MRE11 were 
expressed at only marginally lower levels in Foxm1-/- MEFs compared to WT MEFs. 
The western blot results also showed that although ATM was expressed at 
comparable levels in WT and Foxm1-/- MEFs, P-ATM was induced by epirubicin and 
expressed at much higher levels in WT compared to Foxm1-/- MEFs (Figure 3.9A). 
Consistently, analysis of RT-qPCR data also indicated that upon epirubicin treatment 
the NBS1 and FOXM1 mRNA displayed similar kinetics in WT and Foxm1-/- MEFs, 
further confirming FOXM1 regulates NBS1 expression (Figure 3.9B). Together these 
findings led us to postulate that FOXM1 may target NBS1 expression at the 
transcriptional level to enhance DNA damage repair signalling and epirubicin 
resistance. 
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Figure 3.9: FoxM1-deficient MEFs exhibited decreased mRNA and protein levels of the DNA 
repair gene NBS1 compared with wild type MEFs. Wild type and Foxm1
-/-
 MEFs were treated with 
0.1 µM epirubicin for 0, 1, 2, 4, 8, 24, and 48 h and the expressions of FOXM1 and NBS1 were 
determined by western blot and RT-qPCR analysis. 
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3.2.9 Overexpression of FOXM1 leads to upregulation of NBS1 expression and 
enhances ATM activity. 
I next examined the effect of ectopic expression of FOXM1 on the NBS1 expression 
and ATM activity. To this end, MCF-7 cells were transiently transfected with either an 
empty vector or FOXM1B-pcDNA3 plasmids. Twenty-four hours after transfection, 
cells were treated with 1 µM epirubicin for different time periods (0, 4, 24, and 48 h). 
The expression levels of NBS1 protein and ATM activity were then evaluated by 
western blot analysis. The results showed that overexpression of FOXM1 enhanced 
the expression of NBS1 protein and ATM phosphorylation in MCF-7 cells (Figure 
3.10), further confirming that FOXM1 regulates NBS1 expression and thus MRN 
complex formation to promote ATM activation and phosphorylation. It is notable that 
despite FOXM1 overexpression, NBS1 levels decreased after 24 h of epirubicin 
treatment. This is probably because both FOXM1 and NBS1 are also regulated at 
post-transcriptional levels in response to epirubicin (de Olano, 2012).  
 
Figure 3.10:  FOXM1 regulates NBS1 expression and modulates ATM phosphorylation. MCF-7 
cells were transfected with pcDNA3 empty vector or FOXM1-pcDNA3 plasmids following with these 
cells were subjected to 1 µM epirubicin treatment for 0, 4, 24 and 48 h.  (A) Western blots were 
performed to analyse the protein expression level changes of FOXM1, NBS1, P-ATM, ATM, RAD50, 
MRE11 and β-Tubulin was used as a loading control. (B) Right panel show quantification of proteins 
density using ImageJ software. Each sample was normalised to β-Tubulin (n=2). 
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3.2.10 FOXM1 regulates NBS1 expression through a FHRE in its promoter 
To investigate if the regulation of NBS1 by FOXM1 also occurs at the promoter level, 
MCF-7 cells were transiently co-transfected with increasing amounts of the FOXM1 
expression construct and the luciferase reporter gene under the control of either a 
human NBS1 wild-type (WT) or a mutant (mut) NBS1 (1.5 Kbp) promoter with a 
putative FHRE (forkhead response element) (-78 bp) mutated (Figure 3.11). The 
results showed that the (WT) NBS1 promoter activity was augmented by FOXM1 in a 
dose-dependent manner, whereas the mutant (mut) NBS1 promoter had lower basal 
promoter activity and failed to be induced by FOXM1. Collectively, these results 
suggest that FOXM1 is able to transactivate NBS1 gene through the FHRE located 
at position -78 bp, providing evidence that NBS1 is a direct target gene of FOXM1.   
 
Figure 3.11:  FOXM1 regulates NBS1 expression through a FHRE site within its promoter.  
MCF-7 cells were transiently co-transfected with 20 ng of NBS1-WT or NBS1-mutant promoter 
plasmid (pGL3 -Basic Vector) together with increasing concentrations (0, 10, 15 and 20 ng) of 
pcDNA3-FOXM1 plasmid and transfection control Renilla plasmid (pRL-TK). After 24 h, cells were 
assayed for Firefly and Renilla luciferase activity. The relative luciferase activity was calculated after 
normalising with Renilla activity. 
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3.2.11 FOXM1 and NBS1 required for efficient HR-mediated repair  
Recent studies from our laboratory have shown that FOXM1 is essential for 
homologous recombination (HR) but not non-homologous end joining (NHEJ) DNA 
repair pathway in response to DSBs (Monteiro et al., 2013). To determine the 
potential role of FOXM1 and NBS1 in DSB repair via HR, HeLa cells containing a 
DR-GFP reporter construct (Morris et al., 2009, Pierce et al., 1999) were transfected 
with either FOXM1 siRNA, NBS1 siRNA, pFOXM1 or pNBS1 expression plasmids. 
Subsequently, these cells were transfected with I-Scel expression plasmid. Transient 
expression of I-SceI endonuclease generates a DSB at the integrated GFP gene 
sequences and stimulates HR repair. Three days after I-Scel transfection, GFP 
positive cells were monitored by flow cytometry. For each experiment, 50,000 cells 
were analysed per treatment group and the frequency of HR events was calculated 
from the number of GFP-positive cells divided by the total number of cells analysed 
(Figure 3.12A). Western blot analysis was used to confirm the transfection efficiency 
(Figure 3.12B). The results showed that ectopic expression of either FOXM1 or 
NBS1 significantly enhanced the DNA repair via HR by 82.9% and 87.3%, 
respectively (Figure 3.12C and 12D). In contrast, the depletion of FOXM1 or NBS1 
using siRNA led to a significant reduction in HR frequency when compared with the 
cells transfected with non-specific control siRNA (54.0% and 67.6%, respectively) 
(Figure 3.12C and 12D). These data suggest that both FOXM1 and NBS1 play an 
important role in HR repair. Next, to explore the functional link between FOXM1 and 
NBS1 in HR-mediated DSB repair, HeLa cells carrying DR-GFP were co-transfected 
with FOXM1 plasmid and NBS1 siRNA. The results revealed that overexpression of 
FOXM1 and depletion of its proposed downstream targets, NBS1, caused a 
significant reduction in HR repair efficiency (49.4%) (Figure 3.12C and 12D). 
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Surprisingly, this reduction was not significantly higher than that observed in NBS1 
depletion alone, indicating that the function of FOXM1 to direct DSBs towards HR is 
related with NBS1 expression.   
 
Figure 3.12: FOXM1 and NBS1 are required for efficient HR repair (A) Schematic of DR-GFP 
assay for DSB repair by homologous recombination. The SceGFP reporter is a GFP gene which 
contains an I-SceI endonuclease site within the coding region. Cleavage of the I-Scel site by 
exogenously expressed I-Scel and repair induced by HR leads to GFP expressing cells. (B) 
Transfection efficiency in HeLa cells were monitored by western blot analysis. (C) The percentage of 
GFP positive cells was determined by flow cytometry. (D) Comparison of homologous recombination 
repair in HeLa cells carrying DR-GFP. Bars represent average ± SD of three independent 
experiments. Statistical significance was determined by two-tailed unpaired Student’s t-test (*P ≤ 0.05, 
significant; ns, non-significant). 
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3.2.12 Ectopic expression of NBS1 in Foxm1-/- MEFs reduces the sensitivity to 
epirubicin, as indicated by the decreased accumulation of γH2AX foci  
To further demonstrate that downregulation of NBS1 expression in FOXM1-depleted 
cells is responsible for the accumulation of senescence associated γH2AX foci in 
response to epirubicin treatment. I next determined whether the overexpression of 
NBS1 in Foxm1-/- MEFs is able to reduce the accumulation of γH2AX foci particularly 
at the longer times of 24, 48 and 72 h. To this end, Foxm1-/- MEFs were transiently 
transfected with empty-mCherry alone (control) or co-transfected mCherry with 
NBS1 expression plasmid for 48 h. Then, the transfected cells were either non-
treated or treated with 0.1 µM epirubicin for 0, 0.5, 4, 24, 48 and 72 h and 
immunostained for γH2AX foci to determine DNA double-strand breaks. The analysis 
of γH2AX foci formation revealed that Foxm1-/- MEFs expressing NBS1 displayed a 
significantly lower number of γH2AX foci compared with the neighboring 
untransfected cells at the longer time points (24, 48 and 72 h) after epirubicin 
treatment (Figure 3.13). Interestingly, the overexpression of NBS1 had the same 
effects as reconstituting Foxm1-/- MEFs with mCherry-FOXM1 (Figure 3.2A). By 
contrast, Foxm1-/- MEFs transfected with the empty-mCherry control have similar 
kinetics for senescence-associated γH2AX foci accumulation as the non-transfected 
cells (Figure 3.13 and Figure 3.2). Taken together, these findings clearly confirm that 
the role of FOXM1 in HR-mediated DSB repair is related to its ability to control NBS1 
expression. 
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Figure 3.13: Ectopic expression of NBS1 in Foxm1
-/- 
MEFs reduces the accumulation of γH2AX 
foci. Foxm1
-/-
 MEFs were either transfected with mCherry control plasmids or co-transfected with 
mCherry and NBS1 plasmids (Red) and treated with 0.1 µM of epirubicin for 0, 0.5, 2, 4, 24, 48 and 
72 h. The cells were then immunostained for γH2AX foci (Green) and nuclei were counterstained with 
DAPI (blue) to determine DNA double-strand breaks. γH2AX foci quantification is shown. Bars 
represent the average of γH2AX foci per cell from three independent experiments ± SD. Statistical 
significance was determined by two-tailed unpaired Student’s t-test (*P≤0.05, ***P≤0.005, significant; 
ns, non-significant). 
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3.2.13 Depletion of NBS1 increases sensitivity to epirubicin and induces 
senescence associated phenotypes in MCF-7 breast cancer cells 
To investigate the potential role of NBS1 in epirubicin resistance, I depleted NBS1 
expression using siRNA in both MCF-7 and MCF-7 EpiR cells and studied its effects 
on cell proliferation using the SRB assay. Interestingly, the result showed that 
knockdown of NBS1 revealed dose-dependent cell growth inhibition in both breast 
cancer cell lines, MCF-7 and MCF-7 EpiR, induced by epirubicin (Figure 3.14). As 
FOXM1 is involved in DNA damage-induced senescence after long-term treatments 
with low concentrations (10 or 20 nM) of epirubicin and also controls NBS1 
expression, the effects of NBS1 depletion on the long-term viability of MCF-7 and 
MCF-7 EpiR cells were then examined by clonogenic assays. Similar to FOXM1 
depletion, NBS1-knockdown sensitised MCF-7 and MCF-7 EpiR cells to long-term 
proliferative arrest following treatment with epirubicin (Figure 3.16A and 16C, 
respectively). Consistent with this, NBS1 knockdown in MCF-7 and MCF-7 EpiR cells 
also enhanced the number of cells exhibiting senescence-associated β-gal activity 
and flat morphology at 0 and 10 nM epirubicin (Figure 3.16B and 16D). These 
findings strongly suggest that NBS1 protects MCF-7 and MCF-7 EpiR cells from 
undergoing cellular senescence in response to DNA damage induced by epirubicin. 
Notably, differential effects of NBS1 depletion in the absence of epirubicin treatment 
on cell proliferation were observed only in long term proliferation assay as indicated 
in the 0uM epirubicin condition in Figure 3.16. 
 Next, I studied the effect of NBS1 depletion in the resistant MCF-7 EpiR cells using 
western blot analysis. The result revealed that depletion of NBS1 led to a decrease 
in P-ATM and P-NBS1 expression (Figure 3.15), further supporting the idea that 
NBS1 is needed for ATM activation in response to epirubicin. Consistent with this 
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finding, the previous study in the lab also showed that reconstitution of NBS1 
expression in NBS1-deficient NBS1-LBI cells can restore the activation of ATM in 
response to epirubicin (Khongkow et al., 2014). 
 
Figure 3.14: The depletion of NBS1 increases cell sensitivity to epirubicin.  MCF-7 (A) and MCF-
7 Epi
R 
(B) cells were transfected with either NS siRNA (control) or NBS1 siRNA. 24 h after 
transfection, cells were treated with increasing concentrations of epirubicin for 48 h. Subsequently, 
rates of cell proliferation were analysed by SRB assay. Data shown are an average of three 
independent experiments± SD. Statistical significance was determined by two-tailed unpaired 
Student’s t-test (*P≤0.05, **P ≤ 0.01, significant; ns, non-significant). Western blot analysis was used 
to monitor the transfection efficiency of NBS1 siRNA in MCF-7(C) and MCF-7 Epi
R
 (D) cells. 
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Figure 3.15: MCF-7 Epi
R
 cells depleted in NBS1 expression revealed a decrease in P-ATM and 
P-NBS expression. MCF-7 Epi
R
 cells were either transfected with non-specific control siRNA or 
siRNA smart pool against NBS1 for 48 h. After transfection, cells were treated with 1 µM epirubicin for 
0, 4, 24 and 48 h. The protein expression levels of FOXM1, NBS1, MRE11, and RAD50, ATM, P-ATM 
and Cleaved PARP were determined by western blot analysis.   
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Figure 3.16: NBS1 depletion inhibits cell growth and induces cellular senescence in MCF-7 
breast cancer cells. MCF-7 (A) and MCF-7 Epi
R
 (C) were transfected with NS siRNA or NBS1 
siRNA. 24 hours after transfection, 2,000 cells were seeded in six well plates, treated with epirubicin, 
grown for 15 days and then stained with crystal violet (left panel). The result (right panel) represents 
average of three independent experiments ± SD. Statistical significance was determined by two-tailed 
unpaired Student’s t-test (**P ≤ 0.01, significant; ns, non-significant). In parallel, MCF-7 (B) and MCF-
7 Epi
R
 (D) transfected with NS siRNA or siNBS1 were seeded in six well plates, treated with epirubicin 
for 5 days. Cells were stained for SA-β-galactosidase activities. The graphs show the percentage of 
SA-β-galactpsidase-positive cells as measured from five different fields from two independent 
experiments. Bars represent average ± SD. Statistical significance was determined by two-tailed 
unpaired Student’s t-test test (**P ≤ 0.01, ***P≤0.005, significant; ns, non-significant). 
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3.2.14 Overexpression of FOXM1 or NBS1 confers resistance to epirubicin 
possibly by enhancing DNA repair pathway in MCF-7 cells 
In Figures 3.5 and 3.14, I have shown previously that NBS1 or FOXM1 depletion is 
able to render MCF-7 and MCF-7 EpiR cells more sensitive to epirubicin-induced 
cellular senescence. As a consequence, cells overexpressing FOXM1 or NBS1 
should be less sensitive to epirubicin treatment. To test this hypothesis, MCF-7 cells 
were transiently transfected with control empty vector, pmCherry-FOXM1 or 
pmCherry-NBS1 for 24 h, and then treated with increasing concentrations of 
epirubicin for 48 h and their cell viability measured by SRB proliferation assay. 
Transfection efficiency was examined by western blot analysis as shown in Figure 
3.17A. The result of SRB assay revealed that the overexpression of FOXM1 or 
NBS1 alone was sufficient to confer epirubicin resistance in MCF-7 cells (Figure 
3.17B). Furthermore, cells transfected with the pmCherry-FOXM1 plasmid (stained in 
red) appear to show decreased levels of DNA damage induced by epirubicin (γH2AX 
foci stained in green) compared to non-transfect cells. These data suggest that 
overexpression of FOXM1 and NBS1 could protect breast cancer cells from 
epirubicin-induced senescence by enhancing DNA damage repair. However, this 
experiment was performed only two times, thus there is a need to repeat more 
experiments in order to obtain sufficient sample size for statistical analysis.  
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Figure 3.17: Overexpression of FOXM1 or NBS1 promotes epirubicin resistance and decrease 
DNA damage in MCF-7 cells. MCF-7 cells were transfected with control empty vector, pmCherry-
FOXM1 or pmCherry-NBS1 for 24 h. Overexpression levels of FOXM1 and NBS1 were confirmed by 
western blot analysis (A).  Cells were then treated with increasing concentrations of epirubicin for 48 h 
and their cell viability measured by SRB assay (B). Representative data from three independent 
experiments are shown (n=2). (C) MCF-7 cells were transfected with the control empty vector or with 
pmCherry-FOXm1for 24 h. Cells were then seeded on 4-chamber slides and treated with 1 µM 
epirubicin at 0 and 24 h, as indicated, and stained for yH2AX in green (AlexaFluor 488) , DAPI in blue 
and mCherry in red. 
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3.2.15 Correlation between NBS1 and FOXM1 expression in breast cancer 
samples 
After establishing that NBS1 is a direct transcriptional target of FOXM1 in breast 
cancer cell lines and mouse embryonic fibroblasts, in collaboration with Professor 
Khoo Ui Soon (Department of Pathology, the University of Hong Kong), we analysed 
the correlation of FOXM1 and NBS1 expression on tissue microarray (TMA) slides 
containing 116 human breast cancer patient samples (Chen et al., 2010) using 
immunohistochemistry (Figure 3.18A). The results indicated that FOXM1 and NBS1 
protein were detected in both nuclear and cytoplasmic compartments. Statistical 
analysis of the expression patterns revealed that there was a strong highly significant 
correlation between FOXM1 nuclear staining and total NBS1 staining (Pearson 
coefficient=0.318, p=0.002), providing further physiological evidence that FOXM1 
regulates NBS1 expression in breast cancer patient samples (Figure 3.18A). Survival 
analysis by Kaplan-Meier estimate with log-rank test revealed that the high nuclear 
expression of NBS1 was correlated with overall poor survival (p=0.164) (Figure 
3.18B). In addition, multivariate survival analysis using Cox's regression model, 
when adjusted by patients’ T-stage and lymph-node involvement, indicated that 
NBS1 expression was significantly correlated with poorer survival (RR=2.869, 
p=0.048). Further analysis of FOXM1 and NBS1 mRNA transcript expression in 
another previously published cohort (2878 breast cancer patients) (Györffy et al., 
2010) confirmed that high FOXM1 and NBS1 mRNA expression levels were very 
significantly associated with poor survival (p<0.0001 and p=0.0012, respectively for 
overall survival, Kaplan-Meier analysis) (Figure 3.19). The significance of NBS1 in 
survival analysis suggests a direct involvement of NBS1 in regulating cell 
senescence and DNA damage repair in genotoxic drug response. 
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Figure 3.18: Correlation between NBS1 and FOXM1 expression in breast cancer samples. A) 
Correlation of FOXM1 and NBS1 expression were assessed by immunohistochemistry in breast 
cancer samples (N=116). FOXM1 and NBS1 staining were detected in both nuclear and cytoplasmic 
compartments. NBS1 high and low are categorized according to its median score, so half of the 
samples are NBS1 high and half of samples are NBS1 low. Statistical analysis of the expression 
patterns showed that there was a strong and significant correlation between FOXM1 nuclear staining 
and total NBS1 staining. B) Kaplan–Meier analysis of overall survival for NBS1 staining with log-rank 
test indicated that there was a statistically non-significant trend linking high NBS1 expression to poor 
survival in breast cancer patients.  
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Figure 3.19: Kaplan-Meier analysis of overall survival for FOXM1 and NBS1 mRNA transcript 
expression in a previously web-based published cohort (Györffy et al., 2010). High FOXM1 and 
NBS1 mRNA expression levels are very significantly associated with poor survival (p<0.0001 and 
p=0.0012, respectively). 
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3.3 Discussion 
Epirubicin (Epi) represents a widely used chemotherapeutic agent in the clinical 
treatment of breast cancer (Minotti et al., 2004). The precise mechanism of action of 
epirubicin is likely to be associated with the generation of DNA double-strand breaks 
(DSBs), which lead cells to apoptosis and increased tumour cell death (Choudhury, 
Zhao et al. 2009). However, the failure of epirubicin treatment occurs as a result of 
development of drug resistance and systemic toxicity, because high doses are 
required to obtain a significant anticancer effect. Interestingly, my work in this 
chapter shows that breast cancer cell lines as well as mouse embryonic fibroblasts 
can be induced to enter cellular senescence by DNA damaging agents including 
epirubicin and ionising radiation. Notably, the concentrations of DNA damaging 
agents required for inducing senescent phenotypes in these cells are substantially 
lower than that required to induce cell death, suggesting the possibility that cellular 
senescence may be the predominant mechanism of action for genotoxic anti-cancer 
agents (Millour et al., 2011, Monteiro et al., 2013). 
The development of epirubicin-acquired resistance represents a major obstacle to 
successful treatment of breast cancer. One of the crucial factors in the development 
of chemoresistance is the enhanced DNA repair ability of cancer cells which 
prevents the cells accumulating DNA damage induced by DNA damaging agents 
(Stewart, 2007, Perez, 1998, Fink et al., 1996). Although several recent papers have 
already addressed the role of FOXM1 in genotoxic drug resistance,  its exact role in 
epirubicin resistance are still not yet completely understood (Koo et al., 2012, 
Monteiro et al., 2013, Millour et al., 2011, Kwok et al., 2010b). In this chapter, I found 
that FOXM1 plays a central role in modulating DNA damage-induced senescence 
and epirubicin resistance. Depletion of FOXM1 sensitised MCF-7 breast cancer cells 
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as well as MEFs cells into entering epirubicin-induced senescence, as indicated by 
cellular markers of senescence, including  the accumulation of γH2AX foci, the loss 
in long-term cell proliferation, the induction of β-galactosidase activity as well as the 
flat cell morphology (Figure 3.1, 3.3, 3.4 and 3.5). These results were consistent with 
the previous observation that FOXM1-deficient cells exhibited high level of γH2AX 
foci, enhanced p53 transcription activity and increased expression of the p21 gene in 
response to γ-irradiation (Tan et al., 2005). However, in Figure 3.1, there was no 
significant difference in the level of H2AX foci between WT and Foxm1-/- MEFs at 
basal level (untreated condition). This may be due to the immortalization of Foxm1-/- 
MEFs. Conversely, reintroduction of FOXM1 in FOXM1-deficient MEFs decreased 
the accumulation of senescence-associated γH2AX foci (Figure 3.2). Crucially, I 
have also shown a novel role of FOXM1 in mediating DNA-damage induced 
senescence and epirubicin resistance through the direct regulation of NBS1 
expression and ATM activity. NBS1 is a part of the MRE11-RAD50-NBS1 (MRN) 
complex, which is the main element in cellular response to DSBs including damage 
sensing and activation of cell cycle checkpoints signalling pathways (Kang et al., 
2005, Kobayashi et al., 2004, Saito et al., 2013). Knockdown of FOXM1 in MCF-7 
and MCF-7 Epi
R
 cell lines led to a significant downregulation of NBS1 at both protein 
and mRNA levels, whereas overexpression of FOXM1 enhanced NBS1 expression 
and ATM activity in response to epirubicin treatment (Figure 3.8). These results 
support the notion that FOXM1 is a crucial transcriptional regulator of the DNA repair 
gene NBS1 in response to DNA damage.  Moreover, I found that FOXM1 is 
upregulated in MCF-7 EpiR cells compared with the parental sensitive MCF-7 cells. 
FOXM1 expression is downregulated in response to epirubicin in MCF-7 cells, but 
remains persistently high in the resistant cells following epirubicin treatment. These 
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data suggest that FOXM1 is a target of epirubicin and that it has a role in mediating 
epirubicin action and resistance. Similar to FOXM1, NBS1 was also overexpressed 
in epirubicin resistant MCF-7 cells (Figure 3.7). However, there were slight 
discrepancies between the protein expression of FOXM1 in response to epirubicin 
treatment in Figure 3.7 and 3.8.  This might be due to the effect of cell-cycle, we 
didn’t synchronize the cells, therefore; most cells are at the different stage of cell 
cycle and this might cause the different cellular outcome in response to epirubin 
treatment. 
Interestingly, the depletion of FOXM1 in the resistant cancer cells not only resulted in 
the downregulation of the protein levels of NBS1 but also RAD50 and MRE11 
indicating that the MRN complex might be regulated by FOXM1. However, these 
trends were not reflected at the mRNA level (Figure 3.8A and 8B). The results 
suggest the possible post-transcriptional regulation of MRN complex by FOXM1 in 
response to DNA damage repair as well as drug resistance in breast cancer cells. 
NBS1 appears to act both upstream and downstream of ATM in the DNA damage 
response pathway (You et al., 2005, Uziel et al., 2003, Horejsi et al., 2). The 
interactions of NBS1 with ATM is critical for ATM activation to be functional in 
response to DNA damage (Cariveau et al., 2007 and Kang et al., 2005, Saito et al., 
2013). Another interesting observation drawn from this chapter is that the increased 
number of DNA breaks in Foxm1−/− MEFs and FOXM1-depleted MCF-7 cells after 
epirubicin treatment correlated with decreased activation of ATM, which is the main 
player in the DSB repair pathway. These events resulted in impaired cellular DNA-
damage response and enhanced the sensitivity to DNA-damaging agents 
determined by an apoptosis marker, cleaved-PARP (Figure 3.15). This further 
supports that FOXM1 directly regulates NBS1 expression and, in turn, upregulation 
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of NBS1 indirectly enhances the stability of MRN subunits, leading to the increased 
kinase activity of ATM in response to DNA damage (Figure 3.20).   
 
Figure 3.20: A novel possible role of FOXM1 in DNA damage response pathway (red). FOXM1 
regulates NBS1 expression and ATM kinase activity in response to DNA damage. 
As NBS1 has been implicated in HR repair via the formation of MRN complex (Yuan 
and Chen, 2010), I then asked whether FOXM1 and NBS1 function together in DSB 
repair via HR using the HeLa cells containing a DR-GFP reporter construct. As 
expected, the depletion of either FOXM1 or NBS1 leads to a significant reduction in 
HR. By contrast, overexpression of FOXM1 or NBS1 enhanced the HR repair. These 
data confirmed that FOXM1 and NBS1 play an important role in HR repair. To 
explore the functional link between FOXM1 and NBS1 in HR pathway, HeLa cells 
carrying DR-GFP were co-transfected with FOXM1 plasmid and NBS1 siRNA. The 
results revealed that overexpression of FOXM1 together with depletion of NBS1 lead 
to a strong decrease in HR repair ability of the HeLa cells (Figure 3.12). These data 
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imply that FOXM1 is a crucial regulator of the DNA repair gene, NBS1, and both 
proteins are required for proper DNA DSB repair responses. In agreement, the 
ectopic expression of NBS1 was able to rescue the DNA repair defects and 
epirubicin-induced senescence phenotypes in Foxm1-/- MEFs cells. Taken together, 
these findings clearly confirm that the role of FOXM1 in HR-mediated DSB repair is 
linked to its ability to control NBS1 expression. Consistent with my result, NBS1 has 
been shown previously to play a role in persistent DNA damage-induced 
senescence-associated inflammatory cytokine secretion (Rodier et al., 2009a). 
I next tested the potential of targeting NBS1 to improve the effectiveness of 
epirubicin treatment in both sensitive and resistant MCF-7 breast cancer cells by 
using SRB assays. The result showed that downregulation of NBS1 rendered MCF-7 
EpiR cells more sensitive to epirubicin, suggesting that NBS1 is a novel modulator of 
epirubicin sensitivity (Figure 3.14).  The enhanced epirubicin sensitivity of the NBS1 
depleted MCF-7 EpiR cells were further confirmed by the increased expression of 
cleaved PARP protein (Figure 3.15). As FOXM1 is involved in DNA damage-induced 
senescence after long-term treatments with low concentrations of epirubicin and also 
controls NBS1 expression, I then examined the effects on NBS1 depletion on the 
long-term proliferation. Like FOXM1, NBS1-knockdown inhibited long-term cell 
proliferation and triggered premature senescence in MCF-7 and MCF-7 EpiR cells in 
response to low doses of epirubicin treatment (Figure 3.16A and 16C, respectively). 
Collectively, these findings strongly suggest that NBS1 protects MCF-7 and MCF-7 
EpiR cells from entering senescence/ cell death and it could be used as a potential 
target to improve the effectiveness of epirubicin treatments in the resistant cancer 
cells. In agreement, expression of an NBS1 mutant, which interrupts the MRN 
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function for DNA repair, has been shown to be associated with an increased 
sensitivity to cisplatin in head and neck cancer (Tran et al., 2004, Araki et al., 2010).  
The physiological relevance of the regulation of NBS1 by FOXM1 is further 
underscored by the significant correlation between nuclear FOXM1 and total NBS1 
expression in breast cancer patient samples (Figure 3.18). Furthermore, both 
FOXM1 and NBS1 expression is significantly correlated to poor prognosis in breast 
cancer, supporting a physiological role of FOXM1 and NBS1 in genotoxic drug 
resistance. 
In summary, this study has identified NBS1 as an important novel target of FOXM1 
involved in HR-mediated DSB repair, DNA damage-induced senescence and 
epirubicin resistance. These findings also show the potential therapeutic benefit of 
FOXM1-NBS1 axis as a reliable prognostic marker for monitoring treatment 
efficiency and a promising target for therapeutic intervention to overcome epirubicin 
resistance in breast cancer. 
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CHAPTER 4 
THE ROLE OF FOXM1 IN MITOTIC CONTROL                                        
AND PACLITAXEL RESISTANCE 
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4.1 Introduction 
Paclitaxel represents one of the most widely used mitotic poison agents for treating 
advanced breast cancer.  At the molecular level, paclitaxel bind to the β-tubulin 
subunit of microtubules, promoting the polymerisation of tubulin resulting in the 
formation of microtubule asters in interphase cells, instead of mitotic spindles, during 
mitosis (Bedard et al., 2010). This process blocks cell cycle progression through the 
M-phase by interrupting normal microtubule dynamics and inducing cancer cell death 
(Jiang et al., 2011). Apoptosis has generally been thought to be the most 
predominant mechanism of cell death in response to taxanes chemotherapy at the 
high drug doses (Chang et al., 1999, Roninson et al., 2001). However, in this 
chapter, I hypothesised that other modes of cell death, including treatment-induced 
senescence and mitotic catastrophe may also contribute significantly to the overall 
therapeutic response.  
Mitotic catastrophe is characterised by the occurrence of aberrant mitosis, or mis-
segregation of the chromosomes, followed by cell division. Nuclear envelopes form 
around individual chromosomes or groups of chromosomes forming large cells with 
multiple micronuclei, which are morphologically distinguishable from apoptotic cells 
(Morse et al., 2005). 
Despite clinical effectiveness of paclitaxel, toxic side effects and the development of 
drug resistance represent major obstacles to improve outcome for breast cancer 
patients. Therefore, understanding the molecular mechanisms of drug resistance 
and developing agents to reverse the resistance are pivotal for improving the 
prognosis of cancer patients.  
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Studies on breast cancer have revealed that overexpression of FOXM1 also confers 
resistance to paclitaxel, whereas depletion of FOXM1 can increase sensitivity of 
breast cancer cell to this drug (Carr et al., 2010). However, the exact mechanisms by 
which FOXM1 modulates paclitaxel resistance remain elusive. The possible 
processes could be related to the specific relationship between FOXM1 and co-
factors that are involved in spindle assembly and mitotic control. The mitotic kinesin 
KIF20A has been reported to be a potential downstream FOXM1 target, which are 
involved in mitosis and chromosome segregation (Wonsey and Follettie, 2005). 
Consistently, our microarray analysis result in the laboratory also revealed that 
FOXM1 might regulate the expression of KIF20A in response to paclitaxel treatment 
in MCF-7 cells. KIF20A, also known as RAB6KIFL/MKLP2, is a member of the 
kinesin family of microtubule motor proteins which plays many important roles in 
cellular functions including mitotic spindle assembly, cytokinesis, cell migration as 
well as localisation of organelles and vesicles (Taniuchi, Nakagawa et al. 2005, Hill 
et al., 2000, Gruneberg et al., 2004, Neef et al., 2006). KIF20A expression appears 
to be tissue specific. It is widely expressed in human fetal tissues. It is also 
expressed in the adult during haematopoiesis and in various proliferating tissues, 
including thymus, bone marrow and testis (Lai et al., 2000). By contrast, there is no 
expression of KIF20A in adult quiescent human liver cells, suggesting that KIF20A 
contributes to both normal and pathological proliferation as well as cancer 
progressiveness in human cells (Gasnereau et al., 2012). Interestingly, accumulating 
evidence has shown that KIF20A is overexpressed in pancreatic ductal 
adenocarcinoma (PDAC) cells and its downregulation inhibits cell growth, migration 
and invasion (Taniuchi, Nakagawa et al. 2005, Yan et al., 2012, Stangel et al., 2015, 
Exertier et al., 2013). Recently, a KIF20A-derived peptide vaccine KIF20A-66 has 
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been developed and used as a promising and effective immunotherapy to treat 
advanced pancreatic cancer (Asahara et al., 2013, Suzuki et al., 2014). Moreover, a 
growing number of studies have consistently revealed that KIF20A is also 
abundantly overexpressed in many other types of cancers, such as gastric cancer, 
small lung cancer, melanoma and bladder cancer (Yan et al., 2012, Yamashita et al., 
2012, Ho et al., 2012). However, little is known about the transcriptional regulation of 
KIF20A and it remains to be elucidated whether KIF20A plays a role in 
carcinogenesis or anti-cancer drug resistance in breast cancer cells.  
In this chapter, I hypothesise that FOXM1 might regulate the mitotic regulatory 
protein KIF20A and this ultimately determines the paclitaxel-sensitivity or resistance 
in breast cancer cells. Therefore, the aim of this chapter is to study the functional 
relationship between FOXM1 and KIF20A in mediating paclitaxel sensitivity and 
resistance in breast cancer.  
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4.2 Results 
4.2.1 Deletion of FOXM1 reduces long-term clonogenic survival and induces 
cellular senescence in response to paclitaxel treatment 
Studies in our laboratory and others have shown that FOXM1 overexpression is 
sufficient to render breast cancer cells resistant to a wide range of anticancer 
chemotherapy agents, including epirubicin, lapatinib, gefitinib, imatinib and cisplatin 
(Myatt et al., 2014, Lam et al., 2013). In this chapter, I investigated the possibility that 
upregulation of FOXM1 in cancer cells could confer resistance to paclitaxel. To 
assess the potential requirement of FOXM1 in response to paclitaxel treatment, I 
initially treated early passage WT and Foxm1-/- MEFs with a wide range of 
concentrations of paclitaxel (0, 20, 40, 60, 80 and 100 nM). Long-term cellular 
viability was evaluated by clonogenic assay. The results revealed that Foxm1-/- MEFs 
displayed much higher sensitivity to paclitaxel compared to the WT MEFs (Figure 
4.1A). In order to determine whether this long-term loss of proliferative capacity was 
due to senescence, the WT and Foxm1-/- MEFs were subjected to SA-βgal staining 
to identify senescent cells.  Consistent with the results obtained in the clonogenic 
assays, FOXM1 deletion in MEFs significantly induced cellular senescence in 
response to paclitaxel treatment, as evidenced by the increase in SA-βgal activity 
and flat cell morphology (Figure 4.1B). 
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Figure 4.1: Deletion of FOXM1 reduces long-term clonogenic survival and induces cellular 
senescence in response to paclitaxel treatment in MEFs. (A) Clonogenic assay was performed to 
determine the colony formation efficiency of Foxm1
−/−
 and WT MEFs. 2,000 cells were seeded in six 
well plates, treated with 0, 20, 40, 60, 80 and 100 nM of paclitaxel and grown for 15 days. The cells 
were then stained with crystal violet. The bar graph represents average of three independent 
experiments ± SD. Statistical significance was determined by two-tailed unpaired Student’s t-test (**P 
≤ 0.01). (B) SA-βgal staining of Foxm1
−/−
 and WT MEFs treated with 0, 20, 40, 60, 80 and 100 nM of 
paclitaxel. 5 days after treatment, cells were stained for SA-β-galactosidase activities. 
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4.2.2 Knockdown of FOXM1 suppresses cell proliferation in both paclitaxel 
sensitive and resistance MCF-7 cells 
To confirm the role of FOXM1 in breast cancer progression and paclitaxel resistance, 
MCF-7 and the paclitaxel resistant MCF-7 TaxR breast cancer cells were transfected 
with control siRNA or siRNA targeting FOXM1.  The effect of FOXM1 depletion on 
colony formation was next evaluated by clonogenic assay. The results showed that 
FOXM1 knockdown was able to sensitise MCF-7 cells to paclitaxel at the very low 
concentrations of paclitaxel and there was no difference in cell viability between the 
MCF-7 cells treated with 3, 5 or 10 nM paclitaxel (Figure 4.2A). Interestingly, FOXM1 
depletion alone significantly decreased the colony forming ability of MCF-7 TaxR 
cells which did not depend on the dosage of paclitaxel used suggesting that FOXM1 
can protect cells from paclitaxel-induced cell death (Figure 4.2B). 
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Figure 4.2: FOXM1 knockdown suppresses the clonogenic ability of MCF-7 and MCF-7 Tax
R
 
cells. A) MCF-7 and (B) MCF-7 Tax
R
 were transfected with NS siRNA or FOXM1 siRNA. 24 h after 
transfection, 2,000 cells were seeded in six well plates, treated with 0, 1, 3, 5, 7.5 and 10 nM of 
paclitaxel, grown for 15 days and then stained with crystal violet. The results represent average of two 
independent experiments ± SD. Statistical significance was determined by two-tailed unpaired 
Student’s t-test (* P ≤ 0.05, ** P ≤ 0.01 and n.s. for non-significant). 
155 
 
4.2.3 Elevated expression of FOXM1 confers paclitaxel resistance. 
In order to test if overexpression of FOXM1 is directly responsible for conferring 
paclitaxel resistance, I performed transient transfection with either pcDNA3 empty 
vector or pcDNA3-FOXM1 plasmids in MCF-7 cells, and evaluated cell viability using 
the sulforhodamine-B (SRB) assay. The result showed that the overexpression of 
FOXM1 was sufficient to increase paclitaxel resistance to the parental MCF-7 cells 
(Figure 4.3). These data suggest that overexpression of FOXM1 reduces sensitivity 
to paclitaxel by protecting MCF-7 cells from undergoing proliferative arrest.  
 
Figure 4.3: Overexpression of FOXM1 induces resistance to paclitaxel in MCF-7 cells. MCF-7 
cells were transfected with control empty vector or pcDNA3-FOXM1 plasmid. Cells were then treated 
with increasing concentrations of paclitaxel (1 – 50 nM) for 48 h and their cell viability measured by 
sulforhodamine B (SRB) assay. Representative data from three independent experiments are shown. 
Statistical analyses were performed using Student’s t-tests (**P≤0.05). 
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4.2.4 KIF20A and FOXM1 are upregulated in paclitaxel resistant MCF-7 (MCF-7 
TaxR) cells 
The mitotic kinesin KIF20A has been reported to be a potential downstream FOXM1 
target, which are involved in mitosis and chromosome segregation (Wonsey and 
Follettie, 2005). To elucidate the possible functional role of FOXM1 in paclitaxel 
resistance and the mechanism of action involved, I determined the protein 
expression levels of FOXM1 and its putative target KIF20A upon the paclitaxel 
treatment in both sensitive MCF-7 cells and paclitaxel resistant MCF-7 TaxR cells. 
The western blot analysis revealed that FOXM1 expression greatly decreased in the 
sensitive MCF-7 cells in response to the moderate dose of paclitaxel (10 nM), while 
the expression of FOXM1 in MCF-7 TaxR cells were maintained at high levels upon 
the treatment. Interestingly, the protein expression levels of KIF20A displayed a 
similar kinetic pattern observed for FOXM1 upon the paclitaxel treatment in both cell 
lines, indicating that FOXM1 possibly mediates paclitaxel sensitivity through 
regulation of KIF20A (Figure 4.4A, Figure S6). Interestingly, there was no change in 
the expression of PARP in MCF-7 cells, suggesting that other alternative forms of 
programmed cell death, such as senescence or mitotic catastrophe, can be triggered 
in response to 10 nM paclitaxel treatment. Consistently, RT-qPCR analysis showed 
that FOXM1 and KIF20A mRNA levels were significantly upregulated in MCF-7 TaxR 
cells compared with the sensitive MCF-7 cells which exhibited decreased KIF20A 
transcriptional levels by almost 50% after 24 h paclitaxel treatment (Figure 4.4B). 
However, the reduction in mRNA levels of FOXM1 and KIF20A were observed at 
48h paclitaxel treatment of MCF-7 TaxR cells. It is likely to be due to the MCF-7 TaxR 
cells becoming over-confluent as these cells proliferate rapidly and are not inhibited 
by paclitaxel causing the cells to undergo either cell-cycle arrest or cell death.  Taken 
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together, these results suggest that both KIF20A and FOXM1 proteins might be 
mediators of paclitaxel resistance in MCF-7 breast cancer cells. 
 
Figure 4.4: FOXM1 and KIF20A expression levels were strongly upregulated in paclitaxel-
resistant MCF-7 cells. (A) Protein expression levels of FOXM1 , KIF20A, cyclin B1 and PARP in 
MCF-7 and MCF-7 Tax
R
 cell lines following paclitaxel treatment at different time points were 
determined by western blot analysis (left panel). RT-qPCR analysis determining the relative mRNA 
expression levels of FOXM1 and KIF20A in MCF-7 and MCF-7 Tax
R
 cell lines following paclitaxel 
treatment at different time points. The results represent average of three independent experiments ± 
SD. Statistical significance was determined by Student’s t-test, **P ≤ 0.01. 
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4.2.5 Silencing of FOXM1 downregulates KIF20A expression 
According to the previous western blot analysis (Figure 4.4), FOXM1 and KIF20A 
expression are increased in MCF-7 TaxR cells compared to sensitive MCF-7 cells. To 
test if KIF20A is a downstream target of FOXM1, the expression of KIF20A was 
examined by RT-qPCR and western blot analysis following silencing FOXM1 using 
siRNA in MCF-7 and MCF-7 TaxR cells. The results showed that depletion of FOXM1 
significantly reduced the expression of KIF20A at both mRNA and protein levels 
(Figure 4.5A, Figure 4.5B and Figure S7), indicating that FOXM1 regulates 
expression of KIF20A. To confirm this further, the protein expression levels of 
FOXM1 and KIF20A were investigated by western blot analysis in WT and Foxm1-/- 
MEFs. I observed that in the Foxm1-/- MEFs there was a decreased expression of 
KIF20A (Figure 4.5C). Conversely, ectopic overexpression of FOXM1 in MCF-7 
breast cancer cells induced the expression of KIF20A (Figure 4.5D). In agreement, 
the KIF20A mRNA and protein were also downregulated after FOXM1 depletion in 
MDA-MB-231 cells (Figure 4.6). 
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Figure 4.5: Silencing of FOXM1 downregulates KIF20A expression in MCF-7 and MCF-7 TaxR 
cells. MCF-7 and MCF-7 Tax
R
 cells depleted in FOXM1 expression revealed significant decreases in 
both mRNA (A) and protein (B) levels of KIF20A expression. Bars represent mean± S.D. Statistical 
significance was determined by Student’s t-test, (**P≤0.01, significant). (C) Foxm1
−/− 
MEFs showed 
decreased protein expression of KIF20A. (D) Overexpression of FOXM1 caused an induction KIF20A 
expression levels in MCF-7 cells.  
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Figure 4.6: Depletion of FOXM1 causes a decrease in the expression of KIF20A in MDA-MB-231 
cells. MDA-MB-231 cells were transfected either with FOXM1 siRNA or non-silencing controls (NS). 
(A) FOXM1 and KIF20A mRNA levels were determined by RT-qPCR. Bars represent mean± S.D. 
Statistical significance was determined by Student’s t-test, (**P≤0.01, significant). (B) The expression 
levels of FOXM1, KIF20A and β-tubulin were analysed by western blot analysis.  
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4.2.6 Overexpression of FOXM1 enhances the transcriptional activity of KIF20A 
promoter 
It has been reported that FOXM1 binds to promoter regions of its targets with a 
preference for tandem repeats of a core consensus 'A(T/C)AAA(T/C)AA' recognition 
sequence (Myatt and Lam, 2007, Littler et al., 2010). In order to determine whether 
KIF20A is a direct downstream target of FOXM1, I initially performed luciferase 
assay in MCF-7 cells by co-transfection the KIF20A promoter luciferase reporter 
construct, previously generated in the laboratory by my college Dr Fung Zhao, with 
the FOXM1B-pcDNA3 plasmid. This KIF20A promoter construct contained a 1.1 kbp 
of region (−1150/−61) upstream of the most 5’-transcription start site. Five possible 
FOXM1 consensus binding sites were identified in this region and one of them is 
located at -91, as described in Figure S9. However, the luciferase reporter assay 
result revealed that FOXM1 was unable to transactivate and induce KIF20A 
transcription activity via this 5’-UTR region. Thus, I next analysed the consensus 
FOXM1 binding sequence in other region of KIF20A gene using the MCF-7 ChIP-
Seq data (hg19: GSM1010769) from the Encyclopedia of DNA Elements (ENCODE) 
project (Landt et al., 2012) and identified strong FOXM1 occupancy at a region (-
21/+144) mapped downstream of the most 5’-transcription start site but upstream of 
the 2nd transcription start site (Figure 4.7A). From sequence analysis, a putative 
forkhead responsive element (FHRE) was identified within (+80bp regions) (Figure 
4.7A).  To test whether this FOXM1 binding site in the KIF20A sequence (+80bp) 
was functional, I generated three new reporter plasmids: pGL3-KIF20A-WT, pGL3-
KIF20A-MUT1 (single site mutation at +80) and pGL3-KIF20A-MUT2 (double site 
mutation at -91 and +80 to test the specificity of FOXM1 binding site at +80) (Figure 
4.7A). To construct these three plasmids, the KIF20A-WT, KIF20A-MUT1, and 
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KIF20A-MUT2 fragments (Figure S10) were initially designed and synthesised by 
GeneArt (Life Technologies, Darmstadt, Germany). The synthesised DNA fragments 
were then amplified and cleaved with the restriction enzymes XhoI and Bglll and 
cloned into the XhoI/Bglll sites of the pGL3-basic vector (Promega, Madison, WI). 
DNA extracted from all the positive clones were re-digested with XhoI and Bglll 
enzymes and performed gel electrophoresis to confirm the gene inserts. As seen in 
the Figure 4.7B, the obtained bands correlated with the size of insert fragments (384 
bp) and pGL3-basic empty vector (4818 bp). These results indicate that the 
fragments were successfully cloned into the pGL3-basic luciferase reporter vector.  
I next assayed the ability of FOXM1 to induce KIF20A expression using a transient 
luciferase reporter assays in MCF-7 cells. As shown in the Figure 4.7C, the KIF20A-
WT promoter activity displayed a significant induction in response to ectopic FOXM1 
overexpression, whereas this significant induction was not observed in cells 
transfected with either of the mutant constructs of KIF20A promoter (MUT1 and 
MUT2). Interestingly, there was no further significant reduction in KIF20A promoter 
activity observed in the cells transfected with double mutation at both -91 and 80+bp 
(MUT2) construct, when compared to the cells transfected with single mutation at 
+80 bp (MUT1) construct. This result suggests that FOXM1 is able to activate 
KIF20A transcription activity specifically through the consensus FOXM1 binding site 
located at +80 bp. 
4.2.7 FOXM1 directly binds to KIF20A loci in MCF-7 cells. 
To confirm further that FOXM1 directly binds to KIF20A promoter region at +80 bp, I 
performed ChIP analysis in MCF-7 cells using specific primers (+8/+131) to amplify 
the putative FOXM1 binding site (Figure 4.8A). The chromatin fragments from empty 
vector control and FOXM1-overexpressing MCF-7 cells were immunoprecipitated 
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with either FOXM1 or IgG negative control antibodies. The binding of FOXM1 at 
KIF20A sequence was quantified by RT-qPCR analysis. As shown in Figure 4.8B 
(top-left panel), the ChIP analysis showed that overexpression of FOXM1 enhances 
the enrichment of the binding of FOXM1 to the KIF20A promoter region. In contrast, 
the inhibition of FOXM1 expression and transcription activity by treating with 10 µM 
thiostrepton, as previously described (Kwok et al., 2008), significantly decreases the 
FOXM1 occupancy (Figure 4.8B, bottom-left panel), suggesting that FOXM1 is able 
to bind and transactivate the KIF20A gene through the FHRE located at position 
(+80 bp). Taken together, these results strongly support the notion that FOXM1 is a 
crucial transcriptional regulator of the KIF20A.  
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Figure 4.7: Overexpression of FOXM1 enhances the transcriptional activity of KIF20A promoter 
in MCF-7 cells. (A) Schematic representation of the human KIF20A promoter region depicting the 
FOXM1 binding site (wild-type (+80)) and the FOXM1 binding site-mutated MUT1 and MUT2. (B) 
Cloning of 384 bp KIF20A promoter fragment into pGL3basic. pGL3 basic harbouring either WT, 
MUT1 or MUT2 promoter was re-digested with XhoI and Bglll and ran on a 1% agarose gel to confirm 
the constructs. (C) MCF-7 cells were transiently co-transfected with wild-type or FOXM1 binding site-
mutated (mut) KIF20A reporter plasmids and Renilla luciferase plasmid along with or without FOXM1 
expression plasmids. Twenty-four hours after transfection, cells were lysed, and the luciferase activity 
was examined. Firefly luminescence signal was normalised based on the Renilla luminescence 
signal. The results represent average of three independent experiments ± SD. Statistical significance 
was determined by two-tailed unpaired Student’s t-test (** P ≤ 0.01 and n.s. for non-significant).  
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Figure 4.8: FOXM1 directly binds to the KIF20A promoter region in MCF-7 cells. (A) Schematic 
representation of the human KIF20A promoter region depicting the FOXM1 binding site (FHRE) and 
the ChIP-qPCR specific primer regions: to amplify the putative FOXM1 binding site (+8/+131) and 
negative control site located at the 5’ upstream non-coding region (-813/-938 bp)  of KIF20A gene(B) 
The binding of FOXM1 to the KIF20A promoter was determined by ChIP analysis in FOXM1-
overexpressing (B, upper panel) or FOXM1-depleted (B, lower panel) MCF-7 cells. The chromatin 
fragments obtained from transfected cells were immunoprecipitated with either FOXM1 or IgG 
negative control antibodies. The binding of FOXM1 at KIF20A sequence was then quantified by RT-
qPCR analysis. The results represent average of two independent experiments ± SD. Statistical 
significance was determined by two-tailed unpaired Student’s t-test (** P ≤ 0.01). 
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4.2.8 Low concentrations of paclitaxel cause aberrant mitosis in MCF-7 cells 
Apoptosis has been considered as the main mechanism of cell death in response to 
chemotherapy (Ricci and Zong, 2006). Currently, a more heterogeneous model of 
therapeutic response is acknowledged wherein multiple forms of death combine to 
generate the overall tumour response. The resulting mechanisms of cell death are 
determined by several factors, including the mechanism of action of the therapy, the 
dose regimen used, and the genetic background of the cells within the tumour 
(Morse et al., 2005). Paclitaxel-mediated cell death is usually studied at high 
concentrations of drug (10 to 200 nM) that cause mitotic arrest and rapid cell death 
(Blagosklonny and Fojo, 1999, Zasadil et al., 2014). In this study, I tested whether 
low concentrations of paclitaxel (≤5 nM) are sufficient to render MCF-7 cells to 
undergo cell death. To determine the cellular consequences of treatments with low 
concentrations of paclitaxel, MCF-7 cells were incubated with the indicated doses of 
paclitaxel and the mitotic spindle formation was then examined using α-tubulin 
antibodies to stain microtubules, γ-tubulin to stain centrosome and DAPI to stain 
DNA. Figure 4.9A (top panel) indicates a control (untreated) cell in mitosis, with a 
typical bipolar spindle. Figure 4.9A (lower panels) represent various mitotic 
abnormalities, including bipolar spindles with an irregular chromosome alignment, 
monopolar and multipolar spindles, observed in paclitaxel-treated MCF-7 cells. 
Quantitative analysis of mitotic cells stained with α-tubulin and γ-tubulin antibodies 
(Figure 4.9B) indicates that ~80% of 5 nM paclitaxel treated MCF-7 cells exhibited 
mitotic spindle defects. 
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Figure 4.9: Low concentrations of paclitaxel cause mitotic catastrophe. MCF-7 cells were 
treated with or without 5 nM paclitaxel for 24 h. Cells were then immunostained with α-tubulin 
antibody (Green) and γ-tubulin antibody (Red). Nuclei were stained with DAPI (Blue). Metaphase cells 
were captured using Leica TCS SP5 (63X magnification). For each condition, images of at least 50 
mitotic cells were analysed. (A) Representative confocal images are shown. The metaphase cells 
classified into four distinct spindle formation types, including normal bipolar, bipolar with unaligned-
chromosome, monopolar or multipolar spindles, were quantified. (B)  Bars represent average of three 
independent experiments ± SD. Statistical significance was determined by two-tailed unpaired 
Student’s t-test (* P ≤ 0.05, **P≤0.01, significant; n.s. for non-significant). 
 
 
 
 
 
 
 
 
 
 
169 
 
4.2.9 Knockdown of FOXM1 or KIF20A leads to defects in mitotic spindle 
formation and chromosome alignment. 
To address how the lack of FOXM1 affects mitotic progression in MCF-7 cells, the 
subcellular distribution of α-tubulin and chromosomes was examined in metaphase 
of MCF-7 cells after FOXM1 and KIF20A knockdown (Figure 4.10). In the control 
siRNA-transfected cells, condensed chromosomes were aligned properly at the 
metaphase plate with bipolar spindles. By contrast, the FOXM1 and KIF20A-
depleted cells displayed abnormal mitotic spindles, including monopolar and 
multipolar mitotic spindles as well as bipolar spindles with unaligned chromosomes. 
The frequency of abnormal mitotic spindles in MCF-7 cells was increased 
approximately 3-fold compared to the control by FOXM1 knockdown and about 4-
fold by KIF20A knockdown (Figure 4.10A-C). The failure to establish normal mitotic 
spindles in metaphase induced by KIF20A and FOXM1 depletion also caused a 
significant increase in lagging chromosomes in anaphase (Figure 4.11) and 
ultimately, the accumulation of large multinucleated cells, indicative of mitotic 
catastrophe (Figure 4.12). These results indicated that FOXM1 and KIF20A are 
essential for the formation of normal mitotic spindles, and defects of which lead to 
abnormal chromosome segregation and mitotic progression. Interestingly, in the 
paclitaxel-treated MCF-7 cells the increase in abnormal spindle formation after 
FOXM1 or KIF20A silencing was no longer apparent. Together with my previous 
results, these findings suggest that FOXM1 and KIF20A modulate the cytostatic and 
cytotoxic function of paclitaxel through regulation of mitotic spindle formation. 
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Figure 4.10: Knockdown of FOXM1 or KIF20A leads to defects in mitotic spindle formation and 
chromosome alignment. (A and B) MCF-7 cells were transfected with NS, FOXM1 or KIF20A 
siRNA. 24 h after transfection, cells were treated with 5 nM paclitaxel for 24 h. Cells were then 
immunostained with α-tubulin antibody (Green). Nuclei were stained with DAPI (Blue). Metaphase 
cells were visualised with Leica TCS SP5 (63X magnification). For each condition, images of at least 
50 mitotic cells were captured. Representative confocal images are shown. (C) The number of 
metaphase cells classified into either normal bipolar, abnormal bipolar, monopolar or multipolar 
spindles were quantified. Results represent average of three independent experiments ± S.D. 
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Figure 4.11: Depletion of FOXM1 or KIF20A causes anaphase bridges, lagging chromosomes, 
and chromosome instability in MCF-7. MCF-7 cells were treated with or without 5 nM paclitaxel for 
24 h. immunostained with α-tubulin antibody (Green) and γ-tubulin antibody (Red). Nuclei were 
stained with DAPI (Blue). Metaphase cells were captured using Leica TCS SP5 (63X magnification). 
Mitotic cells were visualised with Leica TCS SP5 (63X magnification).For each condition, images of at 
least 50 anaphase cells were captured to analyse for the frequency of anaphase bridges and/or 
lagging chromosome. Representative confocal images are shown. Results represent average of three 
independent experiments ± S.D. Yellow arrows indicate chromosomal abnormalities, such as lagging 
chromosomes and chromosome bridges. 
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Figure 4.12: Characterisation of mitotic catastrophe in MCF-7 cells following FOXM1 or KIF20A 
knockdown or paclitaxel treatment. MCF-7 cells were transfected with NS, FOXM1 or KIF20A 
siRNA. 24 h after transfection, cells either left untreated or treated with 5 nM paclitaxel for 24 h. Cells 
were then immunostained with antibody against α-tubulin (Green). Nuclei were stained with DAPI 
(Blue). Cells were visualised with Leica TCS SP5 (63X magnification).  
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4.2.10 Intracellular localisation of FOXM1 and KIF20A during mitosis 
To study the functional significance of FOXM1 and KIF20A in mitosis, the subcellular 
localisation of FOXM1 and KIF20A were examined at different stages of mitosis in 
MCF-7 cells by immunofluorescent staining with FOXM1 and KIF20A antibodies 
(Figure 4.13). During interphase, the staining pattern of FOXM1 in the nucleus 
overlapped with KIF20A. However, KIF20A was also detected in the cytoplasm, 
indicating that in the interphase cells, KIF20A participates in retrograde vesicular 
traffic between the Golgi apparatus and the endoplasmic reticulum (Gasnereau et 
al., 2012). In metaphase cells possessing a single spindle, the two proteins co-
localised in cytoplasm. At anaphase, FOXM1 and KIF20A staining accumulated in 
the midzone of the spindle. When cells were at telophase, both FOXM1 and KIF20A 
were present sharply concentrated in the midbody, further suggesting that FOXM1 
and KIF20A may function together and are essential for cell cycle regulation during 
successful cytokinesis. 
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Figure 4.13: Dynamic localisation of FOXM1 and KIF20A during mitosis of MCF-7 cells. 
Immunofluorescence analysis of FOXM1 and KIF20A localisation during mitosis of MCF-7 cells by 
labelling with antibodies against FOXM1 (Green) and KIF20A (Red). Nuclei were counterstained with 
DAPI (Blue). Stained mitotic cells were visualised with Leica TCS SP5 (63X magnification). 
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4.2.11 Depletion of KIF20A or FOXM1 reduces long-term clonogenic survival 
and induces cellular senescence in MCF-7 and MCF-7 TaxR cell lines. 
I next tested the efficiency of targeting FOXM1 and KIF20A in MCF-7 and the 
paclitaxel-resistant MCF7-TaxR breast cancer cell lines. According to previous long 
term clonogenic assay results in Figure 4.2, it showed that there was no difference in 
cell viability between the MCF-7 cells treated with 3, 5 or 10nM paclitaxel. Therefore, 
in this experiment, cells were transfected with siRNA targeting FOXM1 and KIF20A 
and long-term cell viability rates were evaluated by clonogenic assay at very low 
doses of paclitaxel (1 and 3 nM). The results showed that knockdown of FOXM1 
sensitised MCF-7 cells to long-term proliferative arrest at relatively low paclitaxel 
dose. Similar to FOXM1 depletion, knockdown of KIF20A also increased the 
sensitivity of MCF-7 cells to paclitaxel at the same concentration of the drug (Figure 
4.15A). Interestingly, depletion of FOXM1 or KIF20A alone almost completely 
inhibited the colony-forming capacity of MCF-7 TaxR cells irrespective of the dosage 
of paclitaxel used, suggesting that MCF-7 TaxR cells are dependent on high 
expression levels of FOXM1 and KIF20A for long-term survival (Figure 4.17A). 
Consistent with the clonogenic assay results, FOXM1 and KIF20A knockdown in 
MCF-7 Tax
R
 cells significantly induced senescence-associated SA-βgal activity and 
morphology independent of the paclitaxel concentration, suggesting that MCF-7 
TaxR cells have become dependent on FOXM1 and KIF20A expression to override 
the non-apoptotic pathway including cellular senescence (Figure 4.17B). 
Transfection efficiency of FOXM1 siRNA and KIF20A siRNA knockdown in MCF-7 
(Figure 4.14) and MCF-7 TaxR (Figure 4.16) was confirmed by monitoring the uptake 
of the BLOCK-iT fluorescent oligo (green fluorescence) at 48 h following transfection 
using Oligofectamine. The results showed that more than 80% of cells were 
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successfully transfected. The silencing effect was also tested by RT-qPCR and 
western blot analysis. 
 
 
Figure 4.14: The transfection efficiency of FOXM1-siRNA and KIF20A-siRNA in MCF-7 cells. 
(A)Transfection efficiency was monitored by the uptake of the BLOCK-iT fluorescent oligo (green 
fluorescence) at 48 h following transfection using Oligofectamine. More than 70% of cells were 
successfully transfected. (B) FOXM1 and KIF20A mRNA expression levels were detected by real-time 
qPCR at 48 h post-transfection. Bars represent average±S.D. Statistical significance was determined 
by two-tailed unpaired Student’s t-test (**P≤0.01). (C) FOXM1 and KIF20A protein expression levels 
were detected by Western blot analysis at 48 h post-transfection. 
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Figure 4.15: Targeting KIF20A or FOXM1 using siRNA inhibits cell growth and induces 
senescence in MCF-7 cells. (A) MCF-7 cells were transfected with either NS (non-targeting control) 
siRNA, siRNA targeting FOXM1 or KIF20A. 24 h after transfection, 2,000 cells were seeded in six well 
plates, treated with 0, 1, or 3 nM of paclitaxel, grown for 15 days and then stained with crystal violet 
(left panel). The result (right panel) represents average of three independent experiments ± SD. 
Statistical significance was determined by two-tailed unpaired Student’s t-test (*P 0.05, **P 0.01, ***P 
0.005; n.s., non-significant). In parallel, (B) MCF-7 transfected with NS, FOXM1 or KIF20A siRNA 
were seeded in six-well plates, treated with 0, 1, or 3 nM of paclitaxel. Five days after treatment, cells 
were stained for SA-βgal activity. The graph shows the percentage of SAβ-gal-positive cells as 
measured from five different fields from two independent experiments. Bars represent average±S.D. 
Statistical significance was determined by two-tailed unpaired Student’s t-test (*P≤0.05, **P≤0.01, 
***P≤0.005, significant; n.s., non-significant).  
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Figure 4.16: The transfection efficiency of FOXM1-siRNA and KIF20A-siRNA in MCF-7 Tax
R 
cells. (A)Transfection efficiency was monitored by the uptake of the BLOCK-iT fluorescent oligo 
(green fluorescence) at 48 h following transfection using Oligofectamine. More than 70% of cells were 
successfully transfected. (B) FOXM1 and KIF20A mRNA expression levels were detected by real-time 
qPCR at 48 h post-transfection. Bars represent average± S.D. Statistical significance was determined 
by two-tailed unpaired Student’s t-test (**P≤0.01). (C) FOXM1 and KIF20A protein expression levels 
were detected by Western blot analysis at 48 h post-transfection. 
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Figure 4.17: Targeting KIF20A or FOXM1 using siRNA significantly impairs colony formation 
and induces senescence in MCF-7 Tax
R
 cells. (A) MCF-7 Tax
R
 cells were transfected with either 
NS, FOXM1 siRNA or KIF20A siRNA. 24 h after transfection, 2,000 cells were seeded in six well 
plates, treated with 0, 1, or 3 nM of paclitaxel, grown for 15 days and then stained with crystal violet 
(left panel). The result (right panel) represents average of three independent experiments ± SD. 
Statistical significance was determined by two-tailed unpaired Student’s t-test (**P 0.01, significant; 
n.s., non-significant). In parallel, (B) MCF-7 Tax
R
 transfected with NS, FOXM1 or KIF20A siRNA were 
seeded in six-well plates, treated with 0, 1, 3 nM of paclitaxel. Five days after treatment, cells were 
stained for SA-βgal activity. The graph shows the percentage of SAβ-gal-positive cells as measured 
from five different fields from two independent experiments. Bars represent average±S.D. Statistical 
significance was determined by two-tailed unpaired Student’s t-test (*P≤0.05, **P≤0.01, significant; 
n.s., non-significant).  
 
 
181 
 
4.2.12 Correlation between FOXM1 and KIF20A expression in breast cancer 
samples 
After establishing that KIF20A is a direct transcriptional target of FOXM1 in breast 
cancer, in collaboration with Professor Khoo Ui Soon (Department of Pathology, the 
University of Hong Kong), we established further the physiological significance of the 
regulation of KIF20A by FOXM1 in breast cancer using the same set of TMA 
described in chapter 3 (n=116), but only 100 cases had assessable KIF20A scores. 
Tissues of the remaining 16 cases were missing. For the immunohistochemical 
analysis, KIF20A score was dichotomized using the median of all the KIF20A scores. 
So half of the cases were assigned as KIF20A high and half were assigned as 
KIF20A low. The results revealed that FOXM1 and KIF20A proteins were detected in 
both nuclear and cytoplasmic compartments. Statistical analysis of the expression 
patterns of these proteins showed that there was a strongly significant correlation 
between FOXM1 and KIF20A expression (Pearson coefficient r=0.292, P=0.006 for 
total KIF20A; r=0.250, P=0.019 for cytoplasmic KIF20A; r=0.228, P=0.034 for 
nuclear KIF20A) (Figure 4.18A and 4.18B). This further supported my finding in the 
cell lines that FOXM1 directly regulates KIF20A transcription. In addition, survival 
analysis by Kaplan-Meier estimate with log-rank test revealed that overexpression of 
nuclear KIF20A was significantly associated with poor prognosis (P = 0.045 for 
overall survival and P=0.016 for disease-specific survival, respectively) (Figure 
4.19A). In multivariate Cox regression analysis, KIF20A nuclear staining remained 
associated with poor survival after correcting for tumour stage and lymph-node 
involvement (P = 0.047, RR=2.47 for overall survival and P=0.037, RR=2.767 for 
disease-specific survival, respectively) (Figure 4.20A), suggesting that KIF20A 
nuclear score is a prognostic marker independent of the clinicopathological 
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parameters examined. In this cohort, 60% of patients received chemotherapy. For 
these patients, high nuclear KIF20A expression was significantly associated with 
poor survival (log-rank test, P=0.008 for overall survival and P=0.004 for disease-
specific survival, respectively) (Figure 4.19B) and presented a stronger risk marker 
(P=0.013, RR=4.008 for overall survival and P=0.01, RR=5.089 for disease-specific 
survival, respectively) (Figure 4.20B), suggesting that similar to FOXM1, KIF20A 
expression is associated with chemotherapeutic drug resistance. In agreement, 
further Kaplan-Meier analysis of KIF20A and FOXM1 mRNA transcript expression in 
a previously published cohort (1,809 breast cancer patients) (Györffy et al., 2010) 
confirmed that both high FOXM1 and KIF20A mRNA expression levels are very 
significantly related to poor survival (p<0.00001 and p<0.00001, respectively for 
overall survival) (Figure 4.19C). The significance of both FOXM1 and KIF20A 
presented in different survival analyses further strengthened the crucial involvement 
of both genes in breast cancer progression and chemotherapeutic drug response.  
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Figure 4.18: Correlation between FOXM1 and KIF20A expression in breast cancer samples. (A) 
FOXM1 and KIF20A expression was assessed by immunohistochemistry using tissue-microarray 
(TMA) slides containing 100 breast cancer patient samples. KIF20A score is dichotomized using the 
median of all the KIF20A scores. So half of the cases are assigned as KIF20A high and half are 
assigned as KIF20A low. Representative staining images of one patient with high FOXM1 and KIF20A 
expression and one with low expression were shown. Positive correlation between FOXM1 and 
KIF20A was observed. (B) KIF20A staining was detected in both nuclear and cytoplasmic 
compartments and was correlated with FOXM1 staining. Statistical analysis revealed that KIF20A 
expression in all three standard scores, including total, cytoplasmic and nuclear, were significantly 
correlated with FOXM1 expression (P=0.006, P=0.019 and P=0.034, respectively). 
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Figure 4.19: Upregulation of KIF20A significantly associated with poorer survival in breast 
cancer patients. (A) Kaplan-Meier survival analysis of all patients (n=100) and (B) patients received 
chemotherapy (n=60), compared by log-rank test, revealed that nuclear overexpression of KIF20A 
was significantly correlated with poorer survival. (P=0.045 and P=0.016, respectively). (C) The other 
Kaplan-Meier survival analysis of KIF20A and FOXM1 mRNA transcript expression in a previously 
published cohort (n= 1,809) (Györffy et al., 2010) also showed that the overexpression of FOXM1 and 
KIF20A mRNA significantly associated with poorer survival. 
185 
 
 
186 
 
Figure 4.20: Univariate and multivariate Cox-regression analysis using KIF20A nuclear score 
and other clinicopathological parameters. (A) Nuclear KIF20A overexpression is associated with 
higher risk of death in univariate analysis (P = 0.05, RR=2.141 for overall survival and P=0.02, 
RR=2.695 for disease-specific survival, respectively) and remained associated with poor survival after 
correcting for tumour stage and lymph-node involvement (P = 0.047, RR=2.47 for overall survival and 
P=0.037, RR=2.767 for disease-specific survival, respectively) (B) Nuclear KIF20A overexpression 
significantly associated with poorer survival in breast cancer patients who had received chemotherapy 
(log-rank test, P = 0.008 for overall survival and P=0.004 for disease-specific survival, respectively). In 
this cohort, Cox-regression analysis showed that nuclear KIF20A overexpression is an even stronger 
risk marker (P=0.013, RR=4.008 for overall survival and P=0.01, RR=5.089 for disease-specific 
survival, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
187 
 
4.3 Discussion  
Mitosis is a complicated process in actively proliferating cells, leading to the division 
into duplicated sets of chromosomes and two genetically identical daughter cells. 
Failure of cell cycle regulation often causes genetic instability, culminating either in 
cell death or in tumorigenesis (Chan et al., 2012). As the hallmark of cancer is 
involved in cell cycle deregulation, anti-mitotic therapies therefore are effective 
against the abnormal proliferation of transformed cells (Chan et al., 2012). Paclitaxel 
is a powerful anti-mitotic agent which targets the microtubule dynamic, leading to 
mitotic arrest. Cells arrested in mitosis either die during mitosis or undergo a process 
called mitotic slippage, where the cells enter G1 without undergoing anaphase or 
cytokinesis to produce a single, tetraploid cell. Despite the success of paclitaxel, 
toxic side effects and the development of drug resistance represent main obstacles 
to improve the overall response and survival of breast cancer patients (Orr et al., 
2003). To overcome this problem, it is thus necessary to better understand the 
mechanisms of drug action and resistance.  
In this chapter, I found that FOXM1 is overexpressed in paclitaxel-resistant MCF-7 
TaxR breast cancer cell lines when compared with the parental sensitive MCF-7 
cells. FOXM1 expression is downregulated in response to paclitaxel in MCF-7 cells, 
but remains persistently high in the resistant cells following paclitaxel treatment 
(Figure 4.4). These data suggests the possibility that FOXM1 is a target of paclitaxel 
and that it has a role in mediating paclitaxel action and resistance. Consistent with 
this notion, the previous result from our laboratory has shown that paclitaxel exerts 
its cytotoxicity through FOXO3a, which is an upstream negative regulator of FOXM1 
expression and activity (Karadedou et al., 2012, Sunters et al., 2006).  
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It is relatively well established that the elimination of cancer cells by high 
concentrations of paclitaxel is predominantly mediated by triggering apoptosis 
(Chang et al., 1999, Roninson et al., 2001, Blagosklonny and Fojo, 1999, Zasadil et 
al., 2014). Interestingly, this study reveal that in response to low concentrations of 
paclitaxel (≤10 nM), breast cancer cell lines undergo mitotic catastrophe (aberrant 
mitosis) which have typical features including mitotic spindle disorganisation, failed 
chromosome segregation, and formation of multinucleated cells. This aberrant 
mitotic process is followed by cellular senescence and/or non-apoptotic cell death. 
Crucially, similar to paclitaxel treatment, FOXM1 depletion also induces mitotic 
catastrophe, culminating in non-apoptotic cell death and senescence (Figures 4.10 
and 4.12).  Consistently, a previous study also showed that silencing of FOXM1 can 
induce centrosome amplification and mitotic catastrophe as well as senescence in 
cancer cells (Laoukili et al., 2005, Wonsey and Follettie, 2005, Zhao et al., 2014). 
During mitosis, the bipolar mitotic spindle assembly is essential for ensuring 
appropriated chromosome segregation and, hence, for successful cell division (Chee 
and Haase, 2010). Kinesin proteins are the main factors required for proper spindle 
formation, chromosome alignment and segregation (Chee and Haase, 2010). 
Kinesin proteins have been proposed to control microtubule dynamics within a 
mitotic spindle (Walczak and Mitchison, 1996). KIF20A (Kinesin-like family member 
20A), also known as MKPL2 or Rab6 kinesin,  belongs to the family of kinesin 
proteins which was originally involved in Golgi apparatus dynamics through direct 
interaction with Rab6 small GTPase. Recent reports have shown that KIF20A 
accumulates in mitotic cells and is thought to be essential for cell cycle regulation 
during cytokinesis (Zhang et al., 2014b). Here, I found that KIF20A is transcriptionally 
regulated by FOXM1. In agreement, knockdown of FOXM1 in MCF-7 breast cancer 
189 
 
cell lines as well as in MEFs led to a significant downregulation of KIF20A at both 
protein and mRNA levels, whereas overexpression of FOXM1 enhanced KIF20A 
expression level (Figure 4.5). Moreover, Chromation-Immunoprecipitation (ChIP) and 
luciferase assay results showed that FOXM1 also specifically binds and regulates 
the transcriptional activity of KIF20A gene (Figure 4.7- 4.8).  
In MCF-7 cells, the expression of KIF20A, like FOXM1, is simultaneously 
downregulated in response to paclitaxel treatment, suggesting the possibility that 
paclitaxel may exert its cytotoxic action by suppressing the expression of both 
FOXM1 and KIF20A expression. Consistent with this idea, I found that KIF20A or 
FOXM1 knockdown using siRNA results in an increase in the frequency of abnormal 
mitotic spindle formation with non-aligned or misaligned chromosomes (Figure 4.10). 
These results are consistent with the previous study performed in human hepatoma 
cell lines, showing that KIF20A depleted cells exhibited abnormal mitosis, with 
misaligned chromosomes in metaphase and reduced furrow ingression in telophase 
and cytokinesis (Gasnereau et al., 2012). Moreover, studies in Drosophila also 
showed that mutants of Subito, an ortholog of KIF20A in mammalian cells, 
improperly assembled microtubules at metaphase, leading to activation of the 
spindle assembly checkpoint and lagging chromosomes at anaphase. This further 
suggests that KIF20A participates in mitotic spindle assembly and interacts with 
mitotic regulators (Cesario et al., 2006, Zhang et al., 2014b). However, the 
paclitaxel-induced spindle abnormalities and chromosome misalignment defects are 
not further enhanced by depletion of KIF20A or FOXM1, further confirming the idea 
that paclitaxel targets the FOXM1-KIF20A axis to induce mitotic catastrophe in MCF-
7 cells (Figure 4.10). Interestingly, our data also showed an increase in mitotic 
catastrophe which occurred spontaneously in some FOXM1 or KIF20A depleted 
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cells, resembling paclitaxel treatment. This further supports that paclitaxel exerts its 
function through suppressing FOXM1 and KIF20A expression. The spindle assembly 
checkpoint (SAC) ensures proper chromosome segregation and delays the transition 
to anaphase in the presence of is defective mitotic spindle formation with unaligned 
chromosomes (Wolanin et al., 2010, Musacchio and Salmon, 2007). When the SAC 
functions properly, prolonged incubation with paclitaxel causes abnormal mitotic 
spindle formation and metaphase arrest leading to mitotic catastrophe. Therefore, I 
speculate that the elevated expression of FOXM1 and KIF20A observed in the 
paclitaxel resistant cells counteracts the ability of paclitaxel to induce abnormal 
spindles through their downregulation.  
In term of paclitaxel resistance, similar to FOXM1, KIF20A protein was upregulated 
in paclitaxel resistant breast cancer cell, indicating that both FOXM1 and KIF20A 
might contribute to paclitaxel resistance. I next tested the efficiency of targeting 
FOXM1 and KIF20A in MCF-7 and the paclitaxel-resistant MCF-7 TaxR breast 
cancer cell lines. The clonogenic assay results showed that FOXM1-knockdown 
sensitised MCF-7 cells to long-term proliferative arrest at relatively low paclitaxel 
dose (1 and 3 nM). Like FOXM1 depletion, knockdown of KIF20A also sensitised 
MCF-7 cells to paclitaxel at the very low concentrations of the drug (Figure 4.14). 
Interestingly, knockdown of FOXM1 or KIF20A alone almost completely abolished 
the colony-forming capacity of MCF-7 TaxR cells irrespective of the dosage of 
paclitaxel used, suggesting that MCF-7 TaxR cells are dependent on the high 
expression levels of FOXM1 and KIF20A for long-term survival (Figure 4.17A). 
Consistent with the clonogenic assay results, FOXM1 and KIF20A knockdown in 
MCF-7 TaxR cells significantly induced senescence-associated SA-βgal activity and 
morphology independent of the paclitaxel concentration, suggesting that MCF-7 
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TaxR cells have become dependent on the high expression of FOXM1 and KIF20A to 
override non-apoptotic cell death (Figure 4.17B). These findings also appear to be 
consistent with a previous study that identified KIF20A as effective inducer of non-
apoptosis cell death (Groth-Pedersen et al., 2012).  
Finally, in order to evaluate the potential ability of FOXM1 and KIF20A as prognostic 
and predictive biomarkers, I validated my in vitro findings in breast cancer patient 
samples by using immunohistochemistry or Tissue Microarray Analysis (TMA). 
Statistical analysis of the expression patterns revealed that there was a strong and 
significant correlation between the nuclear staining of FOXM1 and total KIF20A 
staining, providing further physiological evidence that FOXM1 regulates KIF20A 
expression in breast cancer patient samples. Crucially, like FOXM1, nuclear KIF20A 
overexpression (Figure 4.18) is also correlated with poor prognosis in terms of 
overall and disease specific survival. As 60% of these patients studied have received 
chemotherapy in the forms of anthracyclines and/or taxanes, these 
immunohistochemistry data also support the idea that FOXM1 regulates KIF20A to 
modulate paclitaxel resistance. In summary, my data suggest that paclitaxel targets 
FOXM1 to downregulate mitotic kinesins, such as KIF20A, to disrupt normal mitotic 
spindle formation, thus inducing senescence-related cell cycle arrest and cell death 
in these cells.  
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5. Final Discussion  
Overexpression of the oncogenic transcription factor FOXM1 has been implicated in 
the development of drug resistance to various cytotoxic agents including epirubicin 
(Millour et al., 2011, Monteiro et al., 2013, Myatt et al., 2014) and paclitaxel (Carr et 
al., 2010, Li et al., 2014). However, the exact molecular mechanisms underlying the 
regulation of sensitivity and resistance to these drugs by FOXM1 is not completely 
understood. 
At the molecular level, the oncogenic potential of FOXM1 is mainly associated with 
its ability to transcriptionally regulate genes which are involved in different aspects of 
cancer development (Halasi and Gartel, 2013a, Koo et al., 2012). Therefore, in order 
to have a better understanding of how FOXM1 contributes to drug resistance, it is 
imperative to identify novel downstream targets, which would be differently 
expressed in sensitive and resistance breast cancer cells. The identification of novel 
targets of FOXM1 will not only be crucial to provide better insights into the precise 
mechanism of the action of chemotherapeutic drugs, but would also provide the 
basis for improving drug design aiming to specifically eradicate cancer cells with a 
limited toxicity towards normal cells. In this thesis, I have identified and characterised 
two novel FOXM1 downstream targets - NBS1 and KIF20A that are involved in 
epirubicin and paclitaxel drug resistance, respectively.   
In chapter 3, I have established that FOXM1 mediates acquired epirubicin resistance 
in breast cancer cells through regulating NBS1, a DNA repair gene. This enhances 
HR repair activity to alleviate epirubicin-induced DNA damage (Khongkow et al., 
2014). Since the mechanism of action of epirubicin is associated with the induction of 
DNA double-strand breaks (DSBs) (Minotti et al., 2004, Nardella et al., 2011, Lord 
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and Ashworth, 2012, Choudhury et al., 2009), I investigated the involvement of 
FOXM1 in DNA damage response signalling and found that FOXM1 directly 
regulates NBS1 expression through a Forkhead response element (FHRE) in its 
promoter and in turn, upregulation of NBS1 could enhance the stability of MRN 
complex, leading to an increased kinase activity of ATM. Together with the results of 
DR-GFP repair assay, this clearly confirms that the functional role of FOXM1 in HR-
mediated DSB repair is directly linked to its ability to regulate NBS1 expression.  
Additionally, FOXM1 has previously been reported to indirectly enhance HR repair 
ability through promoting Skp2 and Cks1 (Wang et al., 2005a), which are key 
components of the Skp2–SCF E3 ligase complex that mediates the K63-linked 
ubiquitination of NBS1 upon DSBs. This process is essential for the interaction of 
NBS1 with ATM and leads to the activation of ATM and its recruitment to the DNA 
damage sites to initiate HR repair (Zona et al., 2014, Wu et al., 2012). Furthermore, 
FOXM1 has also been reported to regulate several other DNA repair effector 
proteins, such as BRIP1 (Monteiro et al., 2013), RAD51 (Zhang et al., 2012), EXO1 
(Zhou et al., 2014), BRCA2, and XRCC1 (Tan et al., 2007). Besides regulating the 
expression of DNA damage sensor and effector proteins, FOXM1 has also been 
shown to modulate chromatin structure remodelling and DNA repair by regulating the 
expression of SIRT1 (Zona et al., 2014). This protein functions to deacetylate NBS1, 
enabling it to activate ATM signalling (Yuan et al., 2007). Altogether, these findings 
strongly suggest that FOXM1 plays a critical role in DNA damage response through 
regulating NBS1 expression and ATM activity. This function of FOXM1 as 
transcription regulator of DNA repair genes makes FOXM1 an attractive target to 
enhance the cellular sensitivity of tumour cells to chemotherapy or radiotherapy- 
induced DNA damage.  
195 
 
In agreement with this finding, I also found that depletion of FOXM1 in both MEFs 
and MCF-7 cells caused a defect in DNA repair in response to epirubicin, as 
indicated by the higher level of γH2AX foci. Conversely, reconstitution of FOXM1 in 
Foxm1-deficient MEFs decreased the accumulation of γH2AX foci in response to 
epirubicin treatment, further supporting that FOXM1 plays a critical role in DNA 
damage response and protects the cells from drug-induced DNA damage.  
Additionally, I found that the protein expression patterns of NBS1 expression was in 
accordance to FOXM1 in epirubicin sensitive and resistant MCF-7 cells. NBS1 
expression was downregulated in MCF-7 cells but persistently upregulated in the 
resistant cells following epirubicin treatment, suggesting that both FOXM1 and NBS1 
play a role in mediating epirubicin action and resistance. In MCF-7, depletion of 
NBS1 significantly inhibited long-term cell proliferation and triggered premature 
senescence in response to low doses of epirubicin. This occurs due to the defects in 
DNA repair, leading to accumulation of irreparable DNA lesions, persistent DDR 
signalling, prolonged p53-dependent cell cycle arrest, and eventually an essentially 
irreversible senescence arrest (Rodier et al., 2009a). More interestingly, FOXM1 or 
NBS1 depletion alone in MCF-7 EpiR cells severely impaired their long-term viability 
and significantly induced cellular senescence independent of epirubicin 
concentrations used. This finding suggests that the epirubicin-resistant phenotype in 
MCF-7 cells depends on the overexpression of FOXM1 and NBS1 to override 
epirubicin-induced DNA damage and senescence and thus promote long-term 
survival (Khongkow et al., 2014). Consistent with this, siRNA targeting NBS1 has 
been shown to increase radiation sensitivity of human non-small cell lung cancer 
cells (Ohnishi et al., 2006). NBS1 has previously been shown to play a role in 
persistent DNA damage-induced senescence-associated with inflammatory cytokine 
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secretion (Rodier et al., 2009a). Interestingly, the expression of an NBS1 mutant, 
which interrupts the MRN function for DNA repair and decreases HR repair activity, 
has been reported to be associated with an increased sensitivity to DNA damaging 
cytotoxic agents in head and neck cancer (Tran et al., 2004, Araki et al., 2010) and 
leukaemia cells (Rink et al., 2007). In the line with these findings, my results strongly 
suggest that FOXM1 and its novel target NBS1 can protect MCF-7 EpiR cells from 
entering senescence/cell death by enhancing DNA repair, making them attractive 
molecular targets for overcoming DNA damaging cytotoxic agents and radiation 
resistance (Figure 5.1). However, concentrations used in γH2AX foci assays (Figure 
3.1, 3.2 and 3.4) were still high. Further γH2AX staining experiments in MEFs and 
MCF-7 cells treated with the lower doses of epirubicin will be required to definitely 
confirm that low doses of epirubicin together with FOXM1 or NBS1 depletion are 
sufficient to induce DNA damage and eventually senescence. 
In response to DSBs, ATM is the main factor, which facilitates checkpoint activation 
and DNA repair. ATM phosphorylates NBS1, a member of the MRN complex that 
reinforces the DDR process and facilitates in DNA repair; CHK2, which promotes 
growth arrest; and p53, a tumour suppressor and transcriptional regulator that 
orchestrates DNA repair and cell cycle arrest. DSBs that cannot be repaired cause 
constitutive DDR signalling, prolonged p53-dependent growth arrest, and eventually 
an essentially irreversible senescence arrest (Rodier et al., 2009b, Campisi and 
d'Adda di Fagagna, 2007).  
As ATM and the MRN complex play critical roles in mediating the DNA damage 
response and cell cycle checkpoints, these proteins have been considered as 
promising targets for radiosensitisation and chemosensitisation (Hosoya and 
Miyagawa, 2014). For example, the use of NBS1 C-terminal small peptides, wild-
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type NBS1 inhibitory peptides (wtNIP), has been demonstrated to specifically inhibit 
ATM activation-mediated DNA damage responses and enhance the radiosensitivity 
of cancer (Cariveau et al., 2007).  ‘Mirin’, a novel small-molecule inhibitor of the 
MRN-ATM signalling pathway has also been isolated and developed to be used as 
cellular radio- and chemosensitisation compounds. This inhibitor prevents ATM 
activation in response to DSBs and blocks HR-repair in mammalian cells (Dupre et 
al., 2008). In addition, several promising ATM inhibitors, such as caffeine (Blasina et 
al., 1999), Wortmannin (Sarkaria et al., 1998), KU55933 and KU559403, were also 
shown to sensitize cancer cells to a variety of DNA-damaging agents in preclinical 
studies (Weber and Ryan, 2015). Therefore, targeting FOXM1 together with DNA 
damage repair inhibitors might be a promising strategy for overcoming DNA 
damaging cytotoxic agents and radiation resistance. 
In the context of paclitaxel sensitivity and resistance, in chapter 4, I identified and 
characterised KIF20A as a novel downstream target of FOXM, involved in mitotic 
spindle assembly and paclitaxel resistance (Khongkow et al., 2015). Firstly, I showed 
that FOXM1 is overexpressed in paclitaxel-resistant MCF-7 cells and its depletion 
sensitised both sensitive and resistant cells to paclitaxel by promoting cellular 
senescence. Additionally, I also found that in MCF-7 cells, the expression of FOXM1 
and KIF20A was simultaneously downregulated in response to paclitaxel treatment, 
suggesting that paclitaxel may exert its cytotoxic action by suppressing the 
expression of these proteins. Since paclitaxel functions primarily by interfering with 
spindle microtubule dynamics, causing cell cycle arrest and apoptosis (Montero et 
al., 2005), I also investigated the functional effects of silencing both FOXM1 and 
KIF20A. Depletion of KIF20A or FOXM1 caused an increase in the frequency of 
abnormal mitotic spindle formation with non-aligned or misaligned chromosomes. In 
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the line with this finding, a specific small molecule inhibitor of KIF20A called 
paprotrain has also been shown to induce the accumulation of the cells at 
metaphase and anaphase and exhibit an increased percentage of misaligned 
chromosomes as well as multipolar spindles (Tcherniuk et al., 2010). However, the 
paclitaxel-induced spindle abnormalities and chromosome misalignment defects 
were not increased by depletion of KIF20A or FOXM1, further confirming that 
paclitaxel targets the FOXM1-KIF20A axis to induce mitotic catastrophe in MCF-7 
cells. The spindle assembly checkpoint (SAC) ensures proper chromosome 
segregation and delays the transition to anaphase in the presence of defective 
mitotic spindle formation with unaligned chromosomes (Wolanin et al., 2010, 
Musacchio and Salmon, 2007). When SAC functions properly, prolonged treatment 
with paclitaxel leads to abnormal mitotic spindle formation and metaphase arrest, 
resulting in mitotic catastrophe. Similar to FOXM1, KIF20A protein was upregulated 
in MCF-7 TaxR cells. Therefore, I speculated that the upregulation of FOXM1 and 
KIF20A observed in the paclitaxel resistant cells could counteract the inhibitory 
effects of paclitaxel on mitotic spindle formation and proliferation through their 
downregulation. In agreement with this, I found that the silencing of FOXM1 or 
KIF20A alone was sufficient to dramatically impair the colony-forming capacity and 
induce the SA-βgal activity in MCF-7 TaxR cells independent of the paclitaxel 
concentration used. This suggested that MCF-7 TaxR cells are dependent on the 
elevated expression levels of FOXM1 and KIF20A, which are essential for long-term 
survival and senescence suppression. These findings also appear to be consistent 
with a previous study that has identified KIF20A as an effective inducer of non-
apoptosis cell death (Groth-Pedersen et al., 2012). Furthermore, KIF20A has been 
shown to be crucial in immortalised human fibroblasts undergoing senescence upon 
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activation of the p16/Rb and p53/p21 pathways (Rovillain et al., 2011, Whitfield et al., 
2002).  
Therefore, targeting FOXM1 together with Kinesin inhibitors, such as paprotrain 
(Tcherniuk et al., 2010) or Eg5 inhibitors (Exertier et al., 2013) could be a promising 
strategy for treating paclitaxel resistant cells. However, the exact functional link 
between FOXM1 and KIF20A in mitotic spindle assembly remains elusive and 
requires further investigation. In addition, KIF2C (Zhao et al., 2014, Ganguly et al., 
2011), PLK1 (Hou et al., 2013, Feng et al., 2012), and Stathmin (Carr et al., 2010, 
Alli et al., 2007) have also been identified as downstream regulators of FOXM1, 
participated in mitotic control and paclitaxel resistance.  
More importantly, the clinical significance of the regulation of NBS1 by FOXM1 was 
further validated by using tissue microarrays (TMAs). The significant correlation 
between nuclear FOXM1 and total NBS1 expression was observed in breast cancer 
patient samples. High expression levels of FOXM1 and NBS1 were significantly 
correlated with poor prognosis in breast cancer, supporting a physiological role of 
FOXM1 and NBS1 in genotoxic drug resistance (Khongkow et al., 2014). Consistent 
with this, NBS1 overexpression has previously been identified as a prognostic 
marker of some human cancers, including head and neck squamous cell carcinoma 
(HNSCC) (Yang et al., 2006, Yang et al., 2005), oral squamous cell carcinoma 
(OSCC) (Hsu et al., 2010), and prostate cancer (Cybulski et al., 2013). 
Together, the findings in chapter 3 led me to conclude that NBS1 is an important 
novel target of FOXM1 involved in HR-mediated DSB repair, DNA damage-induced 
senescence and epirubicin resistance (Figure 5.1). These findings also provide the 
potential therapeutic benefit of FOXM1-NBS1 axis as a promising target for 
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therapeutic intervention to overcome epirubicin resistance and a reliable prognostic 
marker used to monitor treatment efficiency in breast cancer. 
Using the same set of patient samples, similar to FOXM1, the elevated expression of 
nuclear KIF20A was associated with poor prognosis in terms of overall and disease 
specific survival in these breast cancer patient samples. As 60% of these patients 
have received chemotherapy in the forms of either anthracyclines or taxanes, these 
immunohistochemistry data also supports the notion that FOXM1 regulates KIF20A 
to modulate paclitaxel resistance (Khongkow et al., 2015). Accordingly, my findings 
in chapter 4 suggest that paclitaxel targets FOXM1 to downregulate KIF20A to 
disrupt the formation of mitotic spindle, thus inducing senescence and cell death in 
breast cancer cells (Figure 5.2). 
Importantly, this work supports that FOXM1, NBS1 and KIF20A could be useful 
biomarkers for predicting and monitoring chemotherapy response. Through the 
depletion of FOXM1 and its targets, it is possible that chemotherapy resistance can 
be reversed, and these proteins could be new therapeutic targets in chemotherapy-
resistant breast cancer. 
Many advances have been achieved by the use of chemotherapeutic drugs in the 
treatment of breast cancer patients and in many cases these advances have 
resulted in improved survival. Despite initial responses, cancer cells acquire 
resistance to cytotoxic and cytostatic agents reducing the efficacy of current 
interventions and as a result patients relapse (Chabner and Roberts, 2005). 
Traditionally, cancer therapy depends on the cytotoxic effects of chemotherapeutic 
drugs that aim at causing cell death within a tumour but have severe toxic side 
effects in patients. In recent years, cellular senescence has been given much 
201 
 
attention as a tumour suppressive mechanism. Hence, an alternative treatment 
option for cancer patients would be to induce cytostasis, disrupting the proliferative 
capacity of cancer cells without inducing cancer cell death. In line with this, in this 
thesis I also studied the role of FOXM1 in inducing cellular senescence in the 
presence of cytostatic concentrations of epirubicin and paclitaxel. 
Interestingly, I observed that the concentrations of DNA damaging agents required 
for inducing senescent phenotypes in MCF-7 as well as in MEF cells are 
substantially lower than those required to induce cell death (Millour et al., 2011, 
Monteiro et al., 2013), further suggesting that cellular senescence may be the 
predominant mechanism of action for genotoxic anti-cancer agents. Consistent with 
this, Xue and colleagues has previously revealed that reactivation of endogenous 
p53 in p53-deficient tumours results in complete tumour regression (Xue et al., 
2007). However, in this case the primary response triggered by p53 was not an 
apoptotic response, but instead the induction of cellular senescence and these 
senescent cells can be cleared in vivo through the innate immune response (Xue et 
al., 2007).  
Another interesting point obtained from this study is the fact that the inhibition of 
FOXM1 expression sensitises MCF-7 as well as MEF cells into entering epirubicin-
induced senescence, as indicated by cellular markers of senescence, including the 
prolonged accumulation of γH2AX foci, the loss in long-term cell proliferation, the 
induction of β-galactosidase activity as well as the flat cell morphology. Consistent 
with my findings, Wang and colleagues have previously reported that early passage 
Foxm1-/- MEFs failed to proliferate, displayed a block in mitotic progression and 
induced premature senescence, as indicated by high expression levels of SA-β gal, 
p19ARF, p16INK4A, p21CIP1 and p27KIP1(Wang et al., 2005a, Wang et al., 2008, Tan et 
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al., 2007). Moreover, FOXM1 has been identified to be one of the most highly 
downregulated transcription factor in immortalised human fibroblasts undergoing 
senescence upon activation of the p16/Rb and p53/p21 pathways and ectopic 
expression of its constitutive active form (ΔNΔKEN) was sufficient to bypass 
senescence arrest (Rovillain et al., 2011). Furthermore, depletion of FOXM1 in 
gastric cancer cells resulted in increased cellular senescence, which was partially 
dependent on p27KIP1 (Zeng et al., 2009) whereas, CDK4/6 phosphorylation of 
FOXM1 has been shown to suppress senescence in melanoma cells (Anders et al., 
2011).   
In resistant cells, I observed that FOXM1 depletion alone severely impairs their long-
term viability and significantly induced cellular senescence independent of genotoxic 
drug concentrations used. This finding suggests that the resistant phenotype in 
MCF-7 cells depends on the overexpression of FOXM1 to override drug-induced 
DNA damage and senescence and thus promote long-term survival.  According to 
the senescence suppression activity of FOXM1, combined targeting of FOXM1 with 
low doses of chemotherapy could represent a promising strategy to improve patient 
survival with fewer toxic side effects. 
Since elevated expression of FOXM1 confers resistance to various 
chemotherapeutic agents, targeting FOXM1 is a promising therapeutic intervention 
to override resistance to genotoxic cancer agents, including epirubicin, paclitaxel, 
cisplatin and ionising radiation. In recent years, several FOXM1 inhibitors have been 
identified (Halasi and Gartel, 2013b). For example, the thiazole antibiotics Siomycin 
A and thiostrepton have been demonstrated to suppress the transcriptional activity 
and the expression of FOXM1 via proteasome inhibition and induce apoptosis in 
human cancer cells (Radhakrishnan et al., 2006, Bhat et al., 2009b). Accumulating 
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evidence have suggested that treatment with Siomycin A and/or thiostrepton caused 
a significant inhibition of tumour growth in a wide range of human cancer cells 
including breast (Kwok et al., 2008), melanoma (Bhat et al., 2008), leukaemia, 
osteosarcoma (Bhat et al., 2009b), brain (Priller et al., 2011), and prostate cells 
(Pandit and Gartel, 2010). Other well-known proteasome inhibitors, such as 
bortezomib, MG132 and MG115 have also demonstrated to inhibit FOXM1 
transcriptional activity and expression (Bhat et al., 2009a). Recently, an alternative 
mechanism of action of thiostrepton has been proposed that thiostrepton directly 
interacts with FOXM1, blocking its binding to the promoters of its target genes, 
(Hegde et al., 2011, Kwok et al., 2008). Furthermore, the synthetic ARF peptide has 
been shown to effectively suppress FOXM1 transcriptional activity, inhibit FOXM1-
induced colony growth and tumour metastasis and also induce apoptosis of several 
distinct human cancers, including osteosarcoma and hepatocellular carcinoma cells, 
as well as in mouse models (Kalinichenko et al., 2004, Costa et al., 2005b, Gusarova 
et al., 2007, Park et al., 2011). Collectively, it seems that FOXM1 could be targeted 
successfully as a single entity with promising results in the fight against cancer.  
However, accumulating data have suggested that combination therapy may improve 
treatment efficacy as well as lower the drug dose needed for anti-tumour growth 
effects, thus reducing the adverse side effects and the probability of cancer cells 
becoming drug-resistant. For example, Kwok and colleagues have demonstrated 
that thiostrepton synergised with cisplatin to reverse acquired cisplatin resistance in 
breast cancer cells and caused a substantial induction of cisplatin-induced cell death 
(Kwok et al., 2010b). This is the first study suggesting that the use of FOXM1 
inhibitor, thiostrepton, in combination with chemotherapy could provide a novel 
mechanism to reverse the phenomenon of chemoresistance in breast cancer. 
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Another interesting point obtained from this study is the fact that thiostrepton 
selectively targets breast cancer cells but not non-transformed cells, suggesting that 
thiostrepton could be a lead compound for targeted therapy of breast cancer with 
minimal toxicity against non-malignant cells (Kwok et al., 2008, Kwok et al., 2010b). 
In addition to this, Park and colleagues have also demonstrated that silencing of 
FOXM1 also led to higher sensitivity to doxorubicin in breast cancer cells as well as 
in a xenograft mouse model. They also suggested that FOXM1-dependent 
resistance to doxorubicin is mediated by regulating DNA repair genes and proposed 
that FOXM1 is a poor prognosis transcription factor conferring doxorubicin resistance 
in breast cancer (Park et al., 2012). Furthermore, recent studies from our lab have 
also revealed that FOXM1 was found to be overexpressed in epirubicin resistance 
cells and its depletion was able to resensitise these cells to epirubicin (Millour et al., 
2011, Monteiro et al., 2013, Khongkow et al., 2014). We also found that FOXM1-
dependent epirubicin resistance was partially mediated by enhanced expression of 
DNA repair genes, including BRIP1 (Monteiro et al., 2013). Additionally, my findings 
in this thesis also demonstrate that NBS1 and KIF20A are crucial targets of FOXM1 
in mediating resistance to epirubicin and paclitaxel, respectively (Khongkow et al., 
2014, Khongkow et al., 2015). In accordance, an independent study by Carr and 
colleagues reported that FOXM1 overexpression confers resistance to herceptin and 
paclitaxel resistance cells and its depletion by the ARF–derived peptide inhibitor was 
able to resensitise FOXM1 overexpressing breast cancer cell lines to herceptin and 
paclitaxel (Carr et al., 2010). 
The better understanding of the cellular and molecular mechanisms whereby 
chemotherapeutic drugs achieve their toxicity effects may allow for the development 
of better therapeutic choices for patients that have become resistant to treatment. My 
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results indicate that FOXM1 is a crucial cellular target of epirubicin and paclitaxel in 
breast cancer cells. In accordance, the expression and the activity of FOXM1 was 
substantially repressed in response to both epirubicin and paclitaxel treatments. 
However, the exact molecular mechanism by which they modulate FOXM1 remains 
mostly elusive. Therefore, it is crucial not only to identify its downstream targets, but 
also the upstream regulators of FOXM1 in response to chemotherapy treatment. 
Targeting upstream regulators of FOXM1, might prove more useful to prevent drug 
induced DNA damage and senescence than targeting FOXM1 downstream targets 
or FOXM1 itself. Accumulating evidence suggests that this repression of FOXM1 
could occur through transcriptional and post-translational mechanisms.  
At the transcriptional level, Millour and colleagues have previously reported that ATM 
and p53 coordinately regulate FOXM1 expression via its upstream transcriptional 
regulator E2F1 to modulate epirubicin response and resistance in breast cancer. In 
sensitive cells, epirubicin suppressed FOXM1 expression at transcriptional levels 
through the activation of p53 and repression of E2F1 activity (Millour et al., 2011). By 
contrast, they observed that the loss of p53 function and the increased expression 
and activity of ATM, lead to an induction of FOXM1 through E2F1 in chemoresistant 
cells. ATM-E2F1 pathway may have important implications for treatment of drug-
resistant cancers, particularly those lacking functional p53. In addition, ATM and 
FOXM1 inhibitors could also be used in combination with conventional genotoxic 
therapeutics to enhance the drug efficacy and for overcoming resistance (Millour et 
al., 2011).  In agreement with this, small-molecule activators of p53, nutlin-3 and 
RITA, has been shown to retain functional p53 and inhibit FOXM1 mRNA and protein 
expression, leading to the increased sensitivity to chemotherapeutic agents (Barsotti 
and Prives, 2009, Michaelis et al., 2012). Mechanistically, this p53-mediated 
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repression of FOXM1 has also been suggested to partially depend on p21CIP1 and 
pRB (Barsotti and Prives, 2009). In addition to this, the results from our laboratory 
have previously shown that paclitaxel and gefitinib exert their cytotoxic functions 
through FOXO3a which is an upstream negative regulator of FOXM1 expression and 
activity (Karadedou et al., 2012, McGovern et al., 2009). 
Recently, some microRNAs (miRNAs), endogenous small non-coding RNAs are also 
reported to directly target FOXM1 and influence the oncogenic functions of cancer 
cells. For example, miR-134 and miR-149 has been suggested to block epithelial to 
mesenchymal transition (EMT) by targeting FOXM1 in non-small cell lung cancer (Li 
et al., 2012). In addition, miR-320 has been shown to enhance the sensitivity of 
human colon cancer cells to chemotherapy in vitro by targeting FOXM1 (Wan et al., 
2015). Thus, altered expression of miRNAs in cancer cells could also act as potential 
tools for cancer diagnosis, prognosis and treatment.  
Another possibility for targeting FOXM1 could rely on interfering with its post-
translational modifications to disable its activity. Phosphorylation is one of the main 
post-translational modifications, which modulates FOXM1 expression, activity and 
localisation (Myatt and Lam, 2007). Previous studies have demonstrated that 
treatment with DNA-damaging insults, such as γ-irradiation, etoposide and UV, 
promotes CHK2-induced phosphorylation of FOXM1. Such phosphorylation of 
FOXM1 results in its stabilisation leading to the transcriptional activation of 
downstream DNA repair genes (Tan et al., 2007). In addition, FOXM1 has been 
identified as a critical target of the CyclinD-CDK4/6 kinases. This phosphorylation 
leads to its stabilisation and activation, thereby maintaining its expression and 
suppressing the levels of reactive oxygen species (Anders et al., 2011). 
Furthermore, recent studies have shown that SUMOylation is believed to inhibit 
207 
 
FOXM1 activity and delays mitotic transition in response to treatment with epirubicin 
and mitotic inhibitors in MCF-7 breast cancer cells (Myatt et al., 2014). 
In conclusion, my study reveals that FOXM1 is a critical mediator of epirubicin and 
paclitaxel sensitivity and resistance in breast cancer cells. I also define the 
involvement of FOXM1 in DNA damage repair, mitotic spindle formation and 
suppression of senescence, which are vital for cancer progression and drug 
resistance, through the regulation of its novel downstream targets, NBS1 and 
KIF20A. In addition, downregulation of FOXM1 and its targets can enhance the 
sensitivity of resistance breast cancer cells to the cytotoxic agents, thus suggesting 
that FOXM1, NBS1, and KIF20A could be novel therapeutic targets for overcoming 
chemotherapy resistance. According to senescence suppression activity of FOXM1, 
the combination of FOXM1 inhibitors with chemotherapeutic agents or IR may also 
lead to the use of lower effective doses and reduced side effects for the breast 
cancer patients. Apart from mediating chemotherapy resistance, FOXM1, NBS1 and 
KIF20A could also be used as biomarkers to predict and monitor the response of 
breast cancer patients to particular chemotherapeutic agents including epirubicin, 
and paclitaxel. However, additional validation studies are still required to confirm 
these findings in other breast cancer subtypes, in different cancer cell lines, in in vivo 
biological models, as well as in the other cohorts of clinical samples. In addition, the 
relationship between FOXM1, NBS1, and KIF20A should also be examined in 
parallel to test whether these three proteins are the main factors mediating 
resistance to both epirubicin and paclitaxel treatments. Moreover, questions about 
the expression statuses of FOXM1 isoforms and their impact on breast cancer 
development and drug resistance should be addressed in future research. 
Furthermore, future studies should also uncover the molecular details of the post-
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translational modification of these proteins in the context of chemotherapy sensitivity 
and resistance. These, together with the development of more effective and specific 
inhibitors, will definitely assist to open up the excellent therapeutic window in which 
targeting of FOXM1 or its targets can achieve clinical benefits. 
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Figure 5.1 Schematic representation summarising the possible role of FOXM1 in the 
development of epirubicin resistance. In epirubicin sensitive MCF-7 cells, the expression of 
FOXM1 and its downstream targets, including NBS1 are downregulated by epirubicin, leading to the 
impairment of HR repair and the induction of cellular senescence and cell death. Conversely, FOXM1 
is overexpressed in resistant cells, resulting in the enhancement of HR repair through the 
upregulation of DNA repair genes, including NBS1. This leads to the increased cell survival and drug 
resistance.   
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Figure 5.2 Schematic representation summarising the possible role of FOXM1 in the 
development of paclitaxel resistance. In paclitaxel sensitive MCF-7 cells, the expression of FOXM1 
and KIF20A are downregulated by paclitaxel, leading to abnormal mitotic spindle formation and the 
induction of mitotic catastrophe, cellular senescence or cell death. Conversely, FOXM1 and KIF20A 
are overexpressed in resistant cells. These proteins might counteract paclitaxel-induced abnormal 
mitotic spindle formation and also suppress cellular senescence leading to the increased cell survival 
and drug resistance.   
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Figure S1: Quantification of γH2AX foci using FociCounter software (Jucha et al., 2010).  
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Figure S2: FOXM1 depletion leads to increased levels of DNA damage in MCF-7. (A) MCF-7 cells 
were transfected with NS siRNA or with FOXM1 siRNA for 24 h. Cells were cultured on chamber 
slides and treated with 1 μM of epirubicin for 0, 4, 24, 48 and 72 h and then stained for γH2AX (green) 
and DAPI (blue). (B) The graph below shows quantification of γH2AX foci number. Bars represent an 
average of three independent experiments ± S.D. Statistical analyses were conducted using Student’s 
t-tests against the correspondent time point (***P≤0.0001, significant; n.s., non-significant). 
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Figure S3: Optimization of epirubicin treatment doses used in long-term clonogenic assay for 
WT and Foxm1−/− MEFs. Bars represent average ± SD from three independent experiments. 
Statistical significance was determined by two-tailed unpaired Student’s t-test (**P ≤ 0.01, significant; 
ns, non-significant).  
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Figure S4:  Epirubicin resistant cell line exhibits increased FOXM1 and NBS1 protein. 
Densitometric analysis of the western blots in figure 3.7A was carried out using Image J software. The 
intensity of the bands of FOXM1, NBS1, P-NBS1, ATM and P-ATM at each time point was normalised 
to the intensity of the β-Tubulin band at the respective time point and the obtained values were plotted 
(n=3). Bars represent average ± SD. Statistical significance was determined by two-tailed unpaired 
Student’s t-test test (*P ≤ 0.05, **P≤0.01, ***P≤0.005 significant; ns, non-significant). 
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Figure S5: MCF-7 and MCF-7 EpiR cells depleted in FOXM1 expression revealed significant 
decreases at protein level of NBS1. Densitometric analysis of the western blots in figure 3.8 was 
carried out using Image J software. The intensity of the bands of FOXM1, NBS1, P-NBS1, MRE11, 
RAD50, ATM and P-ATM at each time point was normalised to the intensity of the β-Tubulin band at 
the respective time point and the obtained values were plotted (n=3). Bars represent average ± SD. 
Statistical significance was determined by two-tailed unpaired Student’s t-test test (*P ≤ 0.05, 
**P≤0.01, significant; ns, non-significant). 
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Figure S6: FOXM1 and KIF20A expression levels were strongly upregulated in paclitaxel-
resistant MCF-7 cells. Densitometric analysis of the western blots in figure 4.4A was carried out 
using Image J software. The intensity of the bands of FOXM1 and KIF20A at each time point was 
normalised to the intensity of the β-Tubulin band at the respective time point and the obtained values 
were plotted (n=3). Bars represent average ± SD. Statistical significance was determined by two-tailed 
unpaired Student’s t-test test (*P ≤ 0.05, **P≤0.01, significant; ns, non-significant). 
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Figure S7: Silencing of FOXM1 downregulates KIF20A protein expression in MCF-7 and MCF-7 
Tax
R
 cells. Densitometric analysis of the western blots in figure 4.5B was carried out using Image J 
software. The intensity of the bands of FOXM1 and KIF20A at each time point was normalised to the 
intensity of the β-Tubulin band at the respective time point and the obtained values were plotted 
(n=3). Bars represent average ± SD. Statistical significance was determined by two-tailed unpaired 
Student’s t-test test (*P ≤ 0.05, **P≤0.01, significant; ns, non-significant). 
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Figure S8: Knockdown of FOXM1 or KIF20A leads to defects in mitotic spindle formation in 
MCF-7 Tax
R
 cells. MCF-7 TaxR cells were transfected with NS, FOXM1 or KIF20A siRNA. 24 h after 
transfection, cells cultured on chamber slides were treated with 5 nM paclitaxel for 24 h. Cells were 
then fixed, permeabilised, and immunostained with antibody against α-tubulin (Green). Mitotic cells 
were visualised with Leica TCS SP5 (63X magnification). For each condition, images of at least 50 
mitotic cells were captured. Representative confocal images are shown. The number of mitotic cells 
classified into either normal bipolar, abnormal bipolar, monopolar or multipolar spindles was 
quantified. Results represent average of three independent experiments ± S.D. 
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Figure S9. FOXM1 was unable to transactivate a putative KIF20A promoter region containing 
the 5’ UTR (-1150 to -61) in the MCF-7 cells. (A) Schematic representation of a putative KIF20A 
promoter region containing the 5’ UTR located between -1150 to -61. MCF-7 cells were transiently co-
transfected the pGL3 basic luciferase reporter plasmid containing the putative KIF20A promoter, the 
Renilla luciferase plasmid and the FOXM1B expression plasmid. Twenty-four hours after transfection, 
cells were lysed, and the luciferase activity examined. Firefly luminescence signal was normalized 
with the Renilla luminescence signal. (B) Bars represent mean±S.D from three independent 
experiments. 
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Figure S10: Cloning of WT and mut KIF20A luciferase reporter constructs. The KIF20A-WT, 
KIF20A-MUT1, and KIF20A-MUT2 fragments were initially designed and synthesised by GeneArt 
(Life Technologies, Darmstadt, Germany). The synthesised DNA fragments cleaved with the 
restriction enzymes XhoI and Bglll and cloned into the XhoI/Bglll sites of the pGL3-basic vector. 
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Figure S11: Depletion of FOXM1 increases p21 expression and induces G/M arrest in both 
MCF-7 and MCF-7 Tax
R
 cells. (A) and (B) MCF-7 and MCF-7 Tax
R
 cells depleted in FOXM1 
expression revealed significant increase in p21 expression. (C) and (D) Knockdown of FOXM1 
induces G2/M arrest in both MCF-7 and MCF-7 Tax
R
 cells. 
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